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Abstract 
The growing numbers of putative receptors and allosteric sites in which cannabinoids 
have been observed to act upon has called in to question the established action of 
cannabinoids through solely the CB, receptor. 
CB1 receptor mediated inhibition of electrically stimulated contraction of the guinea- 
pig ileum myenteric plexus-longitudinal muscle preparation (MPLM) has been 
elucidated but the influence of cannabinoids on chemically induced contraction has 
not been examined. Cannabinoids appeared to act through multiple pathways. 
Stimulus-evoked contractions by low concentrations of nicotine was blocked by a 
CB1 receptor dependent mechanism while high nicotine concentrations showed CB1 
receptor independent blockade. Contraction evoked by stimulus of nicotinic receptors 
located at the nerve terminal of the excitatory motor neurones displayed CB, receptor 
independent inhibition while whole-cell electrophysiological recording showed a lack 
of WIN 55.212 stereoselectivity corroborating the suggested presence of a CB, 
receptor independent inhibitory pathway. 
The intracellular mechanism through which cannabinoids modulate MPLM activity 
has yet to be established. Using whole-cell electrophysiological recordings in primary 
cultures of guinea-pig ileum myenteric AH neurones, cannabinoids appeared to 
inhibit Ca 2+ currents through a G110 coupled mechanism dependent upon either both 
CB, and CB2 receptors or a novel receptor. 
Guinea-pig ileum myenteric and NG 108-15 neurones demonstrated interaction 
between cannabinoid and opioid signalling pathways in contractile and 
electrophysiological models. Interaction occurred at high agonist concentrations with 
data suggesting the existence of a more complex model than that of simply exhaustion 
of a shared intracellular messenger. 
With the simultaneous abuse of multiple drugs of addiction becoming more common, 
investigation into the interaction of cannabinoids and other drugs of abuse in the 
reward pathway is needed. CP 55,940 induced no change in spontaneous action 
potential firing frequency in the ventral tegmental area (VTA) of rat coronal midbrain 
slices under blind whole cell patch clamp, suggesting cannabinoids may not act 
directly upon dopaminergic neurones within the VTA. 
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Figure 4.15 Hypothesised intracellular interaction between cannabinoids and 
opioids. 
5. Modulation of the rat mesolimbic dopaminergic reward 
pathway by cannabinoids 
Figure 5.1 Gibbs chamber. 
Figure 5.2 (a) Sample spontaneous action potential recorded from a neurone within 
the VTA of a rat brain slice through the use of blind patch clamping. 
Figure 5.2 (b) Sample recording from a neurone within the VTA demonstrating the 
reduction in firing frequency induced by application of dopamine. 
Figure 5.3 (a) Modulation of spontaneous firing frequency in neurones within the 
VTA by dopamine and CP 55,940. Each line represents the firing 
frequency of a single cell over a period of time prior to and post 
application of dopamine and CP 55,940. 
xxv 
Figure 5.3 (b) Bar chart demonstrating modulation of spontaneous firing frequency 
in neurones within the VTA by dopamine and CP 55,940. 
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Chapter 1- General Introduction 
1. Chapter 1- General Introduction 
It is only recently with the discovery of cannabinoid receptors and endogenous ligands 
for these receptors that the importance of the endogenous cannabinoid system has come 
to be accepted in both physiological and pathophysiological conditions. Consequently, far 
greater understanding of the role that the cannabinoid system plays, and its interaction 
with other systems is required in order that full utilisation can be obtained in the 
treatment of pathological conditions. 
I. I. Overview 
Extracts from the hemp plant Cannabis sativa have been used for at least four thousand 
years for their therapeutic properties (reviewed by Mechoulam, 1986). The earliest of the 
Chinese pharmacopoeias, the Pen Ching, dating from the first century B. C., contained 
material describing the psychoactive properties of cannabis, while recommendations for 
relief from the symptoms of malaria, constipation, rheumatic pains and dysmenorrhoea 
have been found in a Chinese medical treatise dating from around 2600 B. C. (Abood and 
Martin, 1996; Grinspoon and Bakalar, 1993). Medicinal use in Europe did not emerge 
until the mid-nineteenth century when Irish scientist and physician W. B. O'Shaughnessy 
administered cannabis resin in an ethanolic solution to patients after observing its 
analgesic, antispasmodic, antiemetic and hypnotic properties with use in India. His report 
(O'Shaughnessy, 1843) generated considerable interest and use expanded rapidly with 
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full endorsement by one of Queen Victoria's physicians (Reynolds, 1890). However, 
variability in potency of preparations coupled with unpredictability in response and poor 
availability led to a steep decline in use. In 1925 the Geneva Convention on the 
manufacture, sale and movement of dangerous drugs imposed a limitation on the use of 
cannabis, restricting use for solely scientific and medicinal purposes. Prescription of 
cannabis in the UK was finally prohibited by the Misuse of Drugs Act (1971). 
Recreational use of cannabis developed a resurgence in the USA during the 1960's and 
1970's, in a period of social turmoil, and illegitimate use has increased strongly since. 
Currently, cannabis is the most widely used recreational drug with 119,922 people in 
Britain charged with possession of cannabis in 2005/2006 (Thorpe and Robb, 2006). 
Partly as a result of the discovery and appreciation of the endogenous cannabinoid 
system, a renewed interest has developed in the potential therapeutic use of cannabis and 
related compounds. Currently, Sativex, a blend of the entire aerial part of the cannabis 
plant formulated to contain tetrahydrocannabinol (THC) and cannabidiol (CBD) in a 
1.08: 1 ratio, was approved by Health Canada under a conditional licence for prescription 
use in April 2005 for the treatment of neuropathic pain in multiple sclerosis sufferers. 
Marinol (Dronabinol), a synthetic A9-THC, was approved by the U. S. Food and Drug 
Administration (FDA) in 1985 for the treatment of nausea and vomiting associated with 
cancer chemotherapy. In 1992, the FDA approved the marketing of Marinol for the 
treatment of anorexia associated with weight loss in AIDS patients. The FDA has also 
approved nabilone (Cesamet), the synthetic (S, S) and (R, R) isomers of A9-THC, for use 
in the prevention of nausea and vomiting that may occur after cancer treatments when 
other medicines are unsuccessful. Sanofi-Aventis have recently been granted permission 
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by the European Medicines Agency to market rimonabant (SR141716), the CB1 
cannabinoid receptor antagonist, within Europe for use as an anorectic anti-obesity drug. 
A large number of other potential therapeutic uses of cannabis and related compounds 
have been suggested including glaucoma, epilepsy, asthma and a number of psychiatric 
disorders. 
Difficulties in medicinal use of these compounds do arise, with similar cognitive effects 
to recreational cannabis if taken in sufficient quantities. However, acute toxicity is low 
with the lethal dose to effective dose ratio, based upon extrapolation from mouse to man, 
of around 40,000: 1 (Grinspoon and Bakalar, 1993). Large doses of cannabis have been 
linked with transient hallucination and delusion (Johns, 2001) but the effects on mental 
health of doses commonly taken are more debatable. Studies suggest a possible 
precipitation and exacerbation of schizophrenia and psychosis in vulnerable individuals 
(Hall et al., 2004). 
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1.2. Cannabinoid receptor ligands 
The term "cannabinoid" was originally given as a collective name for the C21 
terpenophenolic compounds that naturally occur in Cannabis sativa, with (-)-A9-trans- 
(6aR, l OaR)-tetrahydrocannabinol (A9-THC) being the most psychologically active 
constituent (Mechoulam and Gaoni, 1967). The development of synthetic compounds 
which closely mimicked the properties of these cannabinoids and the discovery of 
chemically different endogenous cannabinoid receptor ligands have prompted the use of 
the terms "phytocannabinoids" to describe plant-derived cannabinoids and 
"endocannabinoid" to describe endogenous cannabinoids (Pate, 1999). On the basis of 
chemical structure, cannabinoids have been divided into four main groups: classical, 
nonclassical, aminoalkylindole, and endocannabinoid. 
1.2.1. Classical cannabinoids 
Classical cannabinoids describe a group consisting of dibenzopyran derivatives and are 
either plant-derived or their synthetic analogues. These include the psychotropic 
ingredients in C. sativa (phytocannabinoids) notably A9-tetrahydrocannabinol (A9-THC), 
A8-THC and cannabinol (Figure 1.1), and the synthetic cannabinoids. Notable examples 
of which include 11-hydroxy-A8-THC-dimethylheptyl (HU-2 10) and desacetyl-L- 
nantradol (Gaoni and Mechoulam, 1964; Figure 1.2). A9-THC, first isolated by Gaoni and 
Mechoulam (1964), is considered to be the predominant of at least 66 psychotropic 
constituents of cannabis (ElSohly, 2002). It undergoes significant binding to cannabinoid 
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receptors at submicromolar concentrations, with similar affinities for CB1 and CB2 , 
receptors (CB1 receptor K; ranging between 35.3 and 80.3 nM, and CB2 receptor K; 
between 3.9 and 75.3 nM; Rinaldi-Carmona et al., 1994; Felder et al., 1995; Bayewitch et 
al., 1996; Showalter et al., 1996; Rhee et al., 1997). At both cannabinoid receptors A9- 
THC behaves as a partial agonist with the size of its maximal effect falling far below that 
of other CB, agonists, such as CP 55,940 and WIN 55,212-2 (Gerard et al., 1991; 
Breivogel et al., 1998; Griffin et al., 1998). A9-THC exhibits such reduced efficacy that it 
has been shown to behave as a cannabinoid receptor antagonist in a bioassay system and 
in hippocampal cultures, expressing an IC50 close to its K; (Bayewitch et al., 1996; Kelly 
and Thayer, 2004). A marked stereo selectivity has been demonstrated for A9-THC and 
HU-210 with cis 6a, l Oa isomers displaying an activity less than 1% of that possessed by 
the trans isomer (Herkenham et al., 1990; Matsuda et al., 1990; Felder et al., 1992). The 
first generation classical cannabinoids displayed a lack of CB1/CB2 selectivity. However, 
minor alterations to the THC molecule enabled the generation of CB2-selective agonists, 
an example being 1-deoxy- ll -OH-A8-THC-dimethylheptyl (JWH-051; Huffman et al., 
1996), which retained affinity for the CB 1 receptor but gained a marked increase in 
affinity for the CB2 receptor (CB, receptor K; 1.2 nM, CB2 receptor K; 0.032 nM; 
Huffman et al., 1996). 
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1.2.2. Nonclassical cannabinoids 
The second group, developed by Pfizer, USA, possess a similar structure to classical 
cannabinoids, consisting of bicyclic and tricyclic analogues of A9-THC but missing the 
dihydropyran ring (Johnson and Melvin, 1986). Examples include CP 55,940 that 
possesses less lipophilicity than THC, enabling Devane et al. (1988) to demonstrate 
specific binding sites within the rat brain that led to the discovery of the CB1 receptor. CP 
55,940 expresses the same low nanomolar range affinity for both CB, and CB2 receptors 
(CB, receptor K, ranging between 0.5 and 5 nM, and CB2 receptor K; between 0.69 and 
2.8 nM; Ross et al., 1999; Rinaldi-Carmona et al., 1994; Felder et al., 1995; Showalter et 
al., 1996; Hillard et al., 1999) and displays a relatively high efficacy in vivo being 10 to 
50 times more active than A9-THC in the mouse tetrad model (Johnson and Melvin, 1986; 
Little et al., 1988). Like classical cannabinoids, nonclassical cannabinoids exhibit 
significant stereos electivity (Little et al., 1988; Herkenham et al., 1990; Melvin et al., 
1993). 
1.2.3. Aminoalklindoles 
Developed by Sterling Winthrop, USA, this group is structurally very different when 
compared with classical and nonclassical cannabinoids, being made up of a series of 
structurally constrained analogues of pravadoline (Bell et al., 1991; Pacheco et al., 1991). 
The frequently used cannabinoid agonist WIN 55,212-2 is a member of this group. WIN 
55,212-2 displays a low nanomolar range affinity for both cannabinoid receptors, 
7 
although it possesses a slightly greater affinity for the CB2 receptor (CB, receptor K; 
ranging between 4.4 and 123 nM, and CB2 receptor K; between 0.28 and 16.2 nM; 
Rinaldi-Carmona et al., 1994; Felder et al., 1995; Showalter et al., 1996; Hillard et al., 
1999; Shire et al., 1996). It possesses a relatively high efficacy at both CB, and CB2 
receptors (Bouaboula et al., 1997; Griffin et al., 1998; Tao and Abood, 1998; Pertwee, 
1999). Efficacy has been shown to be enantioselective with the R-(+)-enantiomer, WIN 
55,212-2, being more active than the S(-)-enantiomer, WIN 55,212-3, in inhibiting 
adenylyl cyclase (EC50 0.3 and 10 mM respectively; Pacheco et al., 1991). 
1.2.4. Endocannabinoids 
With the discovery of mammalian cannabinoid receptors, the search began for the release 
of an endogenous receptor agonist. Arachidonyl ethanolamine amide (anandamide) was 
initially isolated from porcine brain by a team led by Prof. Mechoulam (Devane et al., 
1992). This lipophilic molecule was found to readily displace [3H]-HU-243 from rat brain 
membranes with a K; of 52 nM and inhibit electrically evoked contractions of the mouse 
isolated vas deferens with a similar EC50. Anandamide possesses a slightly greater 
affinity for the CB, receptor (CB 1 receptor K; ranging between 52 and 543 nM, and CB2 
receptor K; between 279 and 1940 nM; Lin et al., 1998; Showalter et al., 1996; Felder et 
al., 1995; Hillard et al., 1999; Mechoulam et al., 1995) and behaves as a partial agonist at 
cannabinoid receptors, inhibiting Ca 2+ currents in whole-cell voltage clamped N18 
neuroblastoma cells to an extent 55% less efficacious than that of WIN 55,212-2 (Mackie 
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et al., 1993). Anandamide has also been shown to activate the TRPV 1 (vanilloid) 
receptor, as first noted by Di Marzo et al. (1998). 2-arachidonyl glycerol (2-AG), 
discovered in canine gut and rat brain in 1995, possesses a similar binding affinity for the 
CB1 and CB2 receptors (CB1 receptor K, ranging between 58.3 and 472 nM, and CBS 
receptor K; between 145 and 1400 nM; Ben-Shabat et al., 1998; Mechoulam et al., 1995; 
Sugiura et al., 1995) and exhibits a greater relative intrinsic activity than anandamide at 
both CB 1 and CB2 receptors (Gonsiorek et al., 2000; Savinainen et al., 2001). Both 
endocannabinoids have displayed susceptibility to metabolism via hydrolysis and 
oxidation; the most studied being fatty acid amide hydrolase (FAAH)-mediated 
hydrolysis (McKinney and Cravatt, 2005). More recently an ether-linked analogue of 2- 
AG, 2-arachidonyl-glyceryl ether (noladin), was isolated from porcine brain. It differed 
from anandamide and 2-AG by expressing very little affinity for the CB2 receptor (CB 1 
receptor K; 21.2 nM, and CB2 receptor K; >3000 nM; Hanus et al., 2001) and possessed 
less relative intrinsic activity at the CB, receptor than 2-AG (Savinainen et al., 2001). 0- 
arachidonoyl-ethanolamine (virodhamine), discovered by Porter et al. (2002), displayed 
partial agonism at the CB 1 receptor and full agonism at the CB2 receptor. The weak 
agonist efficacy enabled virodhamine to inhibit the action of anandamide at the CB, 
receptor, suggesting it may play a putative role as an antagonist within the endogenous 
system (Porter et al., 2002). A recent study investigating activity cAMP formation at the 
human neocortical CB, receptor found virodhamine behaved as a antagonist/inverse 
agonist (Steffens et al., 2005). The final member of this group, N-arachidonoyl-dopamine 
(NADA), was first detected in both rat and bovine brain, with highest concentrations in 
striatum and hippocampus (Huang et al., 2002). Bisogno et al. (2000) demonstrated a 
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binding selectivity for the CB, receptor over the CB2 receptor as well as greater efficacy 
than anandamide in stimulating intracellular Ca 2+ mobilization in undifferentiated 
N 18TG2 neuroblastoma cells. NADA has been shown to share ability with anandamide 
to activate TRPV 1 receptors (Huang et al., 2002). Palmitoylethanolamide (PEA), a 
shorter and fully saturated analogue of anandamide, is produced through a similar route 
to anandamide and can be co-released with anandamide from depolarised neurones (Di 
Marzo et al., 1994; Izzo et al., 2000). Unlike anandamide, PEA does not bind efficiently 
to the CB 1 and CB2 receptors (Lambert and Di Marzo, 1999). PEA has been shown to 
exhibit antinociceptive activity in the mouse abdominal stretch test and formalin paw test 
in a mechanism susceptible to SR144528 antagonism (Calignano et al., 1998; 2001). A 
putative "CB2-like" receptor has been suggested to be responsible (Pertwee, 2004). 
1.2.5. Cannabinoid receptor antagonists 
Developed by Sanofi, the diarylpyrazole, SR141716 (rimonabant) was the first highly 
potent and selective CB1 receptor antagonist (CB1 receptor K; ranging between 1.98 and 
12.3 nM, and CB2 receptor K; between 702 and 13,200 nM; Felder et al., 1998; Felder et 
al., 1995; Showalter et al., 1996; Rinaldi-Carmona et al., 1994). It has been shown to 
readily displace CP 55,940 from selective binding sites and prevent typical cannabinoid 
effects both in vivo and in vitro (Rinaldi-Carmona et al., 1994). Other diarylpyrazole CB, 
antagonists include AM251 and AM281 possessing minor structural differences from 
SR 141716. SR 144528, another diarylpyrazole developed by Sanofi, has demonstrated a 
greater binding affinity for the CB-2 receptor as opposed to the CB I (CB I K; ranging 
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between 305 and >10,000 nM, and CB2 K; between 0.30 and 5.6 nM; Rinaldi-Carmona et 
al., 1998; Ross et al., 1999). As well as attenuating the effects of cannabinoid agonists, 
these compounds have been found to produce opposing effects, at least in some 
preparations, to that produced by cannabinoid agonists (Bass et al., 2002; Coutts et al., 
2000; MacLennan et al., 1998; Pertwee, 2005). It has been postulated that this opposing 
action could be due to antagonism of cannabinoid receptor activity evoked by an 
endogenously released endocannabinoid. However, the observance of inverse 
cannabimimetic effects in the absence of any endogenous cannabinoid release prompted 
the hypothesis of `inverse agonism' in which cannabinoid receptors exist in what can be 
described by a "two-state model". According to this model, receptors exist in a 
constitutively active state with some degree of coupling to effector mechanisms occurring 
in the absence of an agonist. The presence of a cannabinoid agonist would evoke a 
change in receptor state resulting in an increase in receptor activity whilst an `inverse 
agonist' would induce the receptor to adopt a less active state resulting in a decrease in 
activity (Pertwee, 2005). Consistent with this hypothesis is the recent development of 
`neutral' competitive CB1 receptor antagonists. An example of this is 0-2050, a 
sulphonamide analogue of A8-tetrahydrocannabinol, which displayed high CB1 receptor 
affinity (K; 2.5 nM) and did not elicit any inverse agonism in mouse vas deferens (Martin 
et al., 2002). Developed by Eli Lilly, the substituted benzofuran LY320135, although 
selective for the CB, receptor, possessed much lower affinity for the receptor than 
SR 141716 (CB 1 Ki 141 nM, and CB2 Ki 14.9 µM; Felder et al., 1998) and showed 
binding at similar ranges to muscarinic and 5-HT2 receptors. Like SR141716, LY320135 
displayed inverse activity at some signal transduction pathways of the CB, receptor 
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(Felder et al., 1998; Christopoulos et al., 2001). The pravadoline analogues WIN 56,098, 
6-bromopravadoline (WIN 54461), and 6-iodopravadoline (AM 630) were the first 
cannabinoid antagonists/inverse agonists to be discovered. AM 630 was shown to be a 
CB2 receptor selective antagonist/inverse agonist in hCB2-transfected CHO cells, 
reversing CP 55,940 inhibition of forskolin-stimulated cAMP production (EC50 128.6 
nM) and when administered alone, enhancing forskolin-stimulated cAMP production 
(EC50 230.4 nM) and inhibiting [35S]GTP-yS binding (EC50 76.6 nM; Ross et al., 1999). 
At the CB] receptor AM 630 was shown through multiple investigations to possess mixed 
agonist/antagonist properties acting as a low-affinity partial agonist, and in one case, as a 
low-potency inverse agonist (Pertwee et al., 1996; Hosohata et al., 1997a; b; Ross et al., 
1999; Landsman et al., 1998). WIN 56,098, discovered by Stirling Winthrop, possessed a 
weak disassociation constant against A9-THC of 1.85 µM in the mouse isolated vas 
deferens (Pacheco et al., 1991). 6-Bromopravadoline showed potency values of 159 and 
251 nM against WIN 55,212-2 and A9-THC respectively and an IC50 value of 515 nM for 
displacement of [3H]-WIN 55,212-2 from rat cerebellar membranes (Eissenstat et al., 
1995). 
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1.3. Overview of cannabinoid receptors 
Cannabinoid receptors are named based upon their response to cannabinoid drugs, 
ligands derived from Cannabis sativa and its biologically active synthetic analogues. 
Cannabinoid receptor types are denoted by the abbreviation CB and numbered in the 
order of their discovery by a subscript (CB1, CB2). Currently, two cannabinoid receptor 
types have been established, displaying differing predicted amino acid sequences, 
signalling mechanisms, and tissue distribution. Synthetic ligands have been developed 
displaying marked selectivity for CB, or CB2 receptors (Section 1.2). Human 
cannabinoid receptors CB1 and CB2 exhibit 48% amino acid sequence identity (Sections 
1.3.2 and 1.3.3). Both receptors possess a structure suggestive of a seven-transmembrane 
domain receptor, and express biochemical and cellular properties suggestive of signal 
transduction via G-proteins through modulation of adenylyl cyclase and mitogen- 
activated protein kinase. The CB, receptor has also been shown to couple via G-proteins 
to calcium and potassium channels (Section 1.3.1.3). CB, receptor mRNA and protein are 
found primarily in brain and neuronal tissue while the CB2 receptor has been reported to 
be found primarily in immune tissue and, until recently, considered absent from normal 
nervous tissue (Sections 1.3.2 and 1.3.3). 
1.3.1. The CB1 receptor 
Due to the highly lipophilic nature of cannabinoids, the elicited effects were originally 
thought to be due to a non-specific interaction with membrane lipids and alteration of 
membrane fluidity. However, Howlett and Flemings' observation of functional inhibition 
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of adenylyl cyclase in a neuroblastoma cell line following addition of A9-THC (Howlett 
and Fleming, 1984) coupled with GTP dependency and pertussis toxin blockade (Howlett 
et al., 1986) suggested effects might be mediated by a G1/0-protein coupled receptor. 
Demonstrations of stereoselectivity of the (-)-enantiomers of A9-THC (Dewey, 1986) and 
specific radiolabelled CP 55,940 binding in rat brain membranes (Devane et al., 1988) 
confirmed the existence of a specific cannabinoid receptor. Subsequent cloning from rat 
brain (Matsuda et al., 1990) led to the naming of the receptor CB 1 and to the confirmation 
of its membership of the G-protein coupled receptor superfamily. The CB1 receptor has 
since been cloned from human and mouse brain, and human testis (Chakrabarti et al., 
1995; Gerard et al., 1991). cDNA cloned encode proteins of 472 (human) and 473 (rat 
and mouse) amino acids. These three receptors possessed 97 to 99% amino acid sequence 
identity. A splice variant of the CB, receptor, CB I A, has been found in the human lung 
(Shire et al., 1995). 
1.3.2. CB1 receptor distribution 
Detailed investigations into the distribution of CB, receptors within the CNS have been 
performed using techniques such as quantitative autoradiography, in situ hybridisation, 
and immunocytochemistry. In addition to the CNS, CB 1 receptors are widely expressed in 
the peripheral nervous system, both on sensory nerve fibres and in the autonomic nervous 
system, although detailed comparative anatomical studies have not been conducted on 
receptor expression. CB, receptors have also been found in moderate levels in the testis 
(Gerard et al., 1991 ; Wenger et al., 2001) and in some immune cells. 
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Autoradiography studies within the CNS, performed with [3H]-CP 55,940 prior to the 
cloning of the receptor in several species including human, monkey, and rat, assisted in 
establishing the existence of a high-affinity cannabinoid receptor (Herkenham et al., 
1990; 1991; Glass et al., 1997). Cannabinoid receptors were found at particularly high 
levels in the cerebral cortex, hippocampus, basal ganglia, and cerebellum, regions 
correlating well with the behavioural effects of cannabinoids. Lower levels were found in 
hypothalamus and spinal cord. The absence of receptor binding in respiratory centres of 
the brainstem showed consistency with the low toxicity of cannabis overdose (Robson, 
2001). Quantitative estimates found expression levels of greater than 1 pmol/mg tissue, 
greater than those of most other G-protein-coupled receptors and comparable with levels 
found for common ionotropic receptors (Greenamyre et al., 1984; Bowery et al., 1987). 
With cloning, the in situ hybridisation identification of CB, receptor mRNA corroborated 
with autoradiography studies (Mailleux et al., 1992; Matsuda et al., 1993). As in situ 
hybridisation detected mRNA within cell bodies, analysis in conjunction with 
autoradiography studies suggested that CB, receptors are often found on axons and 
probably their terminals. 
With the development of antibodies to the CB, receptor, immunocytochemical studies 
demonstrated similar distribution patterns as observed with autoradiography and in situ 
hybridisation studies (Tsou et al., 1998; Egertovä and Elphick, 2000). 
1.3.3. CB2 receptor 
Evidence for a second cannabinoid receptor first came with the cloning of human CB2 
cDNA from HL-60 cells by Munro et al. (1993). It possesses a 360-amino acid sequence 
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that bears only 48% homology with the human CB, receptor between the transmembrane 
domains 1 and 7. Mouse and rat CB2 genes have been cloned, with the mouse expressing 
only 82% homology in the amino acid sequence to the human receptor (Shire et al., 1996; 
Griffin et al., 2000). CB2 receptors are primarily expressed by leukocytes with a rank 
order of B cells > natural killer [NK] cells » monocytes/macrophages > neutrophils > 
CD8+ T cells > CD4+ T cells (Galiegue et al., 1995). While many laboratories have 
reported the absence of CB2 receptor expression in healthy brain (Carlisle et al., 2002; 
Chakrabarti et al., 1995; Derocq et al., 1995; Galiegue et al., 1995; Griffin et al., 1999; 
Shatz et al., 1997; Sugiura et al., 2000), several publications have reported low levels of 
CB2 receptors in specific brain structures, such as the brain stem and hippocampus (Gong 
et al., 2006; Van Sickle et al., 2005). In addition the expression of CB2 receptors in cells 
in pathological conditions has been observed in activated microglial cells in mouse 
models of multiple sclerosis and Alzheimer's disease (Benito et al., 2003). Recently 
expression of the CB2 receptor in the rat myenteric plexus after exposure to LPS has been 
reported (Duncan et al., 2005; 2006) and unpublished studies reviewed by Wright et al. 
(2008) suggested the presence of the CB2 receptor in intestinal epithelial cells. 
1.3.4. Signal transduction mechanisms of CB1 and CB2 receptors 
Cannabinoid receptor activation has been associated with a number of signal transduction 
mechanisms, the majority of which are conveyed via the G; /. -protein, these include 
modulation of ion channel opening, inhibition of adenylyl cyclase, up regulation of 
mitogen-activated protein (MAP) kinase, activation of phospholipase C, and mobilisation 
of arachidonic acid. A sizeable amount of evidence exists for these mechanisms and has 
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been well reviewed (Pertwee, 1997). Under certain conditions the CB, receptor has been 
shown to couple to the GS-protein to activate adenylyl cyclase and reduce outward 
potassium current (Glass and Felder, 1997; Calandra et al., 1999; Hampson et al., 2000; 
Bonhaus et al., 1998). An increasing number of alternative signalling mechanisms are 
emerging through which cannabinoid receptors may act. These include 
phosphatidylinositol-3-kinase (PI3K) activation, focal adhesion kinase (FAK) activation 
and ceramide synthesis. 
1.3.4.1. G-protein coupling 
The CB I and CB2 receptors are members of the G-protein coupled receptor family 
(GPCR) and consists of 7 transmembrane domains interspaced by alternating 
extracellular and intracellular loops. These receptors belong to a subset of the GPCR 
family referred to as the rhodopsin-type or Class I subfamily, which consists of a large 
number of GPCR including the muscarinic, dopamine and opioid receptor families 
(Pierce et al., 2002). 
Ligand binding to the extracellular loops and N-terminal domain stabilises a 
conformation that allows the intracellular loops and C-terminal domain of the receptor to 
associate and activate G-proteins. The heterotrimeric G-protein consists of an a, aß and a 
y subunit. The a subunit is responsible for GTP and GDP binding and GTP hydrolysis, 
while the ß and 7 subunits exist in a tightly bound dimer complex. In the absence of 
GPCR agonists the receptor exists in a bound state with the G-protein complex, which is 
bound to GDP. Binding of an agonist causes the release of GDP and replacement with 
GTP. This leads to a release of the G-protein complex from the receptor and dissociation 
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of the a and ßy complexes, which both activate several effectors. To date, 16 a, 5ß and 
14 y subunits have been cloned, with the CB1 receptor binding to the Ga;,, -protein 
subunit. The Gct io-protein subunit has been shown to inhibit adenylyl cyclases (AC-II and 
AC-IV), while the ßy dimer has been shown to activate G-protein coupled inwardly 
rectifying potassium (GIRK) channels (KIR3.1-3.4) and inhibit voltage-gated calcium 
channels (VGCC) as detailed later within this chapter. The bacterial toxin, pertussis 
toxin, selectively inactivates G110-proteins (Hescheler et al., 1987). 
The ability of the CB, receptor to activate G; -proteins has been demonstrated through the 
analysis of activation of [35S]-GTPyS in brain homogenates (Selley et al., 1996; 
Breivogel et al., 1997). A study by Glass and Northup demonstrated activation of GDP- 
GTP exchange through G; and Go-proteins dependent mechanisms in membranes derived 
from Spodoptera frugiperda cells transfected with the CB, receptor and with 
exogenously added purified G-protein subunits (Ga;, Gao and ßy subunits). In contrast, 
the CB2 receptor induced activation through a G; -protein but not a Go-protein dependent 
mechanism (Glass and Northup, 1999). 
1.3.4.2. Inhibition of adenylyl cyclase 
Cannabinoid evoked inhibition of adenylyl cyclase through negative coupling of the G; /o- 
protein is well established. First observed in 1984 by Howlett and Fleming, adenylyl 
cyclase was inhibited by micromolar concentrations of A9-THC in N 18TG2 
neuroblastoma cells. This inhibition was shown to be PTX sensitive, suggesting G; /o- 
protein involvement (Howlett et al., 1986). Since, cannabinoid receptor inhibition of 
cyclic adenosine monophosphate (cAMP) production has been shown in a number of 
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cultured cell lines expressing CB, receptors and in transfected cell lines (Howlett, 1987; 
Vogel et al., 1993; Hirst and Lambert, 1995; Matsuda et al., 1990; Felder et al., 1993). 
The rank order of potency correlates well with CB I receptor binding affinity (Felder et 
al., 1992,1995) and efficacy is stereoselective (Pacheco et al., 1991,1993; Howlett et al., 
1988,1990; Matsuda et al., 1990). The selective CBS receptor antagonist, SR141716 
readily antagonised inhibition (Ho and Zhao, 1996; Bouaboula et al., 1995; Felder et al., 
1995). Further substantiation is demonstrated by cannabinoids showing greatest efficacy 
in inhibiting adenylyl cyclase in areas of the brain possessing the highest concentration of 
CBI receptors (Bidaut-Russell et al., 1990; Pacheco et al., 1991; Childers et al., 1994). 
An increase in cAMP through coupling of the CB, receptor to GS-proteins has been 
observed in CHO cells, cultured hippocampal neurones and striatal neurones in primary 
culture upon inhibition of G; io-proteins (Glass and Felder, 1997; Calandra et al., 1999; 
Hampson et al., 2000; Bonhaus et al., 1998). 
CB2 receptors expressed in CHO and COS cells have been shown to mediate cannabinoid 
inhibition of adenylyl cyclase activity through a PTX sensitive mechanism (Bayewitch et 
al., 1995; Slipetz et al., 1995). However in contrast to CB1 receptors, GS-protein 
stimulation of cAMP accumulation was not observed with G110-protein inhibition in CHO 
cells transfected with the CB2 receptor (Glass and Felder, 1997; Calandra et al., 1999). 
Nine isoforms of adenylyl cyclase have been identified (Patel et al., 2001). Coexpression 
of adenylyl cyclase isoforms 1,3,5,6, or 8 with either the CB1 or CB2 receptors in COS- 
7 monkey kidney cells, showed cannabinoid inhibition of cAMP accumulation, however 
coexpression of either cannabinoid receptor type with adenylyl cyclase isoforms 2,4, or 7 
resulted in stimulation of cAMP accumulation (Rhee et al., 1998). 
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1.3.5. Modulation of ion channel currents 
Direct CB, receptor modulation of voltage-gated calcium and inward rectifying 
potassium channels through G; /,, -protein ß'y-subunits is well established. Inhibition of A 
and D-type potassium channels have also been shown to occur through phosphorylation 
mediated by a cAMP-dependent protein kinase A (PKA) pathway. The CB2 receptor is 
believed not to modulate ion channel function, with the lack of interaction observed 
solely in artificial models including AtT-20 cells, which express Q-type calcium channels 
and inward rectifying potassium channels, transfected with CB2 receptors (Felder et al., 
1995) and Xenopus oocytes transfected with CB2 and GIRK1/4 (McAllister et al., 1999). 
1.3.5.1. Activation of calcium channels 
The voltage-gated calcium channel family comprises of ten members categorised into 5 
distinct classes; L-type, N-type, P/Q-type, R-type and T-type. L-type calcium currents 
typically require a strong depolarisation for activation, are long-lasting, and are blocked 
by the organic L-type calcium channel antagonists, including dihydropyridines, 
phenylalkylamines, and benzothiazepines. They are the main calcium currents recorded 
in muscle and endocrine cells, where they initiate contraction and secretion. L-type 
currents activating at lower voltages also exist predominantly in neurones and cardiac 
pacemaker cells. N-type, P/Q-type, and R-type calcium currents also require strong 
depolarisation for activation. They are blocked by specific polypeptide toxins from snail 
and spider venoms, and are expressed primarily in neurones, where they initiate 
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neurotransmission at most fast synapses and mediate calcium entry into cell bodies and 
dendrites. N-type channels are highly prevalent in peripheral nerve terminals and are 
largely responsible for synaptic transmission in autonomic and sensory neurones. T-type 
calcium currents are activated by weak depolarisation and are transient. They are 
expressed in a wide variety of cell types, where they are involved in shaping the action 
potential and controlling patterns of repetitive firing (Catterall et al., 2005; Dolphin, 
2006). Dunlap and Fischbach first observed G-protein inhibition of calcium currents in 
1981 in chick dorsal root ganglia neurones by noradrenaline and serotonin. The 
involvement of the Gp., -subunits as opposed to the Ga, -subunit was elucidated by both 
Ikeda in 1996 and Catterall and Hille in the same year through injection or 
overexpression of Gßß subunits (Ikeda, 1996; Herlitze et al., 1996). 
CB, receptor inhibition of N-type voltage-gated calcium channels (VGCC) in the 
NG 108-15 neuroblastoma-glioma cell line by WIN 55,212-2 and CP 55,940 was first 
shown by Mackie and Hille (1992) using whole-cell patch clamp. Inhibition was shown 
to be blocked by prior treatment with pertussis toxin, demonstrating mediation by G; /o- 
proteins but, as the response was not inhibited by the hydrolysis-resistant analogues of 
cAMP, dibutyryl-cAMP and 8-chlorophenylthio-cAMP, it was not dependent upon the 
cAMP pathway. The inactive enantiomer WIN 55,212-3 did not reduce calcium currents 
at high doses. As WIN 55,212-2 inhibition did not occur when applied in conjunction 
with w-Conotoxin GVIA, the N-type VGCC inhibitor, but did occur in the presence of 
the L-type VGCC inhibitor nitrendipine, the majority of cannabinoid inhibition was 
hypothesised to occur through blockade of N-type VGCC (Mackie and Hille, 1992; 
Caulfield and Brown, 1992). Sugiura et al. (1997) demonstrated an inhibition of the rise 
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in intracellular calcium caused by voltage-activated calcium channel opening with the use 
of fura-2 imaging in differentiated NG 108-15 cells. Anandamide inhibition of VGCC was 
demonstrated in N 18 neuroblastoma cells (Mackie et al., 1993; Felder et al., 1993). 
Inclusion of guanosine-5'-O-(2-thiodiphosphate), a nonhydrolyzable analogue of GDP, in 
the intracellular patch pipette solution blocked cannabinoid inhibition in adult rat superior 
cervical ganglion neurones transiently expressing rat brain CB 1 receptors, confirming a 
G-protein dependent mechanism (Pan et al., 1996), while SR141716 antagonism of WIN 
55,212-2 inhibition substantiated the role of the CB, receptor (Pan et al., 1998). WIN 
55,212-2 inhibition of glutamatergic transmission at corticostriatal synapses was 
demonstrated in brain slice preparations to be blocked by SR141716, PTX and co- 
Conotoxin GVIA, suggesting a CB1 receptor, G110-protein mediated inhibition of N-type 
VGCC (Huang et al., 2001). Guo and Ikeda (2004) demonstrated blockade of N-type 
VGCC by the endocannabinoids 2-AG, anandamide and 2-arachidonylglycerol in adult 
rat superior cervical ganglion neurones transiently expressing rat brain CB, receptors. 
Cannabinoids inhibited P/Q-type, but not L-type, calcium currents in AtT-20 pituitary 
cells transfected with CBI receptors. This response was blocked by pertussis toxin 
indicating G110-protein dependence (Mackie et al., 1995). Interestingly, CB1 receptor 
mediated inhibition P/Q-type calcium currents and inwardly rectified K+ currents in AtT- 
20 pituitary cells was shown to be inhibited by protein kinase C phosphorylation of the 
CB, receptor (Garcia et al., 1998). The N-methyl-D-aspartate (NMDA)-induced influx of 
calcium via P/Q-type calcium channels (blocked by T-agatoxin-IVa) was inhibited by 
cannabinoids as determined by fura-2 fluorescence in rat cortical and cerebellar brain 
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slices (Hampson et al., 1998). Inhibition was blocked by SR141716 and pertussis toxin, 
confirming the role of CB, receptors and G110 proteins. 
In cultured rat hippocampal neurones, WIN 55,212-2, CP 55,940 and anandamide 
reduced voltage-gated calcium currents through inhibition of N-type (c)-conotoxin- 
GVIA-sensitive) and P/Q-type ((o-conotoxin-MVIIC-sensitive) channels in an SR141716 
and PTX sensitive manner (Twitchell et al., 1997; Shen and Thayer, 1998). Intriguingly, 
at nanomolar doses of WIN 55,212-2 Shen and Thayer observed a saturating small degree 
of inhibition (17 ± 2% maximal inhibition), which was insensitive to the inactive 
stereoisomer WIN 55,212-3, and blocked by SR141716. However, higher doses 
(micromolar) induced further inhibition which was neither stereoselective nor 
antagonised by SR141716. This suggested CBS receptor mediated inhibition occurred at 
low agonist concentrations while inhibition at higher concentrations was dependent upon 
an alternate mechanism (Shen and Thayer, 1998). 
Inhibition of low-voltage activated T-type calcium channels was observed by Chemin et 
al. (2001) in cells expressing endogenous T-type channels (NG 108-15) and in 
recombinant cells (HEK 293, CHO and COS). Inhibition was not observed upon 
application of synthetic cannabinoids and the CB1 antagonist SR141716 did not prevent 
inhibition. A lack of modulation of anandamide inhibition through the application of G110- 
proteins, phospholipase pathways and phosphorylation pathways inhibitors coupled with 
inhibition of currents in excised inside-out patches in HEK 293 cells suggest direct 
inhibition the T-type channel. Acceleration of inactivation kinetics and a reduction in the 
degree of inhibition with lower holding potentials suggests inhibition is due to 
stabilization of the T-type channel in the inactive state (Chemin et al., 2001). 
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Arterial smooth muscle cells from the cat brain, found to express cDNA for the CB, 
receptor, displayed SR141716 and pertussis toxin sensitive L-type calcium current 
inhibition evoked by cannabinoid agonists (Gebremedhin et al., 1999). Inhibition of L- 
type calcium currents were observed in tiger salamander retinal bipolar cells and large 
single cone photoreceptors via an SR 141716 sensitive mechanism (Straiker et al., 1999; 
Straiker and Sullivan, 2003). Increased activation of L-type channels by WIN 55,212-2 
was observed in rod photoreceptors through the CB 1 receptor and the cAMP/PKA- 
signalling pathway (Straiker and Sullivan, 2003). 
1.3.5.2. Activation of potassium channels 
Potassium-selective channels form the largest and most diverse group of ion channels 
with, in humans, the voltage-gated potassium channel family comprising of over 75 genes 
including Cat+-activated, inwardly-rectifying (Kir) and two-pore families. The inwardly- 
rectifying potassium channel superfamily was first observed by Bernard Katz in 1949, 
and the G-protein regulated family observed with ligand-induced hyperpolarisation in the 
frog heart in 1955 (Del Castillo and Katz, 1955) although association with G-proteins 
was not elucidated until 1985 when work by Pfaffinger et al. reported the involvement of 
a pertussis toxin-sensitive G-protein in the muscarinic receptor induction of the KACh 
current in cardiac atrial myocytes (Pfaffnger et al., 1985). Modulation by the Gßß, subunit 
as opposed to the Ga subunit was first shown by Logothetis et al. (1987) through the 
application of subunits purified from bovine cerebral cortex to single-channel recordings 
from cardiac myocytes. Cannabinoid inhibition of GIRKs was first seen in 1995. Mackie 
et al., (1995) found WIN 55,212-2 and anandamide to activate inwardly rectifying 
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potassium currents in CB, receptor transfected murine tumour AtT-20 cells. Activation 
was shown to be concentration dependent and stereos elective, suggesting mediation via 
the CB, receptor. In Xenopus laevis oocytes transfected with GIRK I channels and CB, 
receptors, cannabinoid agonists increased the inwardly rectifying potassium current 
(Henry and Chavkin, 1995). Expression of CB1/GIRKI/GIRK4 and different G-protein 
subunits revealed mediation by the (3y-subunit (Ho et al., 1999). Transfection with 
GIRKI and GIRK4 channels containing a mutated aspartate residue, shown to be critical 
for G-protein coupling in cannabinoid receptors, decreased the efficacy of cannabinoids 
in Xenopus laevis oocytes (McAllister et al., 1999). HEK 293 cells transfected with the 
CB, receptor displayed WIN 55,212-2 and anandamide inhibition of endogenous 
inwardly rectifying K+ currents through an AM251 sensitive mechanism (Vasquez et al., 
2003). Robbe et al. (2001) demonstrated a SR141716 sensitive CP 55,940 and WIN 
55,212-2 inhibition of glutamatergic signalling in the mouse nucleus accumbens, which 
was blocked by Bat+, suggesting the involvement of inwardly rectifying K+ channels. 
This cannabinoid inhibition was not altered by forskolin, implying an independence from 
the cAMP/PKA pathway. A role for the PKC pathway in governing CB, receptor 
mediated modulation of GIRKs was suggested with the observation that stimulation of 
PKC would inhibit cannabinoid modulation in rat CB, receptor transfected AtT-20 cells 
(Garcia et al., 1998). Mutation of a single serine residue (S317) to an alanine in the CB1 
receptor blocked PKC inhibition suggesting G-protein activation to be dependent upon 
receptor phosphorylation. 
Deadwyler et al. (1995) demonstrated, with cultured hippocampal neurones, 
cannabinoids evoked concentration dependent increases in voltage-dependent A-type 
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outward potassium currents through a pertussis toxin sensitive mechanism. Inhibition of 
the cAMP/PKA pathway mimicked cannabinoid effects whilst 8-Br-cAMP and forskolin, 
activators of the pathway, produced opposing effects suggesting cannabinoids act to 
inhibit phosphorylation of the channel and so increase channel activity (Hampson et al., 
1995; Mu et al., 2000). Okadaic acid, an inhibitor of protein phosphatase 1 and 2A, 
blocked WIN 55,212-2 stimulation adding further weight to the hypothesis that increased 
channel activity occurs through a cannabinoid mediated transition into a 
dephosphorylated state (Mu et al., 2000). 
Hippocampal neurones have also demonstrated inhibition of D-type potassium currents 
with CB1 receptor stimulation (Mu et al., 1999). IP-20, an inhibitor of the cAMP/PKA 
pathway, inhibited D-type currents whilst 8-Br-cAMP increased currents suggesting 
different phosphorylation states govern activation of D-type compared to A-type currents 
(Mu et al., 1999). 
Cannabinoid inhibition of M-type potassium currents was observed in hippocampal CA 1 
neurones through an SR141716 sensitive mechanism (Schweitzer, 2000). 
1.3.5.3. Inhibition of sodium channels 
A cannabinoid-mediated inhibition of voltage-gated sodium currents has been reported. 
The mechanism of action has not been elucidated, although a CB1/CB2 receptor 
independent mechanism has been suggested. 
Inhibition of voltage-gated inward sodium currents in a mouse neuroblastoma cell line 
with exposure to A9-THC has been observed using the whole-cell voltage clamp 
technique. A change in reversal potential and the lack of inhibition of the outward sodium 
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current augmented the suggested modification of channel properties, however the 
principal metabolite of A9-THC, 11-OH-A9-tetrahydrocannabinol, depressed both inward 
and outward sodium currents and did not modify reversal potentials suggesting the 
presence of some degree of ligand specificity (Turkanis et al., 1991a; 1991b). The 
cannabinoid agonists anandamide, AM404 and WIN 55,212-2 and the antagonist AM251 
have been shown to inhibit veratridine, a voltage-gated sodium channel agonist, induced 
depolarisation and neurotransmitter release in a mouse brain synaptoneurosome 
preparation, as well as block tetrodotoxin (TTX)-sensitive sustained repetitive firing in 
cortical neurones (Nicholson et al., 2003; Liao et al., 2004). Kim et al. (2005) observed 
an anandamide mediated inhibition of both TTX-sensitive and TTX-resistant sodium 
currents in rat dorsal root ganglion neurones which was insensitive to the CB 1 and CB2 
receptor selective antagonists AM 251 and AM 630, and the TRPV 1 antagonist 
capsazepine. 
1.3.6. Regulation of Intracellular Ca 2+ Transients 
An increase of intracellular free calcium levels by cannabinoid agonists was first 
demonstrated by Sugiura and colleagues in undifferentiated N 18TG2 neuroblastoma and 
NG 108-15 neuroblastoma-glioma hybrid cells (Sugiura et al., 1996; 1997). HU-2 10, CP 
55,940, A9-THC, anandamide, and R-(+)-methanandamide behaved as partial agonists 
compared with 2-arachidonoylglycerol or 1(3)-arachidonoylglycerol (Sugiura et al., 
1996; 1997; 1999). The role of the CB, receptor was confirmed through SR 141716 
blockade (Sugiura et al., 1996; 1999). Pertussis toxin and a phospholipase C inhibitor 
blocked the 2-arachidonoylglycerol-evoked intracellular Ca 2+ increase, suggesting 
29 
intracellular Ca2+ release may be governed by inositol-1,4,5-triphosphate 
(IP3)/phospholipase Cß and G; io ßy subunits (Sugiura et al., 1996; 1997). Support for this 
mechanism came from the observed interaction between CB] receptors and 
phospholipase C in augmenting the Ca 2+ signal in response to NMDA receptor 
stimulation or K+ depolarisation in cultured cerebellar granule neurones (Netzeband et 
al., 1999). This response was antagonized by SR141716 and pertussis toxin, confirming 
an action through the CB, receptor, and by the phospholipase C inhibitor U-73122 and 
the inositol 1,4,5-trisphosphate (IP3) receptor antagonist xestospongin C, suggesting 
release from an IP3 receptor-sensitive Ca 2+ store (Netzeband et al., 1999). In primary 
cultures of striatal astrocytes, methanandamide depleted IP3-sensitive Ca 2+ stores, in a 
manner inhibited by PTX (Venance et al., 1997). However this mechanism may not be 
active in all cells, as release of IP3 or phosphatidic acid with exposure to anandamide or 
WIN 55,212 was not observed in CHO cells expressing recombinant CBS or CB2 
receptors (Felder et al., 1992; 1995). A A9-THC induced increase in intracellular calcium 
levels has been observed using fura-2 imaging in a hamster vas deferens smooth muscle 
cell line, DDT, MF-2 cells (Filipeanu et al., 1997). This increase in cytosolic calcium 
was shown to comprise of release from both thapsigargin sensitive intracellular stores and 
capacitative calcium entry, and from calcium influx through a mechanism independent of 
calcium release from thapsigargin sensitive stores (Filipeanu et al., 1997). Patch clamp 
recordings from the same cell line demonstrated a CB1 receptor activated Cat+-dependent 
K+ current that required both calcium influx and release from thapsigargin sensitive 
intracellular stores (Begg et al., 2001). The thapsigargin sensitive store-independent 
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calcium entry component was shown to be mediated by a signalling pathway involving 
arachadoinic actid, phospholipase A2 and MAP kinase (DeMuth et al., 2004). 
Anandamide has been demonstrated to evoke a transient increase in intracellular calcium 
levels through the activation of CB2 receptors in a calf pulmonary endothelial cell line. 
Blockade by a phospholipase C inhibitor and an IP3 receptor antagonist suggested release 
from IP3-sensitive Ca 2+ stores while calcium imaging observed depletion of the 
endoplasmic reticulum and a transient elevation of mitochondrial Ca" (Zoratti et al., 
2003). 
1.3.7. Regulation of Mitogen-Activated Protein Kinase and linking mechanisms 
1.3.7.1. Mitogen-Activated Protein Kinase 
The mitogen-activated protein kinase (MAPK) cascade is a family of serine/threonine 
kinases that are involved in the transduction of externally derived signals regulating cell 
growth, division, differentiation, and apoptosis, and are traditionally associated with the 
activation of the tyrosine kinase-linked receptor. The mammalian MAPK family consists 
of three subfamilies with multiple members; the extracellular signal-regulated kinases 
(ERK), the Jun amino-terminal kinases/stress-activated kinases (JUN/SAPK), and the 
p38 MAPKs. ERK has been shown to be involved in regulation of cell division and 
growth whilst JUN/SAPK and p38 MAPKs are activated by stress signals and 
inflammatory cytokines and are associated with cell death and immune disorders. Each 
cascade consists of a three member-protein kinase tandem in which the MAPK is 
activated by phosphorylation of both a tyr residue and a ser/thr residue by a dual MAPK 
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kinase (MEK), which in turn is activated by phosphorylation by a MAPK kinase kinase 
(MEKK). 
CB1 receptor mediated activation of the MAPK cascade was first observed in WI-38 
fibroblasts, where anandamide promoted tyr-phosphorylation of ERKs and increased 
MAPK activity, and in human CB, receptor transfected CHO cells and cultured astrocytic 
cells, which showed activation through a G; 1',, -protein dependent mechanism but did not 
involve the cAMP signal transduction pathway (Wartmann et al., 1995; Bouaboula et al., 
1995). 09-THC and HU-210 was shown to activate the ERK cascade using a SR141716 
and pertussis toxin sensitive mechanism in C6 glioma and primary astrocyte cultures 
(Sanchez et al., 1998; Guzman and Sanchez, 1999). A9-THC and methanandamide have 
been shown to promote Raf-1 translocation to the membrane of human prostate epithelial 
PC-3 cells and ERK kinase phosphorylation through CB, and CB2 receptors (Sanchez et 
al., 2003). 
Inhibition of ERK activity has been observed in primary mouse splenocytes, where 
cannabinol inhibited AP-1 transcription factor binding and upregulation of the ERK 
cascade, and in PC-12 cells transfected with the CB, receptor, where anandamide 
inhibited NGF-induced sustained ERK activation (Faubert and Kaminski, 2000; Rueda et 
al., 2002). This inhibition may result from the multiple roles possessed by cAMP in 
regulating Raf-1 isoforms, which regulate MEK activity. 
Activation of stress-regulated MAP kinases alongside JNK and MAPK p38 has been 
observed in CB, receptor transfected CHO cells with the application of A9-THC, 
anandamide and 2-AG (Cantley, 2002). Anandamide activated p38 kinase and JNK in 
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CB, receptor transfected ECV304 cells (Liu et al., 2000), whilst in hippocampal slices 
A9-THC and 2-AG activated p38 but not JNK (Derkinderen et al., 2001). 
Activation of the ERK cascade and increased expression and activation of the growth- 
related gene Krox-24 has been observed in CB2 receptor transfected CHO cells. 
Activation was blocked by pertussis toxin suggesting G110-protein dependence 
(Bouaboula et al., 1996). In primary murine splenocytes and EL4. IL-2 T cells enhanced 
ERK activity was observed with exposure to cannabinol and suboptimal activation, 
however ERK activity after optimal activation was reduced by cannabinol (Jan and 
Kaminski, 2001). The ERK cascade as well as the MAPK-target gene protein c-Fos 
showed anandamide-induced enhanced activation in haemopoietic cells (Valk et al., 
2000). An increased phosphorylation of two isoforms of ERK was observed in HL-60 
cells was observed with treatment with 2-AG (Derocq et al., 2000; Kobayashi et al., 
2001). 
Mechanisms for CB, receptor-mediated MAP kinase activation have not been fully 
elucidated. Several mechanisms have been proposed which include phosphatidylinositol- 
3-kinase (PI3K) activation, focal adhesion kinase (FAK) activation and ceramide 
synthesis. 
1.3.7.2. Signal Transduction via phosphatidylinositol-3-kinase 
Phosphatidylinositol-3-kinase (P13K) comprises of a family of kinases that phosphorylate 
the inositol ring of phosphatidylinositol and other phosphoinostides, producing 3'- 
phosphoinostides. These enhance migration to the membrane and activation of proteins 
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containing pleckstrin homology domains that include protein kinase B, which is involved 
in regulation of apoptosis. In addition, the P13K isoform IH has been shown to be directly 
regulated by Gßß, subunits suggesting the protein may possess independent kinase activity. 
In primary cultures of rat astrocytes the P13K inhibitors wortmannin and LY 294002 
were able to antagonize the A9-THC-induced stimulation of glucose oxidation to C02, 
phospholipid synthesis and glycogen synthesis (Sanchez et al., 1998b). Furthermore in 
human prostate epithelial PC-3 cells, CB, receptor activation induced a translocation of 
Raf-1 to the membrane and phosphorylation of ERK kinase, which was blocked by P13K 
inhibitors (Sanchez et al., 2003). Activation of protein kinase B was observed in CB, 
receptor transfected CHO cells and was inhibited by CB1 receptor antagonists and P13K 
inhibitors (Gomez del Pulgar et al., 2000). Protein kinase B activation was also observed 
in the human astrocytoma cell line U373 MG, which expresses the CB, receptor, but not 
in the human promyelocytic cell line HL-60, which expresses the CB2 receptor (Gomez 
del Pulgar et al., 2000). 
1.3.7.3. Signal Transduction via Focal Adhesion Kinase 
Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that localises to regions of 
membrane attached to the extracellular matrix, where it acts as part of the intergrin 
signalling pathway transmitting signals controlling cell motility from the membrane to 
the cytoplasm. FAK has been shown to activate a number of biochemical pathways 
including the MAPK cascade. 
Derkinderen et al. (1996) observed in hippocampal slices cannabinoid agonists 
stimulated 4, r-phosphorylation of focal adhesion kinase (FAK) (pp 125). This was 
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blocked by SR 141716A and pertussis toxin suggesting mediation by the CB, receptor and 
the G; /,, -protein. tyr-phosphorylation was reversed by 8-Br-cAMP and mimicked by 
protein kinase A inhibitors, signifying stimulation was mediated through the G10-protein 
inhibition of adenylyl cyclase (Derkinderen et al., 1996). 
1.3.7.4. Signal Transduction via ceramide synthesis 
Ceramide is a ubiquitous sphingolipid second messenger that plays an important role in 
the control of cell survival through the regulation of various targets, for example the Raf- 
1/MEK/ERK cascade. The CB1 cannabinoid receptor has been shown to increase 
generation of ceramide through upregulation of sphingomyelin hydrolysis and ceramide 
synthesis de novo. The coupling of receptors to sphingomyelinases is thought to involve 
different adaptor proteins. Coimmunoprecipitation experiments suggest the factor 
associated with neutral sphingomyelinase activation (FAN) may play a role in binding to 
the CB, receptor and a cytoplasmic nine-amino acid motif of the 55-kDa tumour necrosis 
factor (TNF) receptor, the so-called neutral sphingomyelinase-activating domain, thereby 
coupling the receptor to sphingomyelin breakdown (Sanchez et al., 2001; for review see 
Velasco et al., 2005). Prolonged (days) elevation of intracellular ceramide has been 
associated with events leading to decreased proliferation and apoptosis in glioma cells 
(see Guzman et al., 2001 for review). This response was initiated by chronic stimulation 
of both CB, and CB2 receptors on a susceptible C6 glioma strain and involved increased 
ceramide synthesis via serine palmitoyltransferase, Raf-1 activation, and MAPK (p42/44) 
activation. 
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1.3.8. Regulation of nitric oxide production 
Stimulation of nitric oxide (NO) production by cannabinoids has been observed in a 
number of tissues including human monocytes (Stefano et al., 1996), rat median 
eminence fragments (Prevot et al., 1998), human saphenous vein segments (Stefano et 
al., 1998), cultured human arterial endothelial cells (Fimiani et al., 1999; Mombouli et 
al., 1999), cultured human umbilical vein endothelial cells (Maccarrone et al., 2000), and 
in leech or muscle ganglia (Stefano et al., 1997a, b). These responses were blocked by 
SR141716, suggesting a role for the CB1 receptor and by 1VG-nitro-L-arginine methyl 
ester (L-NAME), confirming regulation of nitric oxide synthase (NOS) (Prevot et al., 
1998). Stimulation of Cat+-regulated constitutive NOS was implicated through the 
required presence of Ca 2+ in the perfusate in saphenous vein endothelia, and the presence 
of a transient increase in intracellular Ca 21- concentration preceding NO generation in 
cultured human arterial endothelial cells (Stefano et al., 1998; Fimiani et al., 1999; 
Mombouli et al., 1999). A cannabinoid induced, and SR141716 blocked, inhibition of 
lipopolysaccharide plus interferon-y activated inducible NOS has been observed in 
saphenous vein endothelium (Stefano et al., 1998), neonatal mouse astrocytes (Molina- 
Holgado et al., 1997) and in rat microglial cells (Cabral et al., 2001). Inducible NOS 
inhibition has been hypothesised to be due inhibition of cAMP production by NO 
generated as a result of stimulus of constitutive NOS (Stefano et al., 1998). 
In the macrophage line RAW 264.7, in which the CB2 receptor and not the CB, receptor 
is expressed, A9-THC markedly attenuated NO production and inducible NOS 
transcription evoked by lipopolysaccharide (Jeon et al., 1996). 
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1.4. Other targets for cannabinoids 
With the availability of CB, and CB2 receptor knockout mice, evidence is now emerging 
for the existence of additional cannabinoid receptors and for the action of cannabinoids 
on established non-cannabinoid receptors. 
1.4.1. The vanilloid type 1 (TRPV1) receptor 
The vanilloid type 1 receptor (TRPV 1) is a non-selective cation channel, activated not 
only by capsaicin but also by heat (>43°C), acid and various lipids (Caterina and Julius, 
2001). As member of the TRP family of ion channels, characterized by a six 
transmembrane domain integral membrane protein, it shares structural similarity with 
Shaker-related voltage-gated K+ channels (Caterina et al., 1997). It is expressed in a 
subset of unmyelinated nociceptive neurones in dorsal root and trigeminal ganglia 
(Caterina and Julius, 2001), in visceral afferents (Tominaga et al., 1998), in airway 
afferent nerve fibres (Kollarik and Undem, 2004), and in cells other than primary afferent 
neurones such as neurones intrinsic to the brain, epithelial cells of the bladder, and 
keratinocytes of the skin (Caterina, 2003). In situ hybridisation, immunohistochemistry 
and autoradiography have shown that several regions of the brain express small but 
possibly functionally active TRPV 1 receptor populations, including: thalamic and 
hypothalamic nuclei, the locus coeruleus, periaqueductal grey and cerebellum, cortical 
and limbic structures (namely the hippocampus), the caudate putamen and the pars 
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compacta of the substantia nigra (Mezey et al., 2000; Sanchez et al., 2001; Cortright et 
al., 2001; Roberts et al., 2004). 
The investigation into the action of anandamide at the TRPV 1 originated with the 
realisation of the chemical similarity held between it and the TRPV 1 agonist capsaicin 
(Di Marzo et al., 1998). Experimentation in cultured cells transfected with rat or human 
TRPV 1 demonstrated production by anandamide of membrane currents or increased 
intracellular calcium (Zygmunt et al., 1999; Smart et al., 2000; Ross et al., 2001). 
Anandamide was also shown to act on naturally expressed vanilloid receptors in neonatal 
rat dorsal root ganglia to produce membrane currents (Tognetto et al., 2001) and in rat or 
guinea-pig isolated arterial strips to produce release of calcitonin-gene-related peptide 
(CGRP) from perivascular sensory nerves and relaxation of precontracted tissues 
(Zygmunt et al., 1999). Anandamide was shown to have a low affinity for the receptor, 
with a Ki of -2 µM, similar to that of capsaicin (De Petrocellis et al., 2001b; Ross et al., 
2001), whilst analyses of efficacy in TRPV 1 currents in sensory neurones suggested 
anandamide to be a partial agonist (Zygmunt et al., 1999; Roberts et al., 2002). The 
endogenous cannabinoids 2-AG and palmitylethanolamide, and synthetic cannabinoids 
HU 210, WIN 55,212-2, CP 55,940 did not activate the TRPV1 channel (Zygmunt et al., 
1999). 
In the guinea-pig ileum myenteric plexus-longitudinal muscle preparation anandamide 
increased basal [3H]acetylcholine release and muscle tone in a capsazepine, a TRPV 1 
antagonist, sensitive manner but inhibited electrically evoked contractions in a 
capsazepine insensitive, SR 141716 sensitive manner, suggesting activity at both TRPV 1 
and CB, receptors (Mang et al., 2001). At high concentrations of anandamide, acting 
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through TRPV 1 channels, the inhibition of electrically-evoked contractions by the 
GABA-releasing agent ethylenediamine was increased (Begg et al., 2002). 
1.4.2. The GPR55 receptor 
GPR55 was first identified as an orphan GPCR in the brain (Sawzdargo et al., 1999). It 
consists of a 319 amino acid protein located on chromosome 6 in humans. Northern blot 
analysis of human tissues, found GPR55 mRNA in caudate and putamen, but not in 
frontal cortex, hippocampus, thalamus, pons, cerebellum, or liver. Analysis of rat tissues 
showed mRNA in spleen, fetal tissues, and intestine. In situ hybridisation studies found 
GPR55 mRNA in rat hippocampus, thalamus, and midbrain (Sawzdargo et al., 1999). 
Patent literature reported human GPR55 mRNA distribution with a rank order of adipose 
> testis > myometrium > adenoid = tonsil > spleen > ileum > brain = stomach (Brown 
and Wise, 2003). 
A second patent application argued that the GPR55 receptor might constitute an 
additional cannabinoid receptor (Drmota et al., 2004). It only shares 13.5% and 14.4% 
homology with CB, and CB2, respectively. However, when expressed in HEK 293 cells, 
GPR55 bound CP 55,940 and SR141716, but not WIN 55,212-2. GTPyS binding was 
stimulated by wide range of cannabinoids, including A9-THC, anandamide, 2-AG, 
virodhamine, and CP 55,940, all with EC50 values less than 20 nM. PEA, which 
possesses no binding affinity for CBI and CB2 receptors stimulated GTP-yS binding with 
an even lower nM potency. Pertussis toxin and cholera toxin did not alter GTP-yS binding, 
suggesting, that in transfected HEK 293 cells, the GPR55 receptor does not activate Gi/0 
or GS proteins. 
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1.4.3. Putative neuronal cannabinoid receptors 
1.4.3.1. A central TRPV1-like receptor 
Häjos et al. (2001) examined cannabinoid actions on excitatory postsynaptic transmission 
in the hippocampus of wild type (CB 1+/+) and CB, receptor knockout mice (CBI-/-). WIN 
55,212-2, CP 55,940 and capsaicin inhibited excitatory transmission with equal efficacy 
in both wild type and CBI-/- mice. Inhibition was blocked by capsazepine and SR 141716 
but not by the SR141716 analogue, AM251 (Häjos and Freund, 2002). The lack of 
expression of the CB2 receptor in the brain (Munro et al., 1993) and the inactivity of WIN 
55,212-2 and CP 55,940 at the TRPV 1 receptor (Zygmunt et al., 1999) rule out a possible 
role for these mechanisms in modulating response, suggesting inhibition occurs through 
activation of a novel receptor. To further complement this data, desensitisation of this 
receptor by capsaicin was not observed although the classical TRPV 1 receptor is readily 
desensitised by capsaicin (Häjos and Freund, 2002). 
1.4.3.2. A central anandamide and WIN 55,212-2 sensitive, non-CB1, non-CB2, non- 
TRPV1 G-protein coupled receptor 
Breivogel and colleagues examined whole brain membranes and homogenates prepared 
from CB1-1- C57BL/6 and CD1 mice, and found that anandamide and WIN 55,212-2 
stimulated 35S-GTPyS binding (Di Marzo et al., 2000; Breivogel et al., 2001). CP 55,940, 
HU 210 and A9-THC did not stimulate binding and SR141716 demonstrated only weak 
inhibition. Distribution of GTPyS binding only partially overlapped distribution of CB, 
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receptors, accentuating a putative role for a novel receptor. It is unlikely that these 
compounds were acting at the TRPV 1 receptor as WIN 55,212-2 shows low affinity and 
efficacy at the TRPV 1 receptor, and the TRPV 1 receptor is not coupled to G-proteins. 
Welch and colleagues found, when examining the analgesic efficacy of cannabinoids in 
spinal cord, the rank order potency of SR141716 in blocking analgesia produced by THC, 
anandamide, and CP 55,490 differed from that predicted for a CBS receptor-mediated 
response (Welch et al., 1998; Houser et al., 2000). To further complement this 
observation, differences in the analgesia synergistically produced by co-administration of 
morphine and THC compared with morphine and anandamide or CP 55,940, suggested 
the involvement of a novel receptor. 
1.4.3.3. An intestinal SR141716-sensitive, non-CB1, non-CB2, non-TRPV1 receptor 
Evidence for a novel SR141716-sensitive, non-CB1, non-CB2, non-TRPV1 receptor was 
obtained in nerve terminals of the myenteric plexus-longitudinal muscle preparation of 
the guinea-pig ileum (Mang et al., 2001). Anandamide, but not CP 55,940, evoked an 
inhibition of electrically evoked release of acetylcholine, similar to that produced by the 
CBI receptor, which was insensitive to capsazepine. Blockade by SR141716 was 
observed, but at a potency far below that observed for the CB1 receptor. 
1.4.4. Putative cardiovascular cannabinoid receptors 
Very strong evidence for novel cannabinoid receptors comes from a continuing series of 
investigations performed by several laboratories studying the effects of cannabinoids on 
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the vasculature. In summary, certain cannabinoids cause vasodilation and hypotension in 
the absence of CB I, CB2, or TRPV 1 receptor activation. The best-characterised response 
is in mesenteric vessels, (Järai et al., 1999) in which anandamide and methanandamide 
induce vasodilation, while the synthetic cannabinoids and THC do not, and are inhibited 
by high concentrations (>1 µM) of SR141716. Similar to studies performed by Häjos and 
colleagues, no blockade was produced by AM25 1. Vasodilation was sensitive to pertussis 
toxin, suggesting a mechanism dependent upon a GPCR and G10-proteins. The 
cannabidiol analogue, abnormal cannabidiol (abn-CBD), which is inactive at CB, and 
CB2 receptors, functioned as an agonist in some studies and was blocked by both 
cannabidiol and the synthetic cannabidiol analogue 0-1918 (Offertäler et al., 2003). 
Work by Begg et al. (2003) suggests this novel cannabinoid receptor is expressed by 
endothelial cells and that activation induces relaxation and vasodilation by the opening of 
potassium channels on vascular smooth muscle through a signalling pathway dependent 
upon the release of nitric oxide. 
1.4.5. Putative cannabinoid receptors on immune cells 
Palmitoylethanolamide (PEA, an analogue of anandamide that contains a 16: 0 fatty acid 
moiety instead of 20: 4 for AEA) has received considerable attention because of its anti- 
inflammatory properties (Lambert et al., 2002). However, it shows little affinity for both 
CB1 and CB2 receptors (Lambert et al., 1999; Griffin et al., 2000). PEA was found to 
reduce the pain associated with an inflammatory response through a mechanism blocked 
by SR 144528 (Calignano et al., 1998; Jaggar et al., 1998). It was hypothesised that PEA 
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might interact with a novel cannabinoid receptor that is antagonised by SR 144528 or that 
PEA might stimulate a novel cannabinoid receptor that couples to phospholipases C and 
diacylglycerol lipase, increases 2-AG production, and thus indirectly activating CB2 
receptors. 
1.4.6. A putative CB2-like cannabinoid receptor 
In the mouse abdominal stretch test and in the mouse formalin paw test both anandamide 
and PEA have been found to exhibit antinociceptive activity (Calignano et al., 1998; 
2001). The synergistic interaction of the two cannabinoids and the antagonism of 
anandamide by SR141716 but not SR144528, and PEA by SR144528 but not SR141716 
suggests activity through different mechanisms. The lack of observed activity of PEA at 
CB2 and TRPV 1 receptors suggested PEA may be acting through peripheral "CB2-like" 
receptors which are sensitive to SR144528, but not to SR141716 and capsazepine. 
1.4.7. Allosteric modulation of non-cannabinoid receptors 
1.4.7.1. Voltage-gated calcium channels 
Direct inhibition of voltage-gated calcium channels (VGCC) by cannabinoids has been 
suggested by a number of studies. The binding of dihydropyridine, phenylalkylamine and 
1,5-benzothiazapine class L-type VGCC antagonists was demonstrated to be inhibited by 
anandamide in T-tubule membrane vesicles from rabbit skeletal muscle fibres (Shiamsue 
et al., 1996). In similar tissue depolarisation-induced 
45Ca2+ fluxes mediated by the 
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activation of L-type VGCC were inhibited by anandamide and methanandamide through 
a mechanism insensitive to SR141716 or PTX treatments (Oz et al., 2000). The synthetic 
cannabinoids CP 55,940 and WIN 55,212-2, and A9-THC did not produce any inhibition. 
Arvanil, an anandamide-capsaicin hybrid compound with affinity for both CB, and 
TRPV 1 receptors, inhibited L-type VGCC in the NG 108-15 neuroblastoma cell line in 
the presence of a TRPV 1 antagonist and PTX (Lo et al., 2003). 
Chemin and colleagues (2000) reported anandamide inhibition of T-type VGCC 
expressed on neuroblastoma NG 108-15, CHO, COS, and HEK-293 cell lines and on 
Xenopus oocytes. Inhibition was not blocked by GDPI3S, an inhibitor of G-protein 
activity, nor by the inhibitors of PLA2, PLC and PLD in HEK-293 cells. CP 55,490 and 
WIN 55,212-2 were ineffective and SR141716 alone produced a strong inhibition. 
Methanandamide produced equipotent inhibition indicating that the metabolic products of 
anandamide hydrolysis were not responsible for inhibition (Chemin et al., 2000). 
Neuritogenesis of NG 108-15 cells, which is dependent upon T-type VGCC, was shown 
to be inhibited by anandamide and methanandamide in the presence of SR141716 
(Chemin et al., 2002). 
In superior cervical ganglion neurones that do not express endogenous cannabinoid 
receptors, N-type VGCC were inhibited by anandamide, but not by 2-AG. The effects 
were not blocked by SR141716 or PTX (Guo and Ikeda, 2004). 
In rat cultured dorsal root ganglion neurones, anandamide induced 33% inhibition of 
high-voltage activated Ca 2+ currents in a mechanism insensitive to SR141716 (Evans et 
al., 2004). In trigeminal sensory neurones, WIN 55,212-2 and the inactive enantiomer 
WIN 55,212-3 inhibited the release of K+-evoked calcitonin gene-related peptide 
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(CGRP), which is governed by the opening of Ca 2+ channels, with similar efficacy (Price 
et al., 2004). 
1.4.7.2. Voltage-gated sodium channels 
Nicholson and colleagues examined the susceptibility of voltage-sensitive sodium 
channels to cannabinoids in mouse cortical neurones and purified synaptosomes 
(Nicholson et al., 2003). Anandamide, AM 404 and WIN 55,212-2 inhibited veratridine- 
dependent depolarisation of synaptoneurosomes and release of L-glutamic acid and 
GABA. The binding of [3H]-batrachotoxinin A 20-alpha-benzoate to voltage-sensitive 
sodium channels was also inhibited by these cannabinoids. In addition, anandamide, AM 
404 and WIN 55,212-2 blocked TTX-sensitive sustained repetitive firing in cortical 
neurones without altering primary spikes. None of the inhibition observed was blocked 
by AM 251. Na+ currents in rat dorsal root ganglion neurones were inhibited by 
anandamide through increasing inactivation of channels. Inhibition was not reversed by 
AM 251, AM 630 or capsazepine, suggesting a mechanism involving either direct action 
at the channel or a novel receptor (Kim et al., 2005) 
1.4.7.3. Voltage-gated potassium channels 
First evidence for the direct interaction of cannabinoids with voltage-gated K+ channels 
was demonstrated on Shaker-related Kv 1.2 K+ channels expressed in the murine 
fibroblast B82 cell line (Poling et al., 1996). Both anandamide and A9-THC inhibited 
current with similar potency and showed no sensitivity to SR141716 and PTX. Internal 
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dialysis with anandamide in outside-out patch recordings demonstrated action upon the 
extracellular side of the membrane (Poling et al., 1996). 
In HEK 293 cells transfected with the large conductance Cat+-activated K+ (BK) channel 
and in mouse aortic myocytes anandamide and methanandamide activated BK current, 
when measured using whole cell patch clamp techniques (Sade et al., 2006). Potentiation 
of BK current was not modulated by AM251, modulators of GS and G110-protein activity 
(cholera and pertussis toxin) or by application of a selective CB2 agonist (JWH 133). 
Inhibition of calmodulin and MAP kinase dependent intracellular pathways also did not 
affect the potentiation. However, in excised inside-out patches methanandamide did not 
alter channel activity suggesting potentiation is mediated by intracellular factors (Sade et 
al., 2006). 
The delayed rectifier K+ current in rat arterial myocytes was inhibited by anandamide and 
methanandamide through a mechanism insensitive to SR141716. These 
endocannabinoids were only active when applied externally but not internally (Van den 
Bossche and Vanheel, 2000). 
The background (leak) K+ (TASK-1) channel, transfected in COS cells, showed full 
inhibition upon exposure to anandamide and methanandamide with an IC50 of 700 nM 
(Maingret et al., 2001). Blockade was not observed with pre-exposure to SR141716. 
High concentrations (10 µM) of WIN 55,212-2 and CP 55,940 produced inhibition, but 2- 
AG, HU2 10 and A9-THC did not produce any inhibition. Following these findings, 
anandamide-induced depolarisations or inward currents due to the inhibition of TASK-1 
channels have been demonstrated in several other preparations including turtle motor 
neurones (Perrier et al., 2003), rat carotid body chemoreceptors (Fearon et al., 2003), rat 
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mesenteric and pulmonary artery (Gardener et al., 2004), rabbit pulmonary artery smooth 
muscle cells (Gurney et al., 2003) and murine ventricular myocytes (Barbuti et al., 2002). 
Oliver et al. (2004) demonstrated, using giant inside-out patches, complete inhibition by 
anandamide of delayed rectifier K+ channels (Kv3.1) transfected in Xenopus oocytes. The 
rapidly inactivating A-type (Kv 1.1+ Kvß 1.1) channel, which is converted into a non- 
inactivating, delayed rectifier channel with exposure to phosphatidyl inositol 4,5 
bisphosphate (PIP2; for a review, see Hilgemann et al., 2001) was shown to revert back 
from the non-inactivating state to the rapidly inactivating state upon exposure to 
anandamide. Anandamide produced pronounced increase in inactivation in oriens- 
alveous interneurones of the hippocampus, which express mainly delayed rectifier K+ 
channels (Kv3 subunits). The lack of expression of CBI, CB2 and TRPV 1 receptors in 
Xenopus oocytes (Henry and Chavkin, 1995) suggest activation through a novel 
mechanism. 
1.4.7.4.5-HT3 receptors 
Cannabinoid inhibition of the 5-HT3 ligand-gated cation channel was first reported by 
Fan et al. (1995) in nodose ganglion neurones, in which anandamide, CP 55,940 and 
WIN 55,212-2 produced inhibition. Addition of Sp-cAMP, the nonhydrolyzable analogue 
of cAMP, and GDP-ß-S, the nonhydrolyzable analogue of GTP, did not affect inhibition 
by anandamide or WIN 55,212-12, suggesting that inhibition occurred through a G- 
protein independent mechanism. 
Anandamide acted as a noncompetitive antagonist at the 5-HT3 receptor transfected in 
Xenopus oocytes (Oz et al., 2002). SR141716 and PTX did not affect the inhibition, 
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neither did preincubation with 8-Br-cAMP, a membrane-permeable analog of cAMP, or 
Sp-cAMPS, a membrane-permeable protein kinase A activator. 
Barann et al. (2002) demonstrated, using excised outside-out patches from HEK 293 cells 
transfected with h5-HT3A receptor cDNA, A9-THC, WIN 55,212-2, anandamide, 
JWH-015 and CP 55,940 inhibited 5-HT induced currents. WIN 55,212-2-induced 
inhibition was not altered by SR141716 and WIN 55,212-3, and the CBS and CB-, 
receptor inactive enantiomer of WIN55,212-2, did not affect the 5-HT-induced current. 
The lack of specific binding of [3H]-SR141716 and [3H]-CP 55,940 to parental HEK 293 
cells suggested specific interaction with the 5HT3A receptor, whilst a lack of competition 
with the binding of [3H]-GR65630, a specific ligand for 5-HT3 receptors, by WIN 
55,212-2, CP 55,940, anandamide and SR141716 suggested noncompetitive antagonism 
(Barann et al., 2002). 
1.4.7.5. Nicotinic receptors 
The nicotinic acetylcholine receptor is a ligand-gated, cation specific channel, which 
plays an essential role in fast synaptic excitation throughout both the peripheral and 
central nervous systems. Nicotinic receptors can be divided into two main families, 
muscle and neuronal nAChR. Functional neuronal nicotinic receptors are composed of 
five subunits comprising of different combinations of a and ß subunits, of which there are 
eight a (a2- a9) and three 0 (02-04) subunits. The properties of different nicotinic 
receptor subtypes are determined by the specific subunit composition of the receptor 
(Colquhoun and Patrick, 1997; Luetje and Patrick, 1991). 
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Oz and colleagues have examined cannabinoid inhibition of nicotinic a7 homomeric 
receptors expressed in Xenopus oocytes. Initial work observed a noncompetitive 
inhibition of nicotine evoked currents which was shown to be GS and G; -o-protein 
independent through lack of modulation by PTX and 8-Br-cAMP (Oz et al., 2002). CB, 
and CB2 receptors, which are not expressed in Xenopus oocytes, were confirmed to not 
play a role through the lack of blockade of inhibition by SR141716 and SR144528. The 
lack of modulation of anandamide inhibition by the antagonists of anandamide 
metabolism, phenylmethylsulfonyl fluoride, superoxide dismutase, and indomethacin, or 
the anandamide transport inhibitor AM404, suggest inhibition is mediated by anandamide 
and not metabolites (Oz et al., 2003). Further work demonstrated a lack of modulation by 
the synthetic cannabinoids WIN 55,212-2 and CP 55,940 and plant derived A9-THC, 
whilst the anandamide metabolite arachadonic acid displayed inhibition, although with 
much lower potency than anandamide (Oz et al., 2004). The endocannabinoid 2-AG was 
shown to possess similar inhibitory properties as anandamide (Oz et al., 2004). Chimeric 
a7-nACh-5-HT3 receptors comprised of the amino-terminal domain of the a7-nACh 
receptor and the transmembrane and carboxyl-terminal domains of the 5-HT3 receptor 
suggested the site of action for anandamide is located in the transmembrane and 
carboxyl-terminal domains of the receptors (Oz et al., 2005). 
Using in vitro intracellular recording of myenteric S-type neurones, Lopez-Redondo et al. 
(1997) showed 46% and 37% inhibition of the fast e. p. s. ps amplitudes by WIN 55,212-2 
(100 nM) and CP 55,940 (100 nM) respectively. Blockade by the CB 1 receptor antagonist 
SR141716 occurred in only 38% of neurones demonstrating WIN 55,212-2 inhibition and 
Nv, hen tested on its own, SR 141716 (1 MM) caused a 40-50% reduction in the amplitude of 
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fast e. p. s. ps. The (-)enantiomer of WIN 55,212-2, WIN 55,212-3 was inactive at a 
concentration of 100 nM. lonophoretic application of acetylcholine induced 
depolarisations, which were inhibited by 63% by WIN 55,212-2 (100 nM) in 5 out of 11 
neurones tested. Reversal of WIN 55,212-2 inhibition by SRI 41716 (1 µM) was observed 
in 5 out of 12 neurones tested (Lopez-Redondo et al., 1997). 
Preliminary findings in disassociated myenteric neurones showed both CP 55,940 and 
anandamide induced full inhibition of nicotine evoked currents (DeMuth et al., 2004). 
Inhibition was not blocked by PTX and anandamide inhibition was not blocked by 
SR141716 (1 µM). When tested alone, SR141716 (300 nM) inhibited current. PEA, 
which does not show binding to CB 1 and CB2 receptors, inhibited current at 
concentrations of 1 µM (DeMuth et al., 2004). 
1.4.7.6. Glycine receptor 
The glycine receptor (GlyR) is an anionic member of the cys-loop superfamily of ligand- 
gated ion channels (Betz et al., 1999; Lester et al., 2004). Although best associated with 
mediating inhibitory neurotransmission in the spinal cord, recent work suggests it may 
also have other physiological roles in various brain regions including cerebral cortex, 
hippocampus, and ventral tegmental area (Legendre, 2001; Lynch, 2004). Local 
alignment of amino acid sequences of cannabinoid receptors and GlyR subunits revealed 
that GlyRs contain few fragments that display a high level of homology with regions 
suggested to be responsible for agonist binding within CB, and CB2 receptors 
(Mahmoudian, 1997; Tao et al., 1999; Shim et al., 2003). 
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Both endocannabinoids, 2-AG and anandamide, were observed in isolated hippocampal 
pyramidal neurones at physiological concentrations (0.2-2 µM) to strongly inhibit peak 
amplitudes of postsynaptic current and accelerate rise time and desensitization (Lozovaya 
et al., 2005). In contrast WIN 55,212-2 (1 µM) did not inhibit peak amplitude, but did 
accelerate rise time and desensitization. The effects of these cannabinoids were not 
inhibited by SR141716 or capsazepine and the G-protein inhibitor GDP3S. Seizure-like 
activity, induced by short bursts of high-frequency stimulation of inputs to the 
hippocampal CAI region, which are inhibited by G1yR antagonists, was reduced in the 
presence of anandamide (Lozovaya et al., 2005). 
A potentiation of GlyR currents by anandamide and A9-THC was reported in acutely 
isolated neurones from rat ventral tegmental area and in Xenopus oocytes expressing 
human homomeric (al) and heteromeric (a11) subunits of GlyR (Sun et al., 2005; 
Hejazi et al., 2006). Persistence of potentiation in the presence of SR141716 and the lack 
of expression of CB, and CB2 receptors in Xenopus oocytes suggest modulation through 
either direct effects or a novel receptor (Hejazi et al., 2006). 
1.4.7.7. tonotropic glutamate receptor 
lonotropic glutamate receptors consist of a family of ligand-gated on channels that 
include NMDA, kainate and AMPA receptors (Madden, 2002). 
Potentiation of NMDA-induced Ca 2+ flux by anandamide and methanandamide in the 
presence of SR141716 or PTX was reported in rat cortical, cerebellar, and hippocampal 
slices (Hampson et al., 1998). Anandamide, but not THC, also augmented NMDA- 
stimulated currents in Xenopus oocytes expressing NR I and NR2A genes and enhanced 
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the amplitudes of field potentials in hippocampal slices in a SR141716 insensitive 
manner (Hampson et al., 1998). 
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1.5. Project aims and objectives 
The overall aim of this study is to investigate the cannabinoid signalling mechanisms 
governing neurotransmission and their interaction with the mechanisms by which other 
neurologically active drugs act. 
Although the action of cannabinoid on gastric motility has been examined for some time, 
work has been restricted to examining the modulation of electrically evoked contractions. 
Chapter 2 examines the role of cannabinoids in modulating contractions evoked through a 
mechanism which bares greater similarity to that found in in vivo conditions, the 
activation of the nicotinic acetylcholine receptor, and investigates the mechanisms by 
which cannabinoids modulate the role of the nicotinic acetylcholine receptor through the 
use of the guinea-pig ileum myenteric plexus-longitudinal muscle (MPLM) organ bath 
preparation and using the whole-cell patch clamp technique to study nicotine evoked 
currents in primary cultures of guinea-pig ileum myenteric AH neurones. 
Furthermore, the mechanisms through which cannabinoids act in the gut have not been 
elucidated. To investigate this chapter 3 explores the effects of cannabinoid receptor 
ligands on Ca 2+ currents in primary cultures of guinea-pig ileum myenteric AH neurones. 
As opioids act through similar intracellular mechanisms to cannabinoids, chapter 4 
examines the interaction between cannabinoid and opioid receptor ligands on electrically 
evoked contractions of the MPLM preparation and opioid-withdrawal evoked 
contractions of the whole ileum, and their action in both primary myenteric and NG 108- 
15 neuronal cell cultures. 
Drugs of abuse, for example cocaine, influence neural activity within the mesolimbic 
reward pathway. Cannabinoids have been shown to also modulate the function of this 
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pathway, although the mechanism by which this occurs has not been fully elucidated. 
Chapter 5 discusses initial work examining the interaction between cannabinoid and 
dopaminergic systems within the ventral tegmental area of brain slices through the use of 
whole-cell blind patch clamping. 
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Chapter 2- The interaction between cannabinoids and the nACh receptor in the 
guinea-pig ileum myenteric plexus 
2. Chapter 2- The interaction between cannabinoids and the nACh receptor in the 
guinea-pig ileum myenteric plexus 
2.1. Introduction 
2.1.1. The guinea-pig ileum myenteric plexus 
Modulation of contractions induced by electrical stimulus of the guinea-pig myenteric 
plexus-longitudinal muscle preparation (MPLM) has been used for some time as a 
measure of cannabinoid activity through the CB, receptor (Pertwee et al., 1996). 
Contractions within the ileum are considered to be evoked through the stimulus of action 
potential firing within neurones, inducing the release of neurotransmitters, including 
acetylcholine, which act upon the longitudinal muscle to cause contraction. This 
preparation consists of a large variety of neurones responsible for conveying both 
excitatory and inhibitory stimulus. As a result of electrical stimulus, both inhibitory and 
excitatory neurotransmitters are released within the myenteric plexus and may interact 
independently with cannabinoids. 
2.1.1.1. Structure of the guinea-pig ileum 
The lumen of the guinea-pig ileum is lined by the mucosa and submucosal plexus, which 
are primarily responsible for secretion into the lumen. The submucosal plexus is 
surrounded by the circular muscle, myenteric plexus and longitudinal muscle, which 
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control gastric motility. Within the myenteric plexus, stimulus from the central nervous 
system, via parasympathetic and sympathetic neurones, and the lumen, via primary 
afferent neurones, is transferred to interneurones, before exciting longitudinal and 
circular muscle motor neurones and initiating peristalsis. 
2.1.1.2. Classification of myenteric neurones 
Enteric neurones are characterised on the basis of electrical, immunological and 
morphological properties. 
Characterisation on the basis of electrical properties is derived from intracellular studies 
by Nishi and North (1973) and Hirst et al. (1974). Neurones were separated into three 
main groups, type 1,2 and 3 by Nishi and North on the basis of their membrane 
properties and ability to fire action potentials in response to depolarising currents. Type 1 
cells demonstrate low membrane potential, high input resistance and an ability to fire 
action potentials initiated by depolarising currents. Type 2 cells exhibited a more 
negative membrane potential, lower input resistance and only fired action potentials at 
the start of a depolarising current pulse. Type 3 cells displayed similar passive properties 
to type 2 cells but did not fire action potentials even with very large depolarisations. 
Hurst divided neurones into AH neurones, which possess a long after-hyperpolarisation 
following action potentials, and S neurones demonstrating fast, cholinergic synaptic 
inputs and no after-hyperpolarisation. These classification schemes have since been 
amalgamated to form a scheme comprising of four classes; type 1/S, type 2/AH, type 3 
and type 4 (Bornstein et al., 1994). Type 3 neurones display S neuron-like excitatory 
input but are unable to generate action potentials in response to large depolarisations, and 
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type 4 neurones are unexcitable immediately after electrode impalement but develop type 
2/AH properties if impalement is maintained. 
Morphologically, enteric neurones were first categorised in a study published over 100 
years ago (Dogiel, 1899). Dogiel type I neurones possess a single axon and short lamellar 
dendrites. Dogiel type II cells have multiple long processes arising from a smooth cell 
body. Other morphological types of cells have been identified by Dogiel and in other 
studies but less consensus exists for the use of this extended classification. Within the 
guinea-pig small intestine Dogiel type II cells possess the electrical characteristics of AH 
neurones and Dogiel type I cells possess the electrical characteristics of S neurones 
(Brookes et al., 1995). Multiple-labelling immunohistochemistry has enabled 
classification on the basis of the presence of particular proteins or peptides either 
possessing a known or unknown functional role within the neurone (figure 2.1). For 
example, the presence of modulatory peptides, such as enkephalin, or proteins 
responsible for the production of neurotransmitters, such as choline acetyltransferase, 
within a nerve cell suggest these neurotransmitters are released and have action on other 
cells under some circumstances. Many of the markers used to distinguish enteric 
neurones have no known physiological role yet are very useful in classifying neurones. 
2.1.1.3. Primary afferent neurones 
By projecting in to the mucosa, primary afferent neurones transmit information regarding 
the nature and intensity of the stimulus to neurones within the myenteric and submucosal 
plexus. They all possess Dogiel type II morphology, comprising of multipolar cell bodies 
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Figure 2.1 Schematic diagram showing morphological classes of enteric neurones and 
axon projections. Letters on the neurones to aid identification are detailed in table 2.1. 
(Adapted from Brookes et al., 1995). 
Table 2.1 Summary of cell types listed in figure 2.1. 
Immunoreactivity Morphology 
a ChAT/Calret/ENK/NFP/SP Dogiel type I/S 
b ChAT/5-HT/NFP Dogiel type I/S 
c ChAT/SOM filamentous 
d ChAT/VIP/NPY/GRP Dogiel type I/S 
e VIP/NOS/NFP/NPY/GRP/AP Dogiel type I/S 
f ChAT/Calret/SP Dogiel type I/S 
g VIP/NOS/NPY/GABA Dogiel type I/S 
h ChAT/SP/ENK/NFP/GABA/ Dogiel type I/S 
AP 
VIP/NOS/ENK/GABA/AP Dogiel type I/S 
j VIP/NOS/NFP/GABA/AP Dogiel type I/S 
Function 
Ascending interneurone 
Descending interneurone 
Descending interneurone 
Descending interneurone 
Descending interneurone 
Excitatory motor neurone, 
longitudinal muscle 
Inhibitory motor neurone, 
longitudinal muscle 
Excitatory motor neurone, 
circular muscle 
Short inhibitory motor 
neurone, circular muscle 
Long inhibitory motor 
neurone, circular muscle 
k ChAT/Calb/SP/NMU Dogiel type II/AH Primary afferent neurone 
1 ChAT/Calb/SP/NMU Dogiel type II/AH Primary afferent neurone, 
long aboral axon 
Abbreviations: 5-HT: 5-hydroxytryptamine, AP: endogenous alkaline phosphatase, Calb: 
calbindin, Calret: calretinin, ChAT: choline acetyltransferase, ENK: enkephalin, GABA: 
gamma amino butyric acid, GRP: gastrin-releasing peptide, NFP: neurofilament protein 
triplet, NMU: neuromedin U, NOS: nitric oxide synthase, NPY: neuropeptide Y, SOM: 
somatostatin, SP: substance P (or related tachykinins), VIP: vasoactive intestinal 
polypeptide. 
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that were flat, thin and smooth on upper and lower surfaces, with neuritis projecting in 
two dimensions from the lateral margins (Hanani et al., 1998), and possessing the 
electrophysiological characteristics of AH cells. Work by Kunze et al. (1993) suggests 
primary afferent neurones may also act as interneurones within the myenteric plexus 
(figure 2.1). 
Electrical currents and channels of primary afferent neurones have been examined using 
intracellular recording from neurones in intact ganglia within dissected, in vitro intestinal 
preparations, patch electrode recordings from neurones in intact ganglia, and using patch 
electrode recordings from dissociated neurones in primary culture. The mode of 
recording is considered to influence both resting and active current states. Lower input 
resistances have been observed with the use of intracellular electrodes compared with 
patch electrodes, and very often neurones are hyperpolarised for a considerably long time 
after impalement suggesting some membrane damage may occur allowing Ca2+ influx 
and activation of Cat+-activated K+ channels (Hodgkiss and Lees, 1983; Baidan et al., 
1992; Rugiero et al., 2002). This is complemented by the observation that input 
resistance increases and resting membrane potential decreases after an hour of recording. 
Conversely, wash-out may occur during patch recordings in which Ca 2+ chelators (such 
as EGTA) may enter the cytoplasm of the neurones and inappropriately buffer 
intracellular Ca 2+ levels. Furthermore, characteristics may change with dissociation and 
primary culture. 
Under resting conditions, AH neurones possess a relatively higher membrane potential of 
approximately -60 mV and display a lower input resistance than S-type neurones. 
Rugiero et al. (2002; 2003) demonstrated that about 20% of the resting conductance was 
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controlled by a hyperpolarisation-activated cation current (IH). This highly sensitive 
inward rectifier carried both Na+ and K+ currents and was blocked by Cs+ but not Ba+. 
RT-PCR, single-cell profiling, and immunostaining experiments indicated that Na,, 1.9 
transcripts and subunits were expressed by myenteric sensory neurones. The A-type K+ 
current (IA) may contribute to resting membrane potential as Starodub and Wood (2000) 
demonstrated an overlap of steady-state activation and inactivation curves at a potential 
close to the resting membrane potential (-55 mV). Resting Ca 2+ conductance may also 
play a role due to the presence of Cat+-dependent K+ and cation channels. However, the 
large conductance Cat+-activated K+ channel (BK) and the intermediate conductance 
Cat+-activated K+ channel (IK) showed little activity at rest, and resting membrane 
potential showed little variation in the presence of the channel blockers charybdotoxin 
and iberiotoxin (Kunze et al., 2000; Vogalis et al., 2002). 
Unlike S-type neurones, AH neurones do not fire repetitively in the resting state and 
possess a long-duration hyperpolarising afterpotential that lasts for several seconds. The 
action potential in AH neurones possess a large amplitude of about 80-90 mV, when 
measured with intracellular electrodes, and a half-width of about 2.5 ms. This inward 
current comprises of a TTX-sensitive Na+ current and a high voltage-activated Ca2+ 
current. Work by Zholos et al. (2002) showed, using whole-cell patch clamp of cultured 
myenteric AH neurones derived from adult guinea pigs, a Na+ current activated between 
-50 and -40 mV that peaked at -10 mV. Steady-state inactivation curves were fit to the 
Boltzmann equation with a potential for half-inactivation of -55.6 mV and a slope factor 
of 6.4 mV. Inactivation was fast with the time constant ranging from a maximum of 161 
± 23 ms at -70 mV to a minimum of 2.3 ± 0.2 ms at -30 mV, and recovery was also rapid 
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with time constants ranging between 7.3 ± 1.1 ms and 21.5 ± 5.1 ms for -100 mV and -80 
mV respectively. Fit of the Boltzmann equation led authors to suggest the presence of 
only one type of Na+ channel, behaving in a "classical" voltage-gated TTX-sensitive fast 
channel manner. RT-PCR has shown expression of Na,, 1.2, Na1.3, Na,. 1.6, and Na, 1.7 
mRNA in small and large intestinal preparations from guinea-pigs (Bartoo et al., 2005). 
Immunohistochemical analysis demonstrated Na, 1.2 presence primarily within the soma 
of the majority of myenteric and submucosal neurones, although faint immunoreactivity 
was occasionally observed in ganglionic and internodal fibres. Nav 1.3 was observed in 
dendrites, soma, and axons in a small group of myenteric neurones, as well as in 
numerous myenteric internodal fibres; immunoreactivity was rarely observed in the 
submucosal plexus. The Na,, 1.6 channel was primarily observed in the initial axonal 
segment of colonic myenteric neurones and the Na,, 1.7 channel was observed in dorsal 
root ganglia neurones but not in the myenteric plexus of the small and large intestine 
(Bartoo et al., 2005). 
The high voltage-activated Ca 2+ current, which is activated during the action potential of 
AH-neurones, has been shown to be mainly mediated by N-type channels (Hirst et al., 
1974; Rugiero et al., 2002). Action potentials, elongated through the inhibition of the 
after-hyperpolarisation potassium current, were shown to be mostly inhibited by the 
highly specific N-type channel blockers w-conotoxin GVIA ((o-CgTX GVIA) and cw- 
CgTX MVIIA. The residual current was not blocked by further addition of the P/Q- and 
N-type channel blocker c)-CgTX MVIIC, and the P/Q-type channel specific blocker co- 
aga IVA had no effect on the prolonged action potential (Rugiero et al., 2002). Exposure 
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to the L-type calcium channel blockers nicardipine and nifedipine is also established not 
to affect action potentials (North and Tokimasa, 1987; Kunze et al., 1994). 
The long after-hyperpolarisation (AH) that characterises these neurones is the result of 
the voltage-dependent influx of calcium opening of calcium-dependent potassium 
channels that render the soma refractory to further stimuli (Nishi and North, 1973; Hirst 
et al. 1974). Unlike in S neurones in which action potentials are completely blocked by 
TTX, this influx of calcium enables action potentials to be evoked in the presence of 
TTX. 
2.1.1.4. Interneurones 
Interneurones are grouped into networks of orally projecting ascending neurones and 
aborally projecting descending neurones. 
Ascending interneurones consist entirely of a single class of neurones comprising of 
Dogiel type I neurones with S cell electrophysiological characteristics and express 
immunoreactivity for choline acetyltransferase and substance P (Brookes et al., 1997). 
Ascending interneurones account for 5% of all myenteric neurones (Costa et al., 1996) 
Descending interneurones consist of at least five different types of neurones showing 
among them immunoreactivity for somatostatin, 5-hydroxytryptamine, vasoactive 
intestinal polypeptide and acetylcholine. They possess Dogiel type I and II morphology 
and, in the presence of somatostatin, numerous filamentous dendrites and a single axon. 
Through the use of pharmacologically divided organ baths, the transmission between 
ascending interneurones, and between interneurones and excitatory motor neurones has 
been shown to be cholinergic, mediated through the nicotinic receptor. Descending 
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inhibition has been shown to be resistant to the nicotinic antagonist hexamethonium 
(Johnson et al., 1996). 
2.1.1.5. Motor Neurones 
Motor neurones are responsible for the transfer of stimulus from interneurones to the 
longitudinal and circular muscle and consist of excitatory and inhibitory Dogiel type I 
neurones (uniaxonal with flattened laminar dendrites) with S cell electrophysiological 
characteristics. 
Longitudinal muscle motor neurones make up approximately 24% of the neurones in the 
guinea-pig myenteric plexus (Brookes et al., 1992). Almost all are immunoreactive for 
choline transferase, while approximately 3% are immunoreactive for VIP and NOS 
(Williamson et al., 1996). This suggests, in the guinea-pig, neural stimulus is only 
capable of inducing contractions of the longitudinal muscle. Approximately half the 
neurones expressing choline transferase show immunoreactivity for tachykinins (Brookes 
et al., 1991 a). 
Circular muscle motor neurones make up approximately 17% of the neurones in the 
guinea-pig myenteric plexus of which approximately 70% display immunoreactivity for 
choline transferase (Brookes et al., 1991b). 
2.1.2. Role of cannabinoids within the myenteric plexus 
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Cannabinoid inhibition of electrically evoked contractions of guinea-pig MPLM through 
the inhibition of ACh release is well accepted. Cannabinoids are considered to act at CB I 
receptors within the ileum due to agonists possessing a similar order of potency as that 
found in other preparations, stereospecificity (Pertwee, 2001), blockade by the CB 1 
specific antagonist SR141716 (Pertwee et al., 1996), inhibition by antagonists of G; o- 
protein signal transduction (Coutts and Pertwee, 1998), and finally by proof of the 
presence of CB, receptors through binding studies (Lynn and Herkenham, 1994), 
immunohistochemistry (Coutts et al., 2002) and the detection of CB, receptor mRNA 
within the MPLM (Griffin et al., 1997). 
The CB, receptor is considered to be located upon excitatory motor neurones based on 
pharmacological and immunohistochemical evidence. Pharmacologicial evidence 
includes the cannabinoid induced reduction of release of acetylcholine from unstimulated 
and stimulated tissue (Coutts and Pertwee, 1997), the reduction in the amplitude of 
electrically evoked action potentials in S type myenteric neurones (Lopez-Redondo et al., 
1997), and the lack of inhibition of contractions evoked by exogenously applied ACh 
(Pertwee et al., 1996). Coutts et al. (2002) recently showed, using dual labelling 
immunohistochemisty, the CB, receptor was expressed in virtually all neurones 
expressing choline acetyltransferase, an enzyme responsible for the production of ACh 
and so present in the majority of excitatory motor neurones. The CB1 receptor was also 
shown to be present on cholinergic sensory and interneuronal neurones. 
2.1.2.1. CB, receptor independent cannabinoid activity 
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Inhibition in the myenteric plexus may not be mediated exclusively by the CB, receptor. 
Mang et al. (2001) observed a vanilloid and tachykinin receptor independent inhibition of 
electrically-evoked contractions by anandamide that was antagonised by SR141716 with 
a potency much lower than expected for a CB 1 receptor mediated effect. Thus KB values 
for the antagonism of anandamide by SR141716 for electrically-evoked acetylcholine 
release and contraction were 251 and 631 nM respectively, while corresponding values 
for the antagonism of CP 55,940, presumably acting on CBS receptors, were 4 and 1.3 
nM. 
Using intracellular recording of myenteric S-type neurones in vitro, Lopez-Redondo et al. 
(1997) showed blockade by the CB, receptor antagonist SR 141716 occurred in only a 
proportion of cells demonstrating cannabinoid inhibition. Reversal of WIN 55,212-2 
inhibition by SR141716 of fast e. p. s. ps was observed in only 38% of neurones and in 
only 42% of neurones when inhibiting ACh-induced depolarisations. When tested alone, 
they showed SR141716 induced a 40-50% reduction in the amplitude of fast e. p. s. ps. 
The SR 141716 evoked inhibition was also reported by DeMuth et al. (2004) who also 
observed a SR 141716-independent cannabinoid inhibition of currents in disassociated 
myenteric neurones. In addition they observed an inhibition by PEA, which does not 
show binding to CB, and CB2 receptors, and a lack of blockade of cannabinoid inhibition 
by pertussis toxin, which inhibits G; 10-proteins thus rendering both CB1 and CB2 receptors 
inactive (Sones et al., 2006). 
In the rat isolated gastric fundus, the CB-2 receptor antagonist AM 630 was shown to 
reverse anandamide but not WIN 55,212-2 inhibition of electrically-evoked contractions 
(Storr et al., 2002). 
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The presence of CB2 receptor mRNA was initially shown by Griffin et al. (1997) to be 
present in the whole ileum, but not in the myenteric plexus-longitudinal muscle segments, 
suggesting the presence solely in immune tissue. However, recent work by Duncan et al. 
(2005; 2006) suggests, using quantitative RT-PCR and immunohistochemistry, a low 
level presence of the CB2 receptor in the myenteric plexus-longitudinal muscle segments, 
which is increased with exposure to LPS. This proposition is reinforced by the 
observation of a CB2 mediated inhibition of gastrointestinal transit after LPS 
enhancement, which was not present in the absence of LPS (Mathison et al., 2004). 
Evaluation of the mode of action through the use of different antagonists suggest 
inhibition is mediated by the cyclooxygenase enzymes and is independent of inducible 
nitric oxide synthase (NOS) and platelet-activating factor. 
2.1.2.2. Mechanism of cannabinoid inhibition of acetylcholine release 
Although the exact mechanism through which cannabinoids act to inhibit acetylcholine 
release in the ileum has not been established, it is believed that they act in a similar 
manner to that established for the CB, receptor in the brain. Possible mechanisms include 
the inhibition of voltage-gated calcium channels which would reduce the rise in 
intracellular calcium that plays a role in the propagation of action potentials in AH 
neurones and is necessary for inducing exocytosis (Parsons et al., 1993), 
hyperpolarisation of the neurone through GIRK channel opening thereby inhibiting action 
potential generation, and a protein kinase A mediated inhibition of release through 
phosphorylation of exocytosis machinery (Evans and Morgan, 2003). 
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2.1.2.3. Endocannabinoids within the ileum 
The selective CBS antagonist SR141716 increases the amplitude of electrically evoked 
contractions when added alone to guinea-pig MPLM and circular smooth muscle 
preparations (Pertwee et al., 1996; Izzo et al., 1998), and increased electrically evoked 
ACh release from MPLM (Coutts and Pertwee, 1997). This suggests SR141716 may be 
inhibiting the action of released endocannabinoids on CB, receptors present on excitatory 
motor neurones. An alternative explanation is that SR141716 may be acting as an inverse 
agonist at the CB, receptor. This hypothesis assumes that the receptor exists in either a 
G110 protein bound precoupled state, the extent to which is reduced by SR141716, or the 
G-protein to which the CB, receptor binds to may change. The existence of an 
endocannabinoid system is backed by the presence of the endocannabinoid 2-AG, 
isolated by Mechoulam et al. (1995) in the canine gut, and the anandamide and 2-AG 
metabolising enzyme FAAH in the rat intestine (Ueda and Yamamoto, 2000). Although 
the FAAH inhibitor phenylmethylsulphonyl potentiates the inhibition of anandamide on 
electrically evoked contractions within the guinea-pig MPLM, it does not induce any 
inhibition when administered alone (Pertwee et al., 1995), suggesting the lack of 
existence of an endocannabinoid based signalling system. 
2.1.3. Role of acetylcholine within the myenteric plexus 
Within the enteric nervous system acetylcholine plays an important role in the 
transmission of stimulus between neurones, and between neurones and muscle. Work 
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carried out by Dale in 1914 distinguished two types of activity, from which the concept 
of muscarinic and nicotinic receptors evolved. 
2.1.3.1. Nicotinic receptors 
The nicotinic acetylcholine receptor is a ligand-gated, cation specific channel, which 
plays an essential role in fast synaptic excitation throughout both the peripheral and 
central nervous systems. Nicotinic receptors can be divided into two main families, 
muscle and neuronal nAChR. Functional neuronal nicotinic receptors are composed of 
five subunits comprising of different combinations of a and ß subunits, of which there are 
eight a ((x2- a9) and three ß (ß2-ß4) subunits. The properties of different nicotinic 
receptor subtypes are determined by the specific subunit composition of the receptor 
(Colquhoun and Patrick, 1997; Luetje and Patrick, 1991). 
Within the guinea-pig enteric nervous system, acetylcholine at nicotinic acetylcholine 
receptors predominantly mediates interneuronal excitatory transmission (Galligan and 
North, 2004). S-type motorneurones in the myenteric plexus, which innervate and induce 
contraction in smooth muscle, have been demonstrated to receive fast nicotinic excitatory 
input mediated via nAChRs located on somatodendritic regions of the neurone (Bornstein 
et al., 1994; Nishi and North, 1973; Hirst et al., 1974; Galligan and Bertrand, 1994). 
nAChRs have also been demonstrated to be present at the nerve endings of longitudinal 
muscle motor neurones (Galligan, 1999). Blockade of axonal conductance through the 
use of tetrodotoxin allowed the segregation of somatodendritic nicotinic receptors and 
those at the neuromuscular junction of motor neurones controlling the release of 
neurokinins. As the majority of neurokinin releasing neurones display immunoreactivity 
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for choline transferase (Brookes et al., 1991 a), this suggests acetylcholine release is also 
mediated by nicotinic receptors present at the neuromuscular junction. Further evidence 
for the existence of nicotine receptors at myenteric nerve endings was observed in an 
early neurochemical study (White, 1982) in which nicotine was shown to induce the 
release of ATP from synaptosomes derived from the guinea-pig ileum myenteric plexus 
(figure 2.2). 
Immunohistochemical and pharmacological studies have revealed, in myenteric neurones 
maintained in cell culture, predominant expression of a3, a5, ß2 and ß4 nicotinic receptor 
subunits (Zhou et al., 2002; Galligan and North, 2004). However, assembly of the 
subunits has not been established and so receptors may exist as either homologous 
populations or as multiple receptors of differing subunit composition. The presence of a7 
nicotinic subunits is debatable. Zhou et al., (2002) observed only a small proportion of 
cultured myenteric neurones showed staining on application of an a7 subunit selective 
antibody and, whilst under whole-cell patch-clamp, no inhibition of nicotinic receptors 
was observed with the a7 subunit specific blockers a-bungarotoxin and a- 
methyllycaconitine. 
The nicotinic receptor has been shown to possess a number of allosteric binding sites 
through which endogenous non-competitive inhibitors, such as fatty acids including 
arachidonic acid a metabolite of anandamide, can act (Arias, 1998). Arachadonic acid has 
been shown to inhibit Torpedo and chick a7 nicotinic receptors, expressed in oocytes, 
possibly through a direct blocking effect on Cat+-modulatory sites on the nicotinic 
receptor (Nishizaki et al., 1998). Unpublished studies investigating cannabinoid activity 
upon other nicotinic receptors have shown inhibition of human a4ß2 nicotinic receptors 
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dpR 
expressed in SH-EP 1 cells by anandamide and a lack of inhibition by anandamide in 
HEK-293 cells expressing the al(31cy6 subunits of mouse muscle nicotinic acetylcholine 
receptors (quoted by Oz, 2006). 
2.1.3.2. Muscarinic receptors 
The muscarinic receptor family comprises of five distinct G-protein coupled receptors 
entitled MI to M5. Within guinea-pig smooth muscle the M2 and M3 receptors are 
expressed at a ratio of approximately 4: 1 (Eglen, 2001). Exogenous agonists are 
considered to act, through the pharmacological selectivity of a collection of ligands, 
mainly through the M3 receptor, triggering phosphoinositide hydrolysis through Gq- 
protein activating, Ca 2+ mobilisation and a direct contractile response (Ehlert, 2003). 
Endogenous acetylcholine release has been show using pertussis toxin and M2 receptor 
selective antagonists to stimulate the M2 receptor, a G; /,, -protein coupled receptor (Sawyer 
cl al., 2000; Murthy and Makhlouf, 1997; Bolton and Zholos, 1997). Activation has been 
shown to decrease potassium channel opening times activated by sympathetic agonists, so 
attenuating relaxation (Kotlikoff et al., 1999), and activate a non-selective cationic 
current (Bolton and Zholos, 1997). This current has been postulated to depolarise 
membrane potential to such an extent as to evoke opening of L-type Ca2+ channels and so 
inducing contraction (Eglen, 2001). 
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2.2. Method 
2.2.1. Guinea-pig 
(MPLM) 
ileum myenteric plexus-longitudinal muscle preparation 
2.2.1.1. Preparation of the MPLM 
Male Dunkin Hartley or Heston-2 guinea-pigs (450-550 g; Harlan, UK) were killed by 
cervical dislocation. The abdomen was exposed and the ileum removed by gentle pulling 
whilst removing the mesentery at the same time. Tissues were immersed in Krebs 
solution (see solutions for composition) maintained at room temperature and supplied 
with 95% 02 and 5% CO2. A5 cm section of ileum was stretched onto a7 mm diameter 
glass pipette and the mesentery was lined up along the length of the pipette. The MPLM 
was dissected from the ileum by stroking tangentially away from it with a small cotton 
wool bud soaked in Krebs solution. This was repeated until a strip of longitudinal muscle, 
along with the myenteric plexus was separated from the underlying mucosal layers. The 
ileum and MPLM were kept moist with Krebs solution throughout the entire procedure. 
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2.2.1.2. Measurement of contraction 
4 cm strips of MPLM were mounted in 30 ml organ baths, connected to an isometric 
transducer, and placed under an initial tension of 0.5 g (figure 2.3). Tissues were 
immersed in Krebs solution maintained at 37°C and supplied with 95% 02 and 5% CO2. 
2.2.1.3. Experimental design 
Nicotinic stimulus of contraction: Contractions were induced by nicotine, administered at 
30 min intervals and washed twice upon achievement of maximum contraction to allow 
removal of nicotine and recovery from desensitisation. Before the addition of any 
subsequent compounds, tissue was allowed an hour to stabilise and three nicotine induced 
contractions were performed and averaged to establish a control response. Due to the 
adhesive nature of cannabinoids (Pertwee et al., 1992) and the required washing upon 
addition of nicotine to recover from desensitisation, the response to only a single 
concentration of nicotine (100 µM) in the presence of a single concentration of 
cannabinoid was obtained per tissue. Upon establishment, cannabinoid agonists were 
applied 20 minutes prior to nicotine. To observe nerve terminal stimulation TTX was 
added after each wash to maintain a constant bath concentration. In competition studies 
the CBS receptor antagonist SR141716 was applied 30 minutes prior to and the 
competitive nicotinic receptor antagonist d-tubocurarine was applied 20 minutes prior to 
the addition of any subsequent compounds. 
Electrical stimulus of contraction: Electrical field stimulation (110% of the voltage which 
produced a maximal contraction, 0.5 ms duration and 0.1 Hz frequency), applied through 
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two parallel platinum plate electrodes fixed at either side of the longitudinal strip, was 
generated using a Multistim D330 System stimulator (Digitimer, U. K. ). Contractions of 
the MPLM were recorded by Dynamometer OF 1 isometric transducers (Pioden Controls, 
U. K. ), connected via a Conditioning Unit (Techman, U. K. ) to a MX216 Chart Recorder 
(Lectromed, U. K. ). The MPLM was electrically stimulated for the entire duration of the 
experiment, and it was noted that the size of contractions increased for up to three hours, 
after which they were stable. Hence, no drugs were added until three hours had elapsed. 
2.2.1.4. Cleaning of the organ bath 
Cannabinoids have been shown to stick to glassware (Pertwee et al. 1992). At the end of 
every experiment involving cannabinoids the organ baths and electrodes were washed 
with dilute hydrochloric acid, absolute ethanol, and copious amounts of distilled water to 
ensure the complete removal of any residual cannabinoids. 
2.2.1.5. Analysis of data 
Electrical stimulus: Each value is expressed as the mean ± standard error of mean 
(S. E. M. ) of experiments on tissues obtained from at least four individual animals. The 
effects of cannabinoid receptor ligands are expressed as percentage inhibition of 
contraction. This was calculated by comparing the amplitude of the electrically evoked 
contraction immediately prior to adding any compound to the amplitude of the 
contraction at the maximal effect of the compound. 
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Nicotinic stimulus: Each value is expressed as the mean ± S. E. M. of experiments on 
tissues obtained from at least four individual animals. The effects of cannabinoid ligands 
are expressed as percentage inhibition of contraction. This was calculated by comparing 
the mean amplitude of the three nicotine evoked contraction prior to adding any 
compound to the amplitude of the nicotine-evoked contraction after addition of the 
compound. 
GraphPAD Prism 4 statistical software (GraphPAD Software Inc, San Diego, CA., 
U. S. A. ) was used to fit the concentration-response results to a sigmoidal function and 
generate 95% confidence intervals using the equation: 
I= 
'rnax 
I+1O'1ýIi 11-19týfLý) :' Hill slope 
Significant difference between mean values were calculated using Student's unpaired t- 
test, aP value of < 0.05 being taken as significant. Mean values of multiple data sets 
were compared using one way-ANOVA followed by either Dunnetts or Newman-Keuls 
multiple comparison post hoc tests. 
2.2.2. Guinea-pig ileum preparation 
2.2.2.1. Preparation of whole ileum 
As described in section 2.2.1, male Dunkin Hartley or Heston-2 guinea-pigs (450-550 g; 
Harlan, UK) were killed by cervical dislocation and ileum removed. Tissues were 
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immersed in Krebs solution (see solutions for composition) maintained at room 
temperature and supplied with 95% 02 and 5% CO2. 
2.2.2.2. Measurement of contraction 
4 cm strips of whole ileum were mounted in 30 ml organ baths, connected to an isometric 
transducer, and placed under an initial tension of 1g (figure 2.3). Tissues were immersed 
in Krebs solution maintained at 37°C and supplied with 95% 02 and 5% CO2. 
2.2.2.3. Experimental design 
Experiments were performed in accordance with details presented in section 2.2.1.3 and 
analysed in a similar manner. 
2.2.3. Disassociated myenteric neurone patch-clamp preparation 
2.2.3.1. Preparation of cultured myenteric neurones 
A4 cm strip of MPLM was prepared as in section 2.2.1 and cut into 0.5 cm sections. 
These sections were transferred into a sterile centrifuge tube containing 3 ml of papain 
solution and placed in a water bath for 10 minutes at 37°C. The papain solution was 
removed and replaced with 3 ml of collagenase solution, and returned to the water bath 
for 10 minutes. The tissue was titurated with a sterile, flame-polished tip pasteur pipette 
and returned to the water bath for a further 10 minutes. The tituration process was 
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repeated a further two times. Cells were centrifuged for 5 minutes at 600 rpm, 
supernatant discarded and resuspended in feeding medium. The centrifugation process 
was repeated and the media replaced. The suspension was transferred to P-60 dishes 
(Falcon, UK) containing collagen-coated glass slides and incubated at 37°C in an 
atmosphere of 95% CO2/5% 02. Feeding media was refreshed every three days. 
2.2.3.2. Whole cell recordings 
Single-cell patch clamping, first described by Neher and Sakmann (1976), comprises of a 
tight seal formed by suction between a blunt, low-resistance microelectrode and the 
surface of the cell membrane. These `Gigaseals' form very high resistance, mechanically 
stable seals, allowing the patch of membrane within the tip of the pipette to be ruptured to 
form an electrical continuity between the conductive media within the pipette and the 
interior of the cell. 
2.2.3.3. Micropipette preparation 
Glass pipettes were pulled (P80 /PC; Stutter Instruments Co., USA) using borosilicate 
glass capillaries (GC 150TF-10; Harvard Apparatus, UK). They were heat polished (MF- 
830; Narishige, Japan) and backfilled with intracellular solution (ICS; see solutions for 
composition) to give a typical resistance of 3-5 M. 
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2.2.3.4. Whole-cell patch-clamp recordings 
Glass slides with attached cells were placed upon the glass bottom of a 150 µl 
superfusion chamber (RC-26; Warner Instruments Inc., USA) and superfused under a 
gravity driven system with a physiological salt solution (ECS; extracellular salt solution; 
see solutions for composition) at a flow rate of 1.2 ml/min (see figure 2.4). Solutions 
were removed through a metal syringe needle located towards the rear of the bath using a 
vacuum fed mechanism. The superfusion chamber was maintained at room temperature. 
Cells were visualised using an inverted microscope (TMS; Nikon, Japan) under high 
power. Filled pipettes were mounted in the pipette holder, with the pipette filling fluid 
connected to the headstage input by a chloride coated silver wire. The pipette holder was 
attached to a tube allowing control over the pressure within the pipette. The headstage 
(CV-7A; Axon Instruments, USA) was mounted on a course manipulator (MC35A; 
Narishige, Japan) and fine movements controlled by using a hydraulic manipulator 
(MHW-3; Narishige, Japan). Cell voltage was amplified and filtered at 2 kHz (-3 dB) 
using a Multiclamp 700A (Axon Instruments, USA), and visualised and recorded using a 
digital interface (Digidata 1322A; Axon Instruments, USA) connected to a personal 
computer running pCLAMP 8 (Axon Instruments, USA). 
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2.2.3.5. Gigaseal formation 
Prior to commencing, a positive pressure was applied to the pipette to prevent 
contaminants blocking the tip. Blockade of the pipette tip and the approach towards 
neurones was monitored by observing resistance changes through the application of a 
square electrical pulse (5 mV, 5 ms, 100 Hz). Contact with the bathing fluid completes an 
electrical circuit allowing the pipette resistance to be recorded (figure 2.5). The pipette 
was visually positioned over the neurone and gently lowered. Contact with the neurone 
caused an increase in resistance. At this point positive pressure was removed and gentle 
continuous suction applied to form the gigaseal. Suction and electrical pulses were 
applied to disrupt the membrane within the gigaseal and achieve an electrical connection 
between the pipette and the interior of the cell. Measurement of, and compensation for, 
resting leak current and cell capacitance through adjustment of current flow was 
performed at this stage. 
2.2.3.6. Patch clamp techniques: voltage clamp 
Upon generation of a whole-cell patch clamp, voltage clamp techniques were 
implemented. The voltage clamp technique comprises of maintaining a constant 
membrane potential within a cell through a negative feedback mechanism whilst 
examining electrical changes in the membrane through the measurement of changes in 
current required to maintain membrane potential. As a result the injection of electrical 
current is recorded to produce a result proportional, but opposite in polarity, to the 
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Figure 2.5 Current responses during gigaseal formation. No current flow is present when 
pipette is out of the bathing solution (A). Upon contact with the bathing solution the 
circuit completes and a current flow is observed when a5 mV voltage step is placed upon 
the pipette (B). Neuronal contact results in an increase in pipette resistance, resulting in a 
decreased current flow (C), signifying the point in which suction is applied to the pipette, 
resulting in gigaseal formation (D). Further suction results in disruption of the cell 
membrane allowing whole cell recording (E). Spikes at the beginning and end of the 
voltage step describe the capacitive transient (RC current; figure adapted from Molleman, 
? 003). 
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membrane current of the patched cell. The voltage clamp technique allows control over 
the opening of ion channels. Whilst examining changes in current flow induced by 
controlled changes in membrane potential, positive/negative (P/N) leak subtraction was 
performed. This technique involves the removal of passive leak components (comprising 
of capacitive transients and leak and membrane resistances) through the use of a voltage 
pulse, which evokes a current response with no active components. As this passive 
response is proportional to the size of the voltage pulse, it can be scaled and subtracted 
from responses containing both active and passive components to leave a `clean' trace. 
The response to four sub pulses of 5 mV in the opposite direction was applied prior to, 
and scaled and subtracted from, the response obtained from each voltage increment. 
2.2.3.7. Experimental design 
Cultures were left to grow for at least three days prior to patch-clamping. Neurones were 
selected for study through the presence of Dogiel type II morphology (multiple long 
processes arising from a smooth cell body) and AH neural electrochemical properties 
(action potential after-hyperpolarisation). Neurones were maintained in ECS and the 
patch pipette filled with ICS unless otherwise stated. Experiments were performed at 
room temperature with cells under voltage clamp at a holding potential of -70 mV. All 
drugs were administered in ECS, superfused at 1.2 ml/min. 
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2.2.3.8. Analysis of data 
Data are transformed to account for cell size by dividing by cell capacitance and are 
expressed as either the mean + S. E. M. of experiments. Significant difference between 
mean values were calculated using Student's unpaired t-test, aP value of < 0.05 being 
taken as significant. Mean values of multiple data sets were compared using own-way 
ANOVA followed by either Dunnetts or Newman-Keuls multiple comparison post hoc 
tests 
2.2.4. Drugs and solutions 
2.2.4.1. Solutions 
The Krebs solution contained (in mM): NaCl 118.3, KC1 4.7, MgSO4 1.2, KH2PO4 1.2, 
NaHCO3 25, glucose 11.1, CaCl2 2.5. Papain Solution (warmed to 37°C before use, pH 
balanced with 0.15 M NaHCO3) comprised of Hank's Balanced Salt Solution (HBSS) 
containing 0.01 ml/ml papain and 0.4 mg/ml L-cysteine. Collagenase Solution (warmed 
to 37°C before use) comprised of HBSS containing 1 mg/ml collagenase Type 1 and 3.1 
mg/ml dipase. Feeding Medium consisted of Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 5% FBS, 1 mM L-glutamine, 8.3 mM glucose, 5 µM 
cytosine ß-D-arabinofuranoside hydrochloride, 50 µM (+)-5-fluorodeoxyuridine, 2.5 µM 
uridine, 150 units/ml penicillin and 150 µg/ml streptomycin. ECS comprised of (mM): 
NaCl 125, KC1 6, MgCl, 2.5, NaH2PO4 1.2, Hepes 10, glucose 11, sucrose 67, CaC12 1.2, 
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pH 7.35. Intracellular solution (ICS) contained (mM): NaCl 5, KCl 142, MgCl2 1.2, 
Hepes 20, glucose 11, K-ATP 5, Na-GTP 0.1, pH 7.2. 
2.2.4.2. Drugs 
CP 55,940 ((-)-cis-3-[2- hydroxy-4-(1,1-dimethylheptyl) phenyl]-trans-4-(3- 
hydroxypropyl) cyclohexanol) was a kind gift from Pfizer U. K. SRI 41716 (N-(piperidin- 
1-yl)-5-(4-chlorophenyl)-1-(2,4, -di-chlorophenyl)-4-methyl-1 H-pyrazole-3-carboxamide 
hydrochloride) was a kind gift from Sanofi Recherche, France. All cannabinoid drugs 
were dissolved in ethanol, shielded from light and kept at -20°C. Atropine sulphate, 
carbachol, acetylcholine chloride and nicotine were obtained from Sigma. Tetrodotoxin 
citrate, WIN 55,212-2 and WIN 55,212-3 were obtained from Tocris Cookson, UK. 
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2.3. Results 
2.3.1. Effects of nicotine on myenteric plexus-longitudinal muscle 
Nicotine evoked rapidly developing contractions of the guinea-pig myenteric plexus- 
longitudinal muscle. The peak amplitude of contraction was concentration dependent 
(EC50 = 22.1 µM, 95% confidence limits of 9.67 to 50.7 µM, n=5, figure 2.6a). A 
maximum peak amplitude of contraction of 2.52 + 0.20 g (n = 10) was evoked by 1 mM 
nicotine. Contractions were fast in onset and transient, only lasting for a short duration in 
the continued presence of nicotine. 
Application of 100 µM nicotine evoked a contraction with peak amplitude of 2.22 ± 0.12 
g (n = 29). Repeat application of 100 µM nicotine, immediately after washing with 
Krebs, evoked a contraction with a smaller peak amplitude than previously evoked (0.52 
+ 0.23, n= 3) suggesting some degree of desensitisation occurs. However, rest for 30 
minutes after washing enabled repeat application of 100 µM nicotine to evoke a similar 
sized contraction (2.21 + 0.12 g, n= 29, figure 2.6b). 
2.3.2. Effects of cannabinoids on nicotine evoked contractions of the myenteric 
plexus-longitudinal muscle preparation and the whole ileum 
Contractions of the myenteric plexus-longitudinal muscle preparation evoked by 100 pM 
nicotine were inhibited by the cannabinoid receptor agonist CP 55,940 in a concentration 
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Figure 2.6 (a) Mean concentration-response curve for nicotine evoked contraction of the 
MPLM preparation. To ensure a stable, repeatable response to nicotine, tissue was 
exposed to three doses of 100 µM nicotine prior to exposure to varying nicotine 
concentrations. Each symbol represents the mean amplitude of peak contraction from 
multiple tissues, expressed as a percentage of the mean amplitude of peak contraction 
derived from prior tissue exposure to 100 pM nicotine (n = 10 different myenteric 
plexus-longitudinal muscle preparations); vertical lines indicate S. E. M. (b) Typical 
contractions of a strip of myenteric plexus-longitudinal muscle evoked by 100 µM 
nicotine prior to and post exposure to 100 nM CP 55,940. 
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dependent manner (peak amplitude IC50 = 215 nM, 95% confidence limits of 181 to 256 
nM, n= 29, figure 2.7). CP 55,940 induced complete inhibition of nicotine evoked 
contractions at a concentration of 10 µM (n = 3). Nicotinic concentration-response curves 
showed a combination of some rightward displacement and decrease in maximal 
contraction upon exposure to 10 nM, 100 nM and 1 µM CP 55,940 (figure 2.8). 1 µM CP 
55,940 significantly reduced the maximum peak amplitude of contraction from 2.52 ± 
0.19 g (n = 10) to 1.97 + 0.18 g (n = 10, p<0.05). A significant shift in EC50 was 
observed in the presence of 100 nM CP 55,940 (p < 0.05, f-test). Because of the adhesive 
nature of cannabinoids and the required washing to recover from desensitisation only a 
single application of cannabinoids per tissue was examined. The specific CB1 receptor 
antagonist SR141716 (300 nM) did not induce a significant rightward shift in CP 55,940 
inhibition (IC50 = 181 nM, 95% confidence limits of 121 to 271 nM, n= 25, figure 2.7). 
However, electrically evoked contractions of myenteric plexus-longitudinal muscle 
preparation were inhibited by CP 55,940 in a similar concentration dependent manner 
(IC50 = 25 nM, 95% confidence limits of 23 to 27 nM, n= 14, figure 2.9) but this 
inhibition was significantly shifted to the right by SR141716 (300 nM, IC50 = 157 nM, 
95% confidence limits of 118 to 218 nM, n=5, p<0.001, figure 2.9). Addition of 
SR141716 alone caused a slight but non-significant increase in size of contraction evoked 
by electrical stimulus. 
To further examine activity at cannabinoid receptors, modulation by the cannabinoid 
receptor agonist WIN 55,212-2 was compared with that of the (-)-enantiomer WIN 
55,212-3, which has been shown not to activate CB, and CB2 receptors (Savinainen et al., 
2005), WIN 55,212-2 (300 nM) inhibited contraction by 73.0 + 4.5% (n = 6) while 
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Figure 2.7 Mean concentration-response curves for the inhibition of contraction of the 
MPLM preparation evoked by 100 pM nicotine by CP 55,940 (") and CP 55,940 in the 
presence of 300 nM SR141716 (0). Preparations were exposed to varying concentrations 
of cannabinoids for 20 mins prior to exposure to nicotine. Each symbol represents the 
mean amplitude of peak contraction expressed as a percentage of the amplitude of peak 
contraction derived prior to application of cannabinoid. Each symbol comprises of at 
least three different MPLM preparations. Vertical lines indicate S. E. M. 
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Figure 2.8 Inhibition by CP 55,940 of the mean concentration-response curve for 
contraction of the MPLM preparation evoked by nicotine. The concentration-response 
curve for nicotine (") showed no significant shift in the presence of 10 nM CP 55,940 
(0). A significant rightward shift in EC50 was observed in the presence of 100 nM CP 
55,940 (Q, p<0.05, f-test) and a reduction in the size of maximal contraction to nicotine 
was observed in the presence of 1 µM CP 55,940 (A, p<0.05). Preparations were 
exposed to varying concentrations of cannabinoids for 20 mins prior to exposure to 
nicotine. Each symbol represents the mean amplitude of peak contraction expressed as a 
percentage of the amplitude of peak contraction derived prior to application of 
cannabinoid. Each symbol comprises of at least three different MPLM preparations. 
Vertical lines indicate S. E. M. 
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Figure 2.9 Mean concentration-response curves for the inhibition of electrically evoked 
contractions of the MPLM preparation by CP 55,940 ( , n= 14) and CP 55,940 in the 
presence of 300 nM SR141716 (Q, n= 4). Each symbol represents the mean amplitude 
of peak contraction evoked by electrical stimulus from multiple tissues expressed as a 
percentage of the mean amplitude of peak contraction derived immediately prior to 
addition of cannabinoid. Vertical lines indicate S. E. M. 
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WIN 55,212-3 (300 nM) reduced the peak amplitude of contraction by a significantly 
lower amount than that induced by WIN 55,212-2 (35.5 6.3% (n = 4, p<0.001, figure 
2.10). 
To further substantiate observations in the MPLM, contraction evoked by 100 µM 
nicotine in the whole ileum was inhibited by CP 55,940 (1 µM) by 38.9 + 6.69% (n = 6, 
figure 2.11). SR141716 (1 µM) did not significantly change nicotine induced contractions 
when added alone (n = 6) and did not reduce CP 55,940 (1 µM) inhibition (40.5 ± 8.01%, 
n=6). 
2.3.3. Effects of cannabinoids on nicotine evoked contraction contractions of the 
myenteric plexus-longitudinal muscle preparation in the presence of tetrodotoxin 
In an attempt to elucidate the location within a neurone in which cannabinoids act, 
activity in the presence of the voltage-gated sodium channel blocker tetrodotoxin (TTX) 
was investigated. TTX prevents action potential propagation, segregating the 
neuromuscular synapse from the remainder of the neurone. TTX (300 nM) reduced 100 
µM nicotine evoked contraction by 68.9 1 1.90% (n = 35, figure 2.12). Addition of CP 
55,940 (300 nM, n= 6) produced a further reduction; lowering contraction to 84.6% of 
the untreated response to 100 µM nicotine evoked. CP 55,940 inhibition proved 
significant when compared with TTX alone (p < 0.001). SR141716 (300 nM, n= 6) also 
induced a further significant inhibition when applied in conjunction with TTX (84.6 ± 
2.23%, n=6, p<0.00 1). With application of TTX (300 nM), CP 55,940 (300 nM) and 
SRI 41716 (300 nM) the peak amplitude of contraction evoked by 100 µM nicotine was 
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Figure 2.10 Effect of WIN 55,212-2 and the inactive (-)-enantiomer WIN 55,212-3 on 
contractions of the MPLM preparation evoked by nicotine (100 µM). Preparations were 
exposed to either WIN 55,212-2 (300 nM, n= 6) or WIN 55,212-3 (300 nM, n= 4) for 20 
mins prior to exposure to nicotine. Each column represents the mean amplitude of peak 
contraction expressed as a percentage of the amplitude of peak contraction evoked prior 
to application of cannabinoid or vehicle. Vertical lines indicate S. E. M. The significance 
of the difference between columns representing WIN 55,212-2 and WIN 55,212-3 was 
calculated using ANOVA followed by Dunnett's test with *** indicating a significant 
difference ofp < 0.001. 
94 
50" 
4D- 
30- 
5- 
20- 
10. 
Z 0. 
0 
0 
10 
C 
-20- 
-30" Control SP 141716 - CP 55 , 
940 - 
(1 µM) t1 µM7 
+SR141716 
(1 µN1) 
Figure 2.11 Effect of CP 55,940 and SR141716 on contractions of the whole ileum 
preparation evoked by nicotine (100 µM). Preparations were exposed to either CP 55,940 
(1 µM, n= 6), SR141716 (1 µM, n= 6) or CP 55,940 (1 µM) and SR141716 (1 µM, n= 
6) for 20 mins prior to exposure to nicotine. Each column represents the mean amplitude 
of peak contraction expressed as a percentage of the amplitude of peak contraction 
evoked prior to application of cannabinoid or vehicles. Vertical lines indicate S. E. M. The 
significance of the difference between columns representing CP 55,940 and CP 55,940 in 
conjunction with SR141716 was calculated using ANOVA followed by Dunnett's test 
with NS indicating no significant difference. 
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Figure 2.12 Effect of CP 55,940 and SR141716 whilst in the presence of tetrodotoxin on 
contractions of the MPLM preparation evoked by nicotine (100 µM). Preparations were 
exposed to TTX (300 nM) and either CP 55,940 (300 nM, n= 6), SR141716 (300 nM, n 
= 6) or CP 55,940 (300 nM) and SR141716 (300 nM, n= 5) for 20 mins prior to exposure 
to nicotine. Each column represents the mean amplitude of peak contraction expressed as 
a percentage of the amplitude of peak contraction evoked prior to application of 
cannabinoid or vehicle. Vertical lines indicate S. E. M. The significance of the difference 
between columns was calculated using ANOVA followed by Dunnett's test with ** 
indicating a significant difference of p<0.01 existing between the column representing 
CP 55,940 in conjunction with SR141716 and the columns representing CP 55,940 and 
SR l 41716 independently. *** indicates a significant difference of p<0.001 existing 
between the column representing SR141716 and that representing TTX alone. 
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Figure 2.13 Effect of WIN 55,212-2 and WIN 55,212-3 whilst in the presence of 
tetrodotoxin on contractions of the MPLM preparation evoked by nicotine (100 µM). 
Preparations were exposed to TTX (300 nM) and either WIN 55,212-2 (300 nM, n= 6) or 
WIN 55,212-3 (300 nM, n= 11) for 20 mins prior to exposure to nicotine. Each column 
represents the mean amplitude of peak contraction expressed as a percentage of the 
amplitude of peak contraction evoked prior to application of cannabinoid or vehicle. 
Vertical lines indicate S. E. M. The significance of the difference between columns was 
calculated using ANOVA followed by Dunnett's test with ** indicating a significant 
difference of p<0.01 and *** indicating a significant difference of p<0.001 versus 
TTX alone. NS indicates no significant difference existing between the column 
representing WIN 55,212-2 and WIN 55,212-3. 
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reduced by 94.3 ± 0.78% (n = 5). Inhibition was significantly greater than that evoked by 
CP 55,940 alone (p < 0.01) and SR141716 alone (p < 0.01). 
WIN 55,212-2 (300 nM) significantly reduced the peak amplitude of contraction evoked 
by 100 µM nicotine in the presence of TTX (300 nM) by an additional 13.75 ± 2.44 upon 
the untreated contraction amplitude (S. E. M. =, n=6, p<0.05, figure 2.13). The 
(-)-enantiomer WIN 55,212-3 (300 nM) reduced the peak amplitude of contraction in the 
presence of TTX (300 nM) by an additional 16.45 ± 0.90% upon the untreated 
contraction amplitude (n = 11, p<0.00 1). The degree of inhibition evoked by WIN 
55,212-3 in the presence of TTX did not significantly differ from that evoked by WIN 
55,212-3 (p > 0.05). 
2.3.4. Effects of cannabinoids on contraction evoked by lower concentrations of 
nicotine or in the presence of tubocurarine 
Experimentation portrayed in figure 2.8 demonstrated 10 nM CP 55,940 inhibition of 
contraction evoked by 10 µM nicotine, however at 100 µM nicotine, inhibition produced 
by 10 nM CP 55,940 was diminished. To investigate this discrepancy further the potency 
of CP 55,940 in the presence of 10 µM nicotine was examined. 
A reduced concentration (10 µM) of nicotine evoked a mean contraction of 0.79 ± 0.07 g 
(n = 8), smaller than that evoked by 100 pM nicotine (2.22 ± 0.12 g, n= 29). CP 55,940 
inhibited contraction with an ICS0 of 0.55 nM (95% confidence limits of 0.22 to 1.38 nM, 
figure 2.14). This proved to be significantly leftward shifted when compared with 
inhibition induced by CP 55,940 of contractions evoked by 100 µM nicotine (IC50 = 215 
98 
nM, 95% confidence limits of 181 to 256 nM, n= 29, p<0.01). In the presence of 
SR141716 (100 nM), the concentration-response curve for CP 55,940 inhibition of 
contraction evoked by 10 µM nicotine was significantly shifted to the right (IC50 19.5 
nM, 95% confidence limits of 3.82 to 99.4 nM, n=4, p<0.01, figure 2.14). 
One possible explanation for the increased potency of CP 55,940 at the lower 
concentration of nicotine was that the cannabinoid receptor agonist acts as a competitive 
antagonist of nicotine binding. The reduced exposure to nicotine would allow CP 55,940 
greater access to the shared binding site thereby producing the observed greater potency. 
To investigate this we examined CP 55,940 inhibition of a nicotine evoked contraction 
reduced through the presence of the nACh receptor competitive antagonist tubocurarine. 
If CP 55,940 acts as a competitive antagonist, the presence of tubocurarine and a larger 
concentration of nicotine competing for binding to the same site would result in CP 
55,940 demonstrating a lower potency. 
Tubocurarine (10 µM) reduced the mean peak amplitude of contraction evoked by 100 
µM nicotine from 1.76 ± 0.11 g (n = 6) to 0.95 ± 0.09 g (52.7% of the untreated 
amplitude). CP 55,940 inhibited peak amplitude of contraction evoked by nicotine in the 
presence of tubocurarine with an IC50 of 0.74 nM (95% confidence limits of 0.20 to 2.76 
nM, n= 8). The IC50 for CP 55,940 was significantly shifted to the left when compared to 
concentration-response curves for CP 55,940 in the absence of tubocurarine (IC50 in 
absence of tubocurarine = 170 nM, 95% confidence limits of 108 to 270 nM, n=6, p< 
0.000 1). A reduced concentration (10 µM) of nicotine evoked a smaller mean contraction 
of 0.79 ± 0.07 g (n = 8), comparable to that evoked by 100 µM nicotine in the presence of 
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10 µM tubocurarine. CP 55,940 inhibited contraction with an IC50 of 0.55 nM (95% 
confidence limits of 0.22 to 1.38 nM, figure 2.15). This proved to be significantly 
100" 
80 
C 
o Eo" 4-1 
c- o 4D- 
0 
20" 
4F 
0" 
Control -10 -9 -8 -7 -6 
Concentration of CP 55,940 (Log M) 
Figure 2.14 Mean concentration-response curves for the inhibition by CP 55,940 of 
contraction of the MPLM preparation evoked by 100 µM nicotine ("), and 10 µM 
nicotine in the absence (") and presence of 100 nM SR141716 (0). Preparations were 
exposed to varying concentrations of cannabinoids for 20 mins prior to exposure to 
nicotine. Each symbol represents the mean amplitude of peak contraction expressed as a 
percentage of the amplitude of peak contraction derived prior to application of 
cannabinoid. Each symbol comprises of at least four different myenteric plexus- 
longitudinal muscle preparations. Vertical lines indicate S. E. M. 
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Figure 2.15 Mean concentration-response curves for the inhibition of contraction of the 
MPLM preparation evoked by 100 µM nicotine by CP 55,940 alone (") and in the 
presence of 10 µM tubocurarine ( ). Preparations were exposed to tubocurarine and 
varying concentrations of cannabinoids for 20 mins prior to exposure to nicotine. Each 
symbol represents the mean amplitude of peak contraction expressed as a percentage of 
the amplitude of peak contraction derived prior to application of cannabinoid. Each 
symbol comprises of at least four different myenteric plexus-longitudinal muscle 
preparations. Vertical lines indicate S. E. M. 
80- 
6p- 
o 40- 
0 
20- 
o- 
101 
leftward shifted when compared with inhibition induced by CP 55,940 of contractions 
evoked by 100 pM nicotine (p < 0.01 for shift in IC50)" 
2.3.5. Effects of nicotine in cultured myenteric neurones 
To further investigate a possible cannabinoid modulation of the nACh receptor 
electrophysiological techniques were used to directly measure nACh receptor channel 
properties and assess the action of cannabinoids. 
Stable voltage-clamp whole-cell patch recordings were made from a total of 54 cultured 
myenteric neurones. Cells were clamped at a holding potential of -60 mV. Application of 
exogenous nicotine (1 mM) induced a transient inward current with a peak amplitude of 
10.17 + 1.54 pA. pF-' (n = 18, figure 2.16). Reapplication of nicotine upon the same cell 
resulted in a transient inward current with a much smaller peak amplitude, probably due 
to channel desensitisation. To combat this, neurones were exposed to only a single 
application of nicotine. 
2.3.6. CP 55,940 modulation of nicotine-evoked currents 
Pre-treatment with the cannabinoid agonist CP 55,940, at concentrations of 300 nM and 3 
µM, significantly depressed the maximum amplitude of current elicited by 1 mM nicotine 
in a concentration dependent manner, producing currents of 4.11 + 0.22 pA. pF-I (n = 3) 
and 1.22 + 0.30 pA. pF-' (n = 5, p<0.0 1, figure 2.17) respectively. 
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Figure 2.16 Superimposed currents in cultured myenteric neurones evoked through the 
application of 1 mM nicotine in the absence and presence of 10 pM CP 55,940. Holding 
potential -70 mV. 
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Figure 2.17 Effect of CP 55,940 on peak nicotinic current in cultured myenteric 
neurones. Each column represents the mean peak current, expressed as pA. pF-' to 
compensate for cell size, evoked by 1 mM nicotine in the absence of (control, n= 18) or 
in the presence of CP 55,940 (300 nM, n =3; 3 µM, n= 5). Vertical lines indicate S. E. M. 
The significance of the difference between columns was calculated using ANOVA 
followed by Dunnett's test with ** indicating a significant difference of p<0.01 versus 
control. 
103 
12 
11 
r 10 
L 
0- 
Q 6- 
7- 
6 
D 5 
U 4 
m 3- 
2 ** ýc 
1 
611 0 
Nicotine +WIN 55,212-2 +WIN 55,212-3 
1 mm 1 µM 10 µM 1 µM 10 µM 
Figure 2.18 Effect of WIN 55,212-2 and the (-)-enantiomer WIN 55,212-3 on peak 
nicotinic current in cultured myenteric neurones. Each column represents the mean peak 
current, expressed as pA. pF-I to compensate for cell size, evoked by 1 mM nicotine in the 
absence of (control, n= 18) or in the presence of WIN 55,212-2 (1 µM, n=3; 10 µM, n= 
8) or WIN 55,212-3 (1 µM, n=3; 10 µM, n= 4). Vertical lines indicate S. E. M. The 
significance of the difference between columns was calculated using ANOVA followed 
by Dunnett's test with * indicating a significant difference of p<0.05 and ** indicating a 
significant difference ofp < 0.01 versus control. 
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2.3.7. Modulation of nicotine-evoked currents by WIN 55,212-2 and CB, receptor 
inactive stereoisomer WIN 55,212-3 
To examine if inhibition was due to CB1 receptor stimulus, transmitted through an 
intracellular second messenger pathway, modulation by the cannabinoid agonist WIN 
55,212-2 and the (-)-enantiomer WIN 55,212-3, which possesses a reduced efficacy at the 
CB1 receptor was investigated. WIN 55,212-2, at concentrations 1 pM and 10 µM, 
significantly reduced the amplitude of nicotine (1 mM) evoked currents from 10.2 ± 1.54 
pA. pF-' (n = 18) to 4.65 ± 4.65 pA. pF-' (n = 3) and 1.26 ± 0.46 pA. pF-' (n = 8, p<0.0 1, 
figure 2.18) respectively. WIN 55,212-3 also significantly reduced the current amplitude. 
A concentration of 1 µM reduced amplitude to 5.16 ± 1.15 pA. pF-' (n = 3) and 10 µM 
reduced amplitude to 0.83 ± 0.30 pA. pF-1 (n = 4, p<0.01). Currents evoked in the 
presence of WIN 55,212-3 did not significantly differ from those evoked in the presence 
of WIN 55,212-2 (p > 0.05). 
2.3.8. Cannabinoid modulation of nicotine-evoked currents in the presence of 8-Br- 
cAMP 
To further examine the mechanism whereby cannabinoids modulated nicotine evoked 
currents, the effects of CP 55,940 were observed in the presence of 8-bromo-adenosine 
3', 5'-cyclic monophosphate (8-Br-cAMP). Modulation of intracellular cAMP levels is a 
major mechanism through which numerous GPCRs, including CBI and CB2 receptors, 
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act to evoke a response. The presence of the hydrolysis resistant cAMP analogue prevents 
GPCR modulation of cAMP-dependent pathways and so helps in determining whether 
cannabinoid inhibition is the result of direct action upon the nACh receptor or by the 
interaction with an intracellular pathway activated by some alternate receptor. 
Application of 0.2 mM 8-Br-cAMP induced a non-significant increase in amplitude of 
current evoked by nicotine (1 mM) to 15.45 ± 3.00 pA. pF"1 (n = 4) from a control 
response of 10.2 + 1.54 pA. pF-' (n = 18, figure 2.19). Exposure to CP 55,940 (3 pM) in 
conjunction with 8-Br-cAMP resulted in a significant reduction in current when 
compared to control current (2.84 ± 1.83 pA. pF-l, n=5, p<0.05). This current amplitude 
did not significantly differ from the current amplitude evoked by nicotine in the presence 
of 3 µM CP 55,940 alone (1.22 ± 0.30 pA. pF-l, n= 5). 
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Figure 2.19 Effect of 8-bromoadenosine 3', 5'-cyclic monophosphate (8-Br-cAMP) on 
inhibition induced by CP 55,940 of peak nicotinic current in cultured myenteric neurones. 
Each column represents the mean peak current, expressed as pA. pF-1 to compensate for 
cell size, evoked by 1 mM nicotine in the absence of (control, n= 18; 8-Br-cAMP 0.2 
mM, n= 4) or in the presence of CP 55,940 alone (3 µM, n= 5) and in the presence of 
8-Br-cAMP (n = 5). Vertical lines indicate S. E. M. The significance of the difference 
between columns was calculated using ANOVA followed by Dunnett's test with * 
indicating a significant difference of p<0.05 between columns representing 8-Br-cAMP 
alone and CP 55,940 and 8-Br-cAMP. 
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2.4. Discussion and conclusion 
Recently the concept of cannabinoids acting solely at the CB, and CB2 receptors has been 
questioned. The action of the endogenous cannabinoid anandamide at the TRPV 1 
receptor, coupled with the proposed activity of cannabinoids at a number of novel 
receptors and allosteric sites, observed in multiple studies, strongly suggest cannabinoids 
play a diverse role in the modulation of physiological activity. This work supports 
electrophysiological data produced by our laboratory suggesting the existence of an 
additional site through which cannabinoid modulation of neuronal activity may occur. 
Data indicates an inhibition of nicotinic receptor activity by cannabinoids exists in 
myenteric neurones in the guinea-pig ileum that is dependent upon either a G110-protein 
independent or an allosteric mechanism. 
Interest first arose with the observation that inhibition by CP 55,940 of nicotine evoked 
contractions in the MPLM preparation was not blocked by SR141716. This was contrary 
to what would be expected from work published previously by Pertwee and colleagues, 
who observed a CB, receptor dependent inhibition of electrically evoked contraction, 
which was blocked by SR141716 (Pertwee et al., 1996; Coutts and Pertwee, 1997). 
Coupled with the partial inhibition of contraction by the CB 1 receptor inactive enantiomer 
WIN 55,212-3, the data suggested an additional CB1 receptor independent mechanism 
might exist through which cannabinoids act to inhibit the action of nicotine in myenteric 
neurones. The lack of antagonism by SR141716 suggests more than one inhibitory 
mechanism exists governing contraction evoked by nicotinic stimulus, but not with 
electrical stimulus, and the presence of some inhibition of contraction suggests a lack of 
stereoselectivity for WIN 55,212-2 over WIN 55,212-3. 
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To further examine this hypothesis, TTX was used to prevent voltage-dependent sodium 
influx and so the generation of action potentials, allowing the stimulation of longitudinal 
muscle contraction through solely nicotinic receptors located at the nerve terminal of the 
excitatory motor neurones (Galligan, 1999; Kirchgessner and Liu, 1998). This enabled 
the examination of cannabinoid modulation of nicotine evoked contractions independent 
of the action potential, which has been shown in chapter 3 to be modulated by 
cannabinoids through CB, and CB2 receptor dependent voltage-dependent calcium 
channel inhibition in cultures of myenteric neurones. Under these conditions, both CP 
55,940 and SR141716 independently inhibited nicotine evoked contractions, and both 
WIN 55,212-2 and the CB, receptor inactive enantiomer WIN 55,212-3 inhibited 
contraction with the same potency, suggesting action at a site other than the CB 1 receptor. 
It is unlikely that the concentration of TTX used was insufficient to block nerve-mediated 
responses as electrically evoked contractions of the guinea-pig MPLM preparation have 
been shown previously to be completely blocked by similar concentrations of TTX (see 
Yunker and Galligan, 1996 for example). 
Examination of cannabinoid inhibition of contraction evoked with either a lower 
concentration of nicotine or in the presence of the competitive antagonist tubocurarine 
showed an intriguing leftward shift in CP 55,940 concentration-response curves, resulting 
in an IC50 in a range similar to that observed by Pertwee et al. (1996) with the inhibition 
of electrically-evoked currents in MPLM. The rightward shift in CP 55,940 
concentration-response curve in the presence of SR141716, coupled with the increased 
potency of CP 55,940 strongly suggests inhibition of contraction evoked with this lower 
concentration of nicotine to be mediated by the CB, receptor. This decrease in sensitivity 
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to cannabinoids may resemble the decreased sensitivity to morphine observed with higher 
frequency electrically induced acetylcholine release in the MPLM (Cowie et al., 1968). 
Higher concentrations of nicotine may result in a large depolarisation of the soma and so 
initiate the firing of multiple action potentials in a manner similar to that evoked by high 
frequency electrical stimulation, while lower concentrations of nicotine may result in the 
firing of a pattern of action potential similar to that evoked by low frequency electrical 
stimulation and so possess more susceptibility to a G-protein mediated inhibition. The 
more simple hypothesis that different potency of cannabinoids to inhibit contraction 
evoked by different neuronal firing frequencies is rebuked by the observation than 
cannabinoid inhibition of contraction evoked by higher nicotine concentrations is not 
blocked by the CBS receptor specific antagonist SR141716. 
Ikeda and colleagues (Pan et al., 1998) observed, in whole-cell patch clamping of rat 
superior cervical ganglion neurones expressing the CB1 receptor, strongly depolarising 
neurones immediately prior to inducing activation of N-type calcium channels prevented 
CBI receptor mediated inhibition of these channels. This nicely corroborates the 
hypothesis that the multiple action potentials evoked by exposure to large quantities of 
nicotine may mimic the strong depolarisation and so inactivate the Gp, -protein mediated 
pathway through which the CB, receptor acts (figure 2.20). 
Whole-cell patch-clamp electrophysiology confirmed a cannabinoid dependent inhibition 
of the opening of the nicotinic ion channel in cultured myenteric neurones. In previous 
work, this inhibition displayed properties not anticipated of the CB1 receptor; being 
inhibited by PEA and showing not only a lack of blockade by SR141716, but an 
inhibition by this CB, receptor selective antagonist. The current study demonstrated no 
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Figure 2.20 Hypothesised model through which cannabinoids act to inhibit nicotinic 
stimulation of contraction of the MPLM. (a) Low frequency electrical stimulus evokes an 
action potential by stimulating the axon. This can be blocked by CB, receptor activation. 
(b) Low concentrations of nicotine cause a moderate degree of depolarisation within the 
soma (bi) evoking a single action potential. (bii) Cannabinoids act at both the CB, 
receptor and the nicotinic receptor to inhibit action potentials. However, as cannabinoids 
show greater potency at the CB, receptor, inhibition of the nicotinic receptor is masked. 
(c) High concentrations of nicotine induce a marked depolarisation within the soma (ci) 
evoking the firing of multiple action potentials. (cii) Cannabinoids act at the CB1 receptor 
to inhibit initial action potentials, but the continued presence of high frequency action 
potentials in the axon desensitise the CB, receptor and/or related pathways allowing 
action potentials to propagate and evoke ACh release. This unmasks an alternative 
mechanism through which cannabinoids act to inhibit contraction, through blockade of 
the nicotinic receptor. 
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stereos electivity for WIN 55,212-2 over the CB1 and CB2 receptor inactive stereoisomer 
WIN 55,212-3. Furthermore, previous data generated within our laboratory showed 
inhibition was not sensitive to either pertussis toxin treatment while current work 
observed no modulation of inhibition by the membrane-permeable cAMP analogue 8-Br 
cAMP, suggesting inhibition involved a mechanism independent of the G110-protein and 
the adenylate cyclase/cAMP intracellular signalling mechanisms (DeMuth et al., 2005). 
Recently, Oz et al. demonstrated, in Xenopus oocytes expressing u7-nACh receptors, a 
reversible inhibition of nicotine induced currents by anandamide, 2-AG and 
methanandamide (Oz et al., 2003; 2004). Inhibition was not reduced by the selective CB I 
and selective CB2 receptor antagonists SR141716 and SR144528, and was insensitive to 
both pertussis toxin or to 8-Br-cAMP treatment. However, in contrast to what was 
observed in current and previous studies, the synthetic cannabinoids WIN 55,212-2, CP 
55,940 and A9-THC did not alter a7-nACh receptor function. This dissimilarity may be 
the result of cannabinoids acting at different receptors, both inducing inhibition of the 
nicotinic channel but expressing differing sensitivity to the cannabinoids or, if 
cannabinoid inhibition is the result of an allosteric interaction with the nicotinic receptor, 
the dissimilarity may be due to a differing subunit composition of the nicotinic receptors 
expressed by cultured myenteric neurones compared to the homologous transfection of 
a7 subunits in oocytes. The properties of different nicotinic receptor subtypes are 
determined by the specific subunit composition of the receptor (Colquhoun and Patrick, 
1997; Luetje and Patrick, 1991). Functional neuronal nicotinic receptors are composed of 
five subunits comprising of different combinations of a and ß subunits, of which there are 
eight a (a2-a9) and three ß (ß2-ß4) subunits. Immunohistochemical and pharmacological 
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studies have revealed, in myenteric neurones maintained in cell culture, predominant 
expression of a3, a5, ß2 and ß4 nicotinic receptor subunits (Zhou et al., 2002; Galligan 
and North, 2004). However, assembly of the subunits has not been established and so 
receptors may exist as either homologous populations or as multiple receptors of differing 
subunit composition. The presence of a7 nicotinic subunits is debatable. Zhou et al., 
(2002) reported only a small proportion of cultured myenteric neurones showed staining 
on application of an 0 subunit selective antibody and, whilst under whole-cell patch- 
clamp, no inhibition of nicotinic receptors was observed with the a7 subunit specific 
blockers a-bungarotoxin and a-methyllycaconitine, similar to what we previously 
observed (DeMuth et al., 2005). Unpublished studies investigating cannabinoid activity 
upon other nicotinic receptors have shown inhibition of human a4ß2 nicotinic receptors 
expressed in SH-EP I cells by anandamide and a lack of inhibition by anandamide in 
HEK-293 cells expressing the a1ß1 cy6 subunits of mouse muscle nicotinic acetylcholine 
receptors (quoted in Oz, 2006). 
One possible manner in which cannabinoids may act is through a mechanism similar to 
that which arachadonic acid, a metabolite of anandamide, acts to inhibit nicotinic 
receptors. Arachadonic acid has been shown to inhibit Torpedo and chick a7 nicotinic 
receptors, expressed in oocytes, possibly through a direct blocking effect on Cat+- 
modulatory sites on the nicotinic receptor (Nishizaki et al., 1998). This suggests the 
existence of an allosteric cannabinoid binding site on the nicotinic receptor. However, 
data so far does not rule out the possibility of binding and activation of an alternate 
receptor, leading to activation of intracellular signalling pathways and so an inhibition of 
the nicotinic receptor. 
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In summary, on the basis of cannabinoids expressing pharmacological properties in 
modulating contraction of the MPLM preparation and currents in myenteric neurones 
evoked by nicotinic receptor stimulus not consistent with that anticipated as a result of 
activation of the CB, receptor, data suggests an alternative mechanism may exist through 
which cannabinoids modulate neural activity as a result of nicotinic receptor stimulation. 
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Chapter 3- Cannabinoid modulation of calcium channel activity in guinea-pig 
myenteric AH neurones 
3. Chapter 3- Cannabinoid modulation of calcium channel activity in 
guinea-pig myenteric AH neurones 
3.1. Introduction 
Modulation of contractions induced by electrical stimulation of the guinea-pig ileum 
myenteric plexus-longitudinal muscle preparation (MPLM) has been used for some 
time as a measure of cannabinoid activity through the CB, receptor (for review see 
Pertwee, 2001). Electrically evoked contractions of the MPLM are considered to 
result from excitation of enteric neurones inducing the release of neurotransmitters, 
including acetylcholine, which act upon the longitudinal smooth muscle to cause 
contraction. Cannabinoids are believed to act through the inhibition of acetylcholine 
release, but as the MPLM preparation consists of a large variety of neurones 
responsible for conveying both excitatory and inhibitory stimuli, electrical stimulation 
would be expected to result in the release of a mixture of both inhibitory and 
excitatory neurotransmitters, which opens the possibility of a more complex role for 
cannabinoids within the gastrointestinal tract. 
Morphologically, enteric neurones were first categorised in a study published over 
100 years ago (Dogiel, 1899). Dogiel type I neurones possess a single axon and short 
lamellar dendrites while Dogiel type II cells have multiple long processes arising from 
a smooth cell body. Hirst et al. (1974) divided enteric neurones according to their 
electrical characteristics into AH neurones, which show a long after-hyperpolarisation 
following action potentials, and S neurones demonstrating fast, cholinergic synaptic 
inputs and no after-hyperpolarisation. The distinct after-hyperpolarisation is the result 
of a voltage-dependent influx of Ca`+, opening Ca2+ dependent K+ channels that 
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render the soma refractory to further stimuli (Nishi and North, 1973; Hirst et al. 
1974). Unlike in S neurones in which action potentials are completely blocked by 
TTX, in AH neurones the influx of calcium induces membrane potential changes 
enabling (slow) action potentials to be evoked. 
This high voltage-activated Ca 2+ current has been shown pharmacologically to be 
mainly mediated by N-type channels because of the inhibitory effects of the highly 
specific N-type channel blocker w-conotoxin GVIA, and the lack of effect of the P/Q- 
type channel specific blocker w-aga IVA and the L-type calcium channel blockers, 
nicardipine and nifedipine (Rugiero et al., 2002; North and Tokimasa, 1987; Kunze et 
al., 1994). The existence of a low-voltage activated T-type channel has been 
hypothesised by Starodub and Wood (1999) based upon the continued presence of a 
low-voltage activated calcium current after application of the duel N-type and P/Q- 
type channel blocker w-conotoxin MVIIC. Within the guinea-pig small intestine, 
Dogiel type II cells possess the electrical characteristics of AH neurones while the 
majority of Dogiel type I cells possess the electrical characteristics of S neurones 
(Brookes et al., 1995). Motor neurones, responsible for the transfer of stimulus 
directly to the longitudinal muscle, consist of excitatory and inhibitory Dogiel type I 
neurones with S cell electrophysiological characteristics, while primary afferent 
neurones, which project to the mucosa transmitting information regarding the nature 
and intensity of the stimulus to neurones within the myenteric and submucosal plexus, 
all possess Dogiel type II morphology and possess the electrophysiological 
characteristics of AH cells. 
CBS receptor agonist inhibition of N-type voltage-gated calcium channels (VGCC) 
was first shown by Mackie and Hille (1992) using the whole-cell patch clamp 
technique in the NG 108-15 neuroblastoma-glioma cell line. Inhibition was shown, 
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through pertussis toxin blockade, to be mediated by the CB1 receptor acting via G- 
protein subunits (Mackie and Hille, 1992; Caulfield and Brown, 1992). 
Within the ileum, there is evidence that cannabinoids act at CB, receptors. The 
potency of cannabinoid agonists in the inhibition of electrically evoked contractions 
correlates well with that of their psychotropic potencies and of their affinities for 
specific CB, receptor binding sites in brain tissue (Nye et al., 1985; Pertwee et al., 
1996). The inhibition shows ligand stereospecificity, is reduced by CB, receptor 
specific antagonists, and attenuated by inhibitors of G110-protein signal transduction 
(Roth, 1978; Pertwee et al., 1992; 1996; Coutts and Pertwee, 1997; 1998). Binding 
studies, immunohistochemistry, and the detection of CB, receptor mRNA within the 
MPLM, confirm their presence (Lynn and Herkenham, 1994; Coutts et al., 2002; 
Griffin et al., 1997). Using intracellular recordings, Lopez-Redondo et al. (1997) 
demonstrated in S type neurones an inhibition of the amplitude of action potentials 
elicited by presynaptic electrical stimulus and through the application of acetylcholine 
(ACh) in approximately two thirds of neurones treated with the cannabinoids WIN 
55,212-2 and CP 55,940. The CB1 receptor specific antagonist, SR141716 (1 µM), 
inhibited only a small proportion of the neurones it was tested on (3 out of 8 
electrically stimulated neurones and 5 out of 12 stimulated with ACh), suggesting 
cannabinoid activity at more than just the CBI receptor. 
The presence of the CB2 receptor in the MPLM is equivocal. Griffin et al. (1997) 
demonstrated the presence of CB2-like mRNA in guinea-pig whole ileum, but not in 
MPLM, and found the CBS receptor specific antagonist SR141716 completely 
reversed the inhibition of electrically evoked contractions produced by a non-specific 
cannabinoid receptor agonist in the MPLM. Binding assays in the MPLM showed 
displacement of [3H]-CP 55,940 by the CB-2 receptor specific antagonist SR144528 
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with a K; of 0.36 µM (Ross et al., 1998). However, in CHO cells expressing the hCB2 
receptor and in rat spleen, SR144528 gave K; values of 0.30 and 5.6 nM respectively, 
while K; values of 0.31 and >10 µM were observed in rat brain and CHO cells 
expressing the hCB1 receptor (Rinaldi-Carmona et al., 1998; Ross et al., 1999). This 
suggested an absence of CB2 receptors in the MPLM. No modulation of action 
potential amplitude or area above the amplitude-versus-time curve was observed 
through intracellular recordings in AH neurones upon exposure to WIN 55,212-2 
(Lopez-Redondo et al., 1997). In contrast, other studies have suggested the presence 
of the CB2 receptor in the gut. In the rat fundus, Storr et al. (2002) observed increased 
nerve stimulation-elicited relaxation in response to a CB2 receptor antagonist and 
were able to isolate CB2 receptor mRNA. Gastrointestinal transit in the rat is inhibited 
by a CB1 receptor mediated mechanism. Lipopolysaccharide (LPS) treatment 
increased transit and prevented a CB, receptor mediated inhibition. However, 
application of a CB2 receptor agonist, which did not affect transit in animals not 
treated with LPS, reduced transit to control levels, suggesting a possible role for the 
CBS receptor in pathophysiological conditions (Mathison et al., 2004). More recently, 
immunohistochemical studies have detected the CB2 receptor co-localised with 
neuronal markers in the myenteric plexus and, using quantitative real time-PCR, have 
shown an increase in CB2 receptor mRNA in tissue derived from LPS treated rats 
(Duncan et al., 2005; 2006). However, in contrast, mice experiencing croton oil 
induced diarrhoea showed WIN 55,212-2 inhibition of intestinal transit that was 
blocked by SR141716 but not by SR144528 (Izzo et al., 2000b). 
Several studies have suggested the presence of non-CB 1 and CB2 receptors in the 
intestinal tract. Izzo and colleagues observed decreased intestinal transit in mice with 
exposure to palm itoylethanol amide (PEA), a cannabinoid that has been shown not to 
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act at CB I and CB2 receptors, but at a putative "CB2-like" receptor (Lambert and Di 
Marzo, 1999; Calignano et al., 1998; 2001; Izzo et al., 2001). However, as the CB, - 
like receptor displayed sensitivity to SR144528 (Calignano et al., 2001), the lack of 
inhibition observed by Izzo et al. (2001) by both SR141716 and SR144528 suggests 
an alternative mechanism may be responsible. A CB1, CB2 and TRPV 1 receptor 
independent inhibition was reported by Mang et al. who showed anandamide 
inhibition of guinea-pig MPLM motility and acetylcholine release that possessed 
lower sensitivity to SR141716 than CP 55,940, while TRPV1 activation was ruled out 
by insensitivity to capsazepine (Mang et al., 2001). 
With CB, receptor activation established to inhibit Ica in other neuronal preparations, 
this chapter investigates whether cannabinoid receptors act to inhibit ICa in AH 
neurones isolated from the guinea-pig ileum myenteric plexus. 
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3.2. Methods 
3.2.1. Preparation of ileum 
Methods for preparation of MPLM tissue are detailed in Section 2.4.1. Briefly, 
Heston-2 guinea-pigs (300-500 g) of either sex were killed by cervical dislocation and 
strips of myenteric plexus-longitudinal muscle derived from segments of small 
intestine were prepared using the method of Paton and Zar (1968). Tissues were 
immersed in Krebs solution, maintained at 37°C and supplied with 95% 02 and 5% 
C02- 
3.2.2. Preparation of cultured myenteric neurones 
Methods for disassociation of myenteric neurones are detailed in Section 2.3.2.1. 
Briefly, sections of myenteric plexus-longitudinal muscle were first digested in HBSS 
containing 0.01 ml/ml papain. This was followed by tituration whilst digesting in 1 
mg/ml collagenase Type 1 and 3.1 mg/ml dispase. Cells were incubated in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 5% FBS, 1 mM L-glutamine, 
8.3 mM glucose, 5 µM cytosine ß-D-arabinofuranoside hydrochloride, 50 gM (+)-5- 
fluorodeoxyuridine, 2.5 µM uridine, 150 units/ml penicillin and 150 µg/ml 
streptomycin, plated on to collage-coated glass slides and incubated at 37°C in an 
atmosphere of 95% CO2 and 5% 02. 
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3.2.3. Patch clamp 
Methods for patch clamping of myenteric neurones are detailed in Section 2.3.2. 
Briefly, glass pipettes were pulled from borosilicate glass capillaries (Clark (UK) 
GC 150TF-10) using a P-87 Flaming-Brown micropipette puller, fire polished on a 
microforge (Narishige, Japan) and backfilled with an intracellular solution (see 
solutions) to give a typical resistance of 3-7 MO. Chloride-coated silver wire 
connected the pipette filling fluid to the probe input. The probe of the patch clamp 
amplifier (Multiclamp 700A, Axon Instruments, USA) was mounted on a course 
manipulator (MC35A, Narishige, Japan) and directed to the cells by means of a 
hydraulic micromanipulator (MHW-3, Narishige, Japan). Data acquisition was 
performed at 10 kHz sampling rate using a digital interface (Digidata 1322A, Axon 
Instruments, USA) connected to a personal computer using the software Clampex 8.2 
(Axon Instruments, USA). Clampfit 8.2 (Axon Instruments, USA) was used for 
offline data analysis. Whole cell patch clamp measurements under voltage clamp were 
performed after gigaseal formation (Hamill et al., 1981), followed by disruption of the 
membrane under the pipette by a suction pulse. The process was monitored by 
applying a test pulse (10 mV, 5 ms, 100 Hz) to the cell, which allowed the analysis of 
a resting leak current and enabled optimal capacitive transient cancellation. Leakage 
current was accounted for using P/N leak subtraction. Whole-cell currents were low- 
pass filtered at 2 kHz with the four-pole Bessel filter of the clamp amplifier. 
3.2.4. Experimental design 
All experiments were performed at room temperature (22°C). Neurones were selected 
for study through the presence of Dogiel type II morphology (multiple long processes 
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arising from a smooth cell body) and AH neural electrochemical properties (action 
potential after-hyperpolarisation). Voltage-gated calcium currents were measured 
through the addition of tetrodotoxin (300 nM) to the extracellular solution to inhibit 
voltage-gated Na+ currents and the presence of CsC1 and tetraethylamonium-C1 in the 
intracellular medium to inhibit K+ currents. Amplification of calcium currents was 
obtained through the use of a high calcium extracellular solution (see section 3.3.6). 
To account for Cl- currents only data generated at the Cl- reversal potential was 
examined. Cells were clamped at a holding potential of -70 mV and stepped to 
varying potentials for 100 ms every 10 s. To compensate for cell size, data are 
expressed as pA. pF-1 membrane capacitance. 
3.2.5. Drugs 
All drugs were obtained from SigmaAldrich, UK, unless stated otherwise. 0-2050 and 
AM 251 were obtained from Tocris, UK. SR144528 was a kind gift from Sanofi 
Recherche, France. Penicillin and streptomycin were obtained from Gibco, UK. All 
stock solutions of cannabinoid drugs were dissolved in ethanol, shielded from light 
and kept at -20°C. 
3.2.6. Solutions 
Dulbecco's modified Eagle's medium and HBSS were obtained from SigmaAldrich, 
UK. Electrophysiological measurements were performed in high calcium extracellular 
solution (high Ca') 4-ECS) containing (mM): NaCI 125, KC1 6, MgC12 2.5, NaH2PO4 
1.2, HEPES 10, glucose 11, sucrose 67, CaCI2 2.4, pH 7.35. Intracellular solution 
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contained (mM): NaCI 10, CsCI 132, MgC12 1.2, HEPES 20, glucose 11, Na-ATP 5, 
Na-GTP 0.1, tetraethylamonium chloride 10, EGTA 0.1, pH 7.2. All drugs were 
administered in the ECS, superfused at a rate of 2 ml min-' with the exception of 
pertussis toxin, which was added to the cell culture medium 18 hr before recording to 
allow entry into the cell. After each experiment the apparatus was thoroughly washed 
with dilute hydrochloric acid, ethanol and distilled water to remove any adhering 
cannabinoid. 
3.2.7. Analysis of data 
Each value is expressed as the mean + standard error of the mean (S. E. M. ) of at least 
four experiments. Concentration-response curves were calculated using non-linear 
regression to fit data to a standard sigmoidal dose-response curve. The concentration 
which produced 50% of the maximum response (IC50), and the maximal level of 
inhibition were calculated for certain experiments using the GraphPAD Prism 
statistical software (GraphPAD Software, CA, USA). Mean values of two sets of data 
were compared using Student's unpaired t-test, aP value < 0.05 being taken as 
significant. Mean values of multiple data sets were compared using ANOVA followed 
by either Dunnetts or Newman-Keuls Multiple Comparison Test. Gaussian 
distribution of data was examined using the Kolmogorov-Smirnov test. 
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3.3. Results 
Stable patch-clamp recordings were made from a total of 164 neurones derived from 
30 independent preparations of myenteric neurones. AH neurones, chosen for the 
presence of Ca 2+ currents, were identified on the basis of morphological and 
electrophysiological characteristics upon suppression of K+ and Na+ currents. Seals 
remained stable for at least 10 minutes, after which degradation would occur. To 
ensure loss of seal did not occur during the recording of results, cells were exposed to 
cannabinoids for at least 5 minutes prior to patching. 
An inward Ca 2+ current of 892 ± 79 pA (28.9 ± 2.1 pA. pF-1) was elicited in 30 
neurones (derived from 30 guinea pigs) by a 100 ms depolarising pulse to 0 mV from 
a holding potential of -70 mV. The current consisted of a sharp transient increase 
followed by a slowly decreasing component (figure 3.1). The maximum inward 
current evoked by this depolarisation possessed a distribution between neurones not 
significantly different from a Gaussian distribution (P > 0.05, Kolmogorov-Smirnov 
normality test) suggesting all AH neurones possess Ca 2+ channels with similar 
characteristics. Inward current initiated upon a depolarising pulse to -30 mV and 
achieved a peak inward current between -10 to 0 mV (figure 3.2b). An outward 
current was observed at positive potentials greater than 50 mV (figure 3.3b). The 
majority of inward current elicited by a depolarising pulse to 0 mV was inhibited by 
the specific N-type Ca 2+ channel blocker co-conotoxin GVIA (100 nM reduced current 
to 10.0 ± 2.4 pA. pF-1, reducing by 65.6% of control; n= 3) whilst the L-type Ca 2+ 
channel blocker nifedipine (10 µM) did not induce any significant reduction in current 
(a current of 34.2 + 1.6 pA. pF-' was observed, n= 4). 
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Figure 3.1 Superimposed traces derived from cultured myenteric neurones held under 
voltage clamp. (a) Depicts current flow evoked by 100 ms, 10 mV steps in membrane 
potential ranging from -80 to 90 mV. (b) Depicts current flow evoked voltage steps in 
the presence of TEA and CsCI. (c) Depicts current flow evoked by a voltage step to 0 
mV in the absence and presence of TTX. 
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Figure 3.2 Cannabinoid agonist CP 55,940 inhibits Ca 2+ currents in cultured 
myenteric neurones. (a) Superimposed calcium current traces elicited by 100 ms 
depolarising pulses from a holding potential of -70 mV to a membrane potential of 0 
mV in the absence and pre-treated presence of CP 55,940 (1 µM). Each point 
represents the mean current, expressed as pApF-' membrane capacitance to 
compensate for cell size, over a5 ms period required to maintain membrane potential 
and consists of at least 7 neurones. (b) CP 55,940 significantly inhibited (***, P< 
0.001, ANOVA followed by Newman-Keuls) peak Ca 2+ current elicited by a0 mV 
depolarising pulse. Columns show the mean current, expressed as pApF-' membrane 
capacitance, in the absence and pre-treated presence of CP 55,940 at concentrations of 
300 nM, 1 pM and 10 µM. Bars show S. E. M. Non-linear regression to a sigmoidal 
concentration-response curve presented an IC50 and maximal blockade for CP 55,940 
of 0.54 pM and 80.0% respectively. 
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Figure 3.3 (a) Calcium current traces in cultured myenteric neurones under control 
conditions and after exposure to CP 55,940 (1 µM) prior to patching. Currents were 
activated by 100 ms voltage steps in 10 mV increments from a holding potential of 
-70 mV to potentials ranging from -80 mV to 90 mV. (b) Superimposed I-V curves of 
peak ICa, expressed as pApF-1 membrane capacitance, in myenteric neurones in the 
absence of (0) and presence of CP 55,940 (1 µM, 0). Each point represents the mean 
± S. E. M. of at least 5 neurones. 
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3.3.1. Cannabinoid inhibition of Ca 2+ currents 
When administered alone the vehicle ethanol, at a concentration of 0.1%, did not 
significantly reduce the Ca 2+ current elicited by a depolarising pulse to 0 mV 
(reduction to 23.8 + 2.1 pA. pF 1, n= 10, P>0.05, unpaired t-test). Pre-treatment with 
the non-selective cannabinoid agonist CP 55,940 significantly depressed the 
amplitude of the Ca 2+ current elicited by a depolarising pulse to 0 mV, with maximal 
inhibition occurring over the voltage range of -10 to 0 mV or at the peak of the I-V 
relationship (n = 5, figure 3.3b). Inhibition occurred over a concentration range of 300 
nM to 10 µM. CP 55,940, at a concentration of 300 nM, did not significantly inhibit 
Ca2+ current (current was reduced to 24.7 ± 5.3 pA. pF-', n= 7), but at a concentration 
of 1 µM the Ca 2+ current was reduced to 14.0 ± 1.8 pA. pF-I (current was reduced by 
51.5%, n= 11, P<0.001, ANOVA followed by Newman-Keuls). At a concentration 
of 10 µM, CP 55,940 significantly reduced current to 5.9 ± 1.4 pA. pF-' (79.7% 
inhibition, n=7, P<0.001, figure 3.2b). Regression to a sigmoidal dose-response 
curve yielded an IC50 for CP 55,940 of 0.54 . iM and a maximum reduction of current 
of 80.0%. 
Another non-selective cannabinoid agonist, WIN 55,212-2, at a concentration of 10 
µM, significantly inhibited the Ca 2+ current elicited by a depolarising pulse to 0 mV. 
Current was reduced to 7.3 + 1.8 pA. pF-' (74.7% inhibition, n=5, P<0.001, figure 
3.4). 
To examine whether inhibition was the result of CB, or CB2 receptor stimulation, the 
(-)-enantiomer, WIN 55,212-3 (10 µM), which does not activate CBS or CB2 receptors 
was applied. This also significantly inhibited the Ca 
2+ current, reducing it to 16.5 + 
2.7 pA. pF-' (43.1 "o inhibition, n=5, P<0.05). However, the 
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Figure 3.4 Stereoselectivity of the cannabinoid agonist WIN 55,212-2. The active 
enantiomer WIN 55,212-2 ((+)-WIN, 10 µM) significantly reduced (***, P<0.001) 
mean current, evoked by depolarisation to 0 mV. WIN 55,212-3 ((-)-WIN, 10 µM), 
the inactive enantiomer, produced significantly less inhibition (#, P<0.05) of mean 
current when compared with WIN 55,212-2. Each column represents the mean ± 
S. E. M. of at least 5 neurones. 
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degree of inhibition evoked by the (-)-enantiomer was significantly less than that 
evoked by WIN 55,212-2 (P < 0.05, unpaired t test). 
This was confirmed by the observation that palmitoylethanolamide (PEA), a putative 
"CB2-like" receptor agonist which does not activate CB, or CB2 receptors, did not 
inhibit Ca 2+ currents, but produced a non-significant increase in size of 4.8 ± 5.1 
pA. pF-1 (n = 3, figure 3.5). 
3.3.2. Effects of cannabinoid receptor antagonists 
To further examine the mechanism through which cannabinoid inhibition was evoked, 
the role of the cannabinoid CB1 receptor specific antagonist SR141716 was 
investigated. When applied alone at a concentration of 1 pM a non-significant 
decrease in amplitude of the inward current elicited by a depolarising pulse to 0 mV 
was observed (current was reduced to 21.3 + 1.7 pA. pF-l, n= 6). At a concentration of 
10 µM a significant decrease in amplitude to 13.6 ± 3.7 pA. pF-' was observed (n = 5, 
P<0.01, figure 3.6a). In the combined presence of 1 µM CP 55,940 and 1 µM 
SR141716 the depolarising pulse elicited a current of 13.3 ± 3.5 pA. pF-I (n = 6). This 
current did not significantly differ from the current evoked by depolarisation in the 
presence of 1 pM CP 55,940 alone (P > 0.05, figure 3.6b). The combined presence of 
1 µM CP 55,940 and 10 µM SR141716, when compared with 1 µM CP 55,940 alone, 
significantly reduced the amplitude of inward current from 14.0 ± 1.8 pA. pF-' to 3.0 ± 
0.5 pA. pF-' (n = 4, P<0.05, figure 3.6c). 
AM 251, another CB I receptor specific antagonist that possesses a similar chemical 
structure to SR141716, at a concentration of 1 µM did not induce a significant 
inhibition of evoked current. A current of 30.1 + 5.6 pA. pF-l (n = 7, P>0.05) was 
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Figure 3.5 PEA does not inhibit current. PEA, a cannabinoid that has been shown not 
to act at CBI or CB2 receptors, at a concentration of 10 µM did not inhibit current 
evoked by depolarisation to 0 mV. Each column represents the mean ± S. E. M. of at 
least 3 neurones. 
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Figure 3.6 Modulation of cannabinoid agonist activity by the CB1 receptor 
antagonists SRI 41716 and AM 251. (a) Myenteric neurones exposed prior to patching 
to SR 141716 (10 µM) displayed a significant reduction in the amplitude of peak 
current evoked by a depolarising step to 0 mV (**, P<0.01). 1 µM SR141716 did not 
significantly reduce amplitude. (b) In the presence of SR 141716 (1 PM), the decrease 
in amplitude of peak current induced by CP 55,940 (1 µM) did not significant differ 
from that induced by CP 55,940 (1 µM) alone (NS, P>0.05). (c) In the presence of 
SR141716 (10 µM), the decrease in amplitude of peak current induced by CP 55,940 
(1 µM) was significant greater than that induced by CP 55,940 (1 µM) alone (*, P< 
0.05). (d) AM 251 (1 µM) did not significantly change the amplitude of peak current 
when compared to control currents (P > 0.05). The reduction in amplitude induced by 
CP 55,940 (1 µM) was not significantly decreased in the presence of AM 251 (1 µM). 
Each column represents the mean ± S. E. M. of at least 4 neurones. 
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recorded. Combined application of 10 µM AM 251 and 1 µM CP 55,940 inhibited the 
inward current, when compared to control, reducing current to 19.6 + 1.7 pA. pF-1 (P < 
0.001, n= 7). When compared with the inhibition produced by 1 µM CP 55,940 
alone, AM 251 did not significantly reduce this inhibition (P > 0.05, figure 3.6d). 
To further investigate the inhibition observed by SR141716,0-2050, a novel CB1 
receptor ligand that possesses putative `silent antagonist' properties, was applied. At a 
concentration of 10 µM, 0-2050 significantly reduced the amplitude of 
depolarisation-elicited current to 5.1 + 1.4 pA. pF-' (P < 0.001, n=4, figure 3.7). 
With SR141716 not antagonising CP 55,940 inhibition, a role for the CB2 receptor 
was investigated through the use of the CB2 receptor specific antagonist SR144528. 
When applied alone prior to patching at a concentration of 0.1 µM, no significant 
change in the amplitude of the current elicited by a depolarising pulse to 0 mV was 
observed (an increase of 0.3 ± 4.7 pA. pF-' was present, n=4, P>0.05, figure 3.8). 
When applied in conjunction with 1 µM CP 55,940, the amplitude of the current 
decreased to 21.2 1 1.2 pA. pF-' (n = 5). This current did not significantly differ from 
that elicited in the presence of CP 55,940 alone (P > 0.05). 
As the lack of antagonism observed in the presence of the selective CB, receptor 
antagonist and CB2 receptor antagonists does not rule out the possible presence of 
either receptor, when expressed in conjunction with the other, the activity of CP 
55,940 in the presence of both selective antagonists was investigated. Combined pre- 
treatment with both CB 1 and CB2 receptor antagonists, SR 141716 (1 µM) and 
SR144528 (0.1 µM) produced a non-significant reduction in the amplitude of 
depolarisation-elicited current, reducing size of current to 25.2 ± 3.3 pA. pF-' (n = 7, P 
> 0.05, figure 3.9). When applied in combination with 1 µM CP 55,940, the amplitude 
of current evoked by depolarisation (24.9 ± 3.8 pA. pF-', n= 5) was significantly 
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Figure 3.7 The `silent' antagonist 0-2050 inhibits current. 0-2050 (10 µM) 
significantly reduced (* * *, P<0.001) mean current, evoked by depolarisation to 0 
mV. Each column represents the mean ± S. E. M. of at least 4 neurones. 
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Figure 3.8 Modulation of CP 55,940 inhibition by the CB2 receptor antagonist 
SR144528. Myenteric neurones exposed prior to patching to SR144528 (0.1 . iM) did 
not significantly reduce the amplitude of peak current (P > 0.05). The amplitude of 
peak current evoked in the presence of CP 55,940 (1 µM) and SR144528 (0.1 µM) 
did not significantly differ from that evoked in the presence of CP 55,940 (1 PM) 
alone (P > 0.05). Each column represents mean ± S. E. M. of at least 5 neurones. 
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Figure 3.9 Modulation of CP 55,940 inhibition by the combined presence of the CB1 
receptor antagonist SR141716 and the CB2 receptor antagonist SR144528. Exposure 
of myenteric neurones prior to patching to both SR141716 (1 µM) and SR144528 (0.1 
µM) did not significantly reduce the amplitude of peak current (P > 0.05). The 
amplitude of peak current evoked in the presence of CP 55,940 (1 µM), SR 141716 (1 
µM) and SR144528 (0.1 µM) was significantly greater than that evoked in the 
presence of CP 55,940 alone (*, P<0.05) and did not significantly differ from that 
evoked in the presence of the antagonists alone (P > 0.05). Each column represents 
mean ± S. E. M. of at least 5 neurones. 
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greater than that evoked in the presence of 1 . tM CP 55,940 alone (P < 0.05). When 
compared with the amplitude of the current evoked in the presence of SR141716 and 
SRI 44528 no significant change was observed (P > 0.05). 
3.3.3. Effects of pertussis toxin 
To provide further confirmation of the role of CB, and CB2 receptors, which are both 
G; 10-protein coupled receptors, modulation by the G, /,, -protein inhibitor pertussis toxin 
(PTX) was examined. Incubation with PTX (100 ng/ml) for 18 firs prior to patching, 
to ensure entry into the cell, induced no significant change in current elicited by 
a depolarising pulse to 0 mV (a current of 23.1 + 3.6 pA. pF-' was observed, n=7, P> 
0.05, figure 3.10). PTX significantly reduced the degree of inhibition evoked by 
addition of 10 pM CP 55,940, increasing the amplitude of current evoked by a 
depolarising pulse from 5.9 ± 2.1 pA. pF-' to 19.0 ± 5.8 pA. pF-' (n = 5, P<0.05). The 
blockade of CP 55,940 inhibition by PTX was further confirmed by the observation of 
a lack of significant difference between current evoked in the presence of PTX alone 
and that evoked in the presence of PTX and CP 55,940 (P > 0.05). 
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Figure 3.10 Blockade of CP 55,940 inhibition by pertussis toxin (PTX). Myenteric 
neurones incubated with the G1/0-protein inhibitor PTX (100 ng/ml) for 18 hrs prior to 
patching induced a non-significant reduction in the amplitude of current elicited by a 
depolarising pulse to 0 mV (P > 0.05). PTX significantly reduced the degree of 
inhibition evoked by addition of 10 µM CP 55,940 (*, P<0.05). Each column 
represents mean ± S. E. M. of at least 5 neurones. 
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3.4. Discussion and conclusion 
The results from this investigation pose an intriguing story. The reduction of calcium 
entry coupled with the presence of inhibition in all neurones exposed to cannabinoids 
at a concentration of 1 µM and greater suggests cannabinoids can play a major role in 
the modulation of action potentials in AH neurones within the myenteric plexus. This 
is contrary to what was hypothesised by Lopez-Redondo and colleagues (1997) who 
detected, through intracellular recordings, a lack of any alteration of action potentials 
in response to application of WIN 55,212-2 in AH neurones. The dissimilarity of the 
results of our studies is probably the consequence of our measurement of a single 
component of the action potential, as opposed to the entire action potential within AH 
neurones. In AH neurones, calcium channel opening is triggered by the depolarisation 
within an action potential. Action potential amplitude is mainly governed by sodium 
influx and potassium efflux, calcium entry produces a prominent `shoulder' upon the 
repolarisation phase as well as extending the duration of the action potential. The 
modulation of action potentials by calcium does however markedly differ in shape 
and duration within the same neurone, and so Bornstein et al. (1994) recommend the 
measurement of the slow after-hyperpolarisation as a more robust measure of calcium 
entry. This slow after-hyperpolarisation, lasting at least 4 s, occurs in all AH neurones 
50-70 ms after an action potential as a result of calcium-dependent potassium channel 
opening. By measuring solely changes in the action potential, and not examining the 
slow after-hyperpolarisation, it is possible that the change in calcium entry observed 
with application of cannabinoids may have been masked from Lopez-Redondo et al. 
by the variability it possesses when measured as a component of the action potential. 
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The outward current at positive potentials greater than 50 mV in figure 3.3b has been 
observed by other laboratories (Baidan et al., 1992). With the blockade of Na' and K+ 
channels it probably results from the influx of Cl- anions. Under conditions in this 
study, the Cl- reversal potential (Eci) is approximately 0 mV, so by restricting data 
analysed to that evoked by a step to 0 mV, the passage of CY anions should not induce 
a sizeable change in total current. 
The high cannabinoid agonist concentrations required to produce inhibition in this 
study may be due to a reduced agonist efficacy often found with endogenous systems 
in cell cultures as a possible result of reduced receptor expression. 
Modulation of calcium channel activity through the activation of TRPV 1 channels is 
also unlikely to have occurred as the TRPV 1 channel was reported by Zygmunt et al. 
(1999) to possess, on exposure to anandamide, pronounced outward rectification 
characteristics with a reversal potential of approximately 0 mV. If the TPRV 1 channel 
were to be activated by the applied cannabinoids, then only a small influx of calcium 
would occur, which would not be expected to produce much, if any, change to the 
voltage dependent calcium influx. 
The stereoselectivity indicated by the significantly reduced inhibition observed with 
application of WIN 55,212-3, the (-)-enantiomer of WIN 55,212-2 which has been 
shown not to activate CB 1 and CB2 receptors (Savinainen et al., 2005), strongly 
suggests the decrease in calcium entry on depolarisation is mediated by cannabinoid 
receptors. However, the inhibition that is evoked by WIN 55,212-3 may be the result 
of non-specific inhibition due to the high concentrations (10 µM) used. The lack of 
inhibition observed with palmitoylethanolamide suggest inhibition is not due to 
activation of a putative "CB2-like" receptor. 
141 
Blockade by pertussis toxin implies that cannabinoids act via a G; -o-protein mediated 
mechanism to inhibit calcium currents in myenteric neurones. 
The inhibition of depolarisation induced calcium currents by the antagonist/inverse 
agonist SR141716 and the silent antagonist 0-2050 when applied alone at a 
concentration of 10 pM is similar to that observed by Lopez-Redondo et al. in which 
SR 141716 reduced the amplitude of fast synaptic excitatory synaptic potentials in S 
type myenteric neurones. Pan et al. (1998) reported a SR141716 evoked increase in 
calcium current in transfected rat superior cervical ganglion neurones and major 
pelvic ganglion neurones with an EC50 of 32 nM. The most probable explanation for 
this observation is a loss of specificity at the high concentration used, but the lack of 
any inhibition evoked by AM 251, which possesses a very similar chemical structure 
to SR141716, does induce an element of doubt. 
The complete reversal of CP 55,940 inhibition we observed in the presence of both 
the CB, and CB2 antagonists, SR 141716 and SR144528, coupled with the partial 
antagonism induced by SR144528 alone and the lack of antagonism displayed by 
SR141716 and another CB, receptor antagonist, AM 251, strongly suggest both the 
CB, and CB2 receptors play a role in governing calcium influx in acutely 
disassociated myenteric AH neurones. This is contrary to the pharmacological and 
binding studies that found SR144528 to play no role in reducing cannabinoid 
inhibition of contraction or displacement of [H3]-CP 55,940 in guinea-pig MPLM 
(Pertwee et al., 1996; Ross et al., 1998). One possible explanation for the presence of 
the CB2 receptor may be derived from recent studies that detected a greater role for 
the CBS receptor in the rat intestinal tract upon exposure to LPS through the 
measurement of intestinal transit, immunohistochemistry and mRNA expression 
(Mathison et al., 2004; Duncan et al., 2005; 2006). An upregulation of the CB2 
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receptor may have resulted from the damage induced by the enzymic and mechanical 
dissociation required in the production of these primary cultures. 
The inhibition by both CB, and CB2 receptor antagonists when applied in conjunction 
and not independently however does not rule out the possibility of the cannabinoid 
ligands acting at a non-CB1, CB2 Glio-protein coupled receptor, in which the two 
antagonists display low potency in the inhibition of response when applied 
independently, but act synergistically when applied together. One possible reason 
could be the presence of two binding sites, each of which activates the receptor to 
inhibit calcium currents, but one sensitive to only SR 141716 and the other to only 
SR144528. Further conjecture would suggest that SR141716 might be acting as a 
weak partial agonist rather than an antagonist. Action through a novel receptor would 
explain the low potency of CP 55,940 and WIN 55,212-2, and the inhibition by WIN 
55,212-3. In vivo and in vitro studies by Izzo et al. (2001) and Mang et al. (2001) 
have proposed the presence of non-CB 1 and CB2 receptors in the ileum suggesting the 
existence of a non-CB1, CB2 G; io-protein coupled receptor may not be implausible 
(figure 3.11). 
In summary cannabinoids play a prominent role in governing the electrical properties 
of myenteric AH neurones in the guinea-pig ileum. Data suggests this is mediated 
through the activation of Gpy-protein subunits by either both CB 1 and CB2 receptors or 
by a non-CB 1, CB2 G; 10-protein coupled receptor. 
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Figure 3.11 Hypothesised inhibition of calcium channels in guinea-pig myenteric 
neurones. Continuous lines represent activation of while segmented line represent 
inhibition of hypothesised pathways. 
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Chapter 4- Cannabinoid modulation of opioid activity in guinea-pig myenteric 
neurones and NG108-15 neurones 
4. Chapter 4- Cannabinoid modulation of opioid activity in guinea-pig 
myenteric neurones and NG108-15 neurones 
4.1 Introduction 
4.1.1 Opioid ligands and receptors 
The analgesic and euphoric properties of extracts of the opium poppy have been 
known for centuries, but it was not until the 20th century when an understanding of 
how opiates produced their powerful and selective effects on the body was established. 
Opioid interaction with a specific receptor was proposed in the 1950s with the 
observed structural and stereochemical requirements essential for activity. Evidence 
for multiple receptors arose in the 1960s and 1970s when Martin and colleagues 
demonstrated that a series of opioids displayed different profiles of pharmacological 
activity in vivo (Martin, 1979). They proposed the existence of three different types of 
receptor µ, K and 6. With the discovery of the endogenous opioid ligands [Met]- and 
[Leu]-enkephalin (Hughes et al., 1975), the existence of a fourth receptor, 6, was 
proposed with the observation of a pattern of agonist activity which differed to that 
possessed by the opium derived ligands (Lord et al., 1977). In the 1990s, MOR-1, 
DOR- 1, and KOR-1 genes, encoding the µ-, b- and x- receptors respectively, were 
cloned and the `orphan' receptor, ORL1, identified on the basis of high homology 
(>60%) with the classical opioid receptors (for review see Henderson and McKnight, 
1997). The a-receptor ceased to be classified as an opioid receptor as it does not 
display similar responses to opioid antagonists nor the stereoselective characteristic of 
other opioid receptors. The existence of subtypes of µ-, 6- and x- and ORL1-receptors 
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has been proposed largely on the basis of radioligand binding studies. Little evidence 
for different genes encoding these subtypes has been published but in some cases 
receptor heterodimerisation and splice variants have been proposed as possible 
explanations. All four opioid receptors are thought to form homomeric and hetromeric 
complexes, not only with other opioid receptors, but also nonopioid receptors (for 
example, µ and (X2A-adrenoceptors; for review see Devi, 2001; Milligan, 2004). 
4.1.2 Endogenous opioids 
Hughes and colleagues (1979) identified the first endogenous opioids, the 
pentapeptide enkephalins, from pig brain. Soon after this discovery, it was noted that 
a fragment of the pituitary hormone ß-lipotropin contained the sequence of [Met]- 
enkephalin at its amino-terminus. This 31 amino acid fragment was shown to be a 
potent opioid agonist and was subsequently called ß-endorphin. Three more families 
of opioid peptides, proenkephalin, pro-opiomelanocortin and prodynorphin, were 
rapidly discovered, all containing the sequence of either [Met]-enkephalin or [Leu]- 
enkephalin as the first five amino acids. All possessed no affinity for ORL1-receptors 
(Corbett et al., 1993). An endogenous ligand specific for the ORL 1 -receptor, 
nociceptin/orphanin-FQ, was discovered in 1973 (for review see Henderson and 
McKnight, 1997), whilst the endomorphins, which possess high affinity and 
selectivity for the [t-receptor but bare little semblance to the enkephalins, were 
discovered by Zadina et al. (1997). 
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4.1.3 Intracellular signalling of opioid receptors 
All opioid receptors mediate many of their cellular effects via activation of the PTX 
sensitive G; /,, -proteins. The µ-, b- and K- receptors have been shown to interact with 
the pertussis toxin-insensitive GZ and G16-proteins (Connor and Christie, 1999). The 
most common second messenger pathways activated include inhibition of adenylyl 
cyclase, activation of a potassium conductance, inhibition of calcium conductance, 
and an inhibition of transmitter release. More recent observations have extended the 
actions of opioids to include the activation of protein kinase C (PKC), the release of 
calcium from extracellular stores, the activation of the mitogen-activated protein 
kinase (MAPK) cascade (for review see Williams et al., 2001). 
Two effects have been associated with the inhibition of adenylyl cyclase by opioids. 
A modulation of a voltage-dependent nonselective cation current, which is activated 
at hyperpolarised potentials to cause an inward current that depolarizes the membrane 
potential, has been identified. As voltage dependence of this current is regulated by 
cAMP, the decrease in intracellular cAMP by opioid receptor activation shifts the 
voltage dependence to more negative potentials (Ingram and Williams, 1994). The 
second consequence of the inhibition of adenylyl cyclase was an inhibition of 
transmitter release that was dependent on the activation of cAMP-dependent protein 
kinase (PKA) (for review see Williams et al., 2001). 
Opioids have been shown to activate at least three separate potassium conductances 
including the G protein-activated inwardly rectifying conductance (GIRK), which is 
activated by Gpy-subunits (Jan and Jan, 1997). Activation of a voltage-dependent 
potassium conductance, suggested on the basis of the blockade of opioid inhibition of 
transmitter release and activation of the BK calcium sensitive potassium conductance, 
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which has been associated with the release of Ca 2+ from internal stores, has been 
observed (for review see Williams et al., 2001). 
The inhibition of calcium currents by activation of all opioid receptor subtypes has 
been observed in many studies (for review see Williams et al., 2001). Inhibition 
possessed similar properties to other G; /,, -protein coupled receptors, acting through the 
13'y-subunit which directly couples to the calcium channel (see section 1.6.3). 
Inhibition of neurotransmitter release has been observed at numerous sites both in the 
CNS and periphery. Inhibition is thought to be mediated through mainly increased 
potassium conductance and inhibition of voltage-activated calcium currents. However, 
inhibition of adenylyl cyclase has been shown to be responsible for some of the 
decrease in transmitter release, whilst direct inhibition of the release machinery, 
independent of potassium and calcium conductances, has also been reported (Capogna 
et al., 1993; for review see Williams et al., 2001). 
4.1.4 Opioids and cannabinoids 
Although cannabinoids and opioids possess very dissimilar structures, both share 
similar pharmacological profiles, inducing analgesia, catalepsy, hypothermia, motor 
depression, hypotension, immunosuppression, sedation and reward effects 
(Manzanares et al., 1999; Massi et al., 2001; Varvel et al., 2004). Both cannabinoid 
and opioid receptors are coupled to G;; o-proteins and activate similar 
intracellular 
signalling pathways. Within the central nervous system a similar distribution of CB1 
and µ- receptors in the dorsal horn of the spinal cord has been reported (Hohmann et 
al., 1999; Salio et al., 2001), while areas such as the caudate putamen, dorsal 
hippocampus, and substantia nigra express high levels of both cannabinoid and opioid 
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receptors (Mansour et al., 1988; Herkenham et al., 1991; Mailleux and 
Vanderhaeghen, 1992; Rodriguez et al., 2001). 
An interaction between cannabinoids and opioids have been observed in studies 
examining antinociceptive properties. A synergistic interaction between cannabinoid 
and opioid agonists has been reported in various models of acute pain (for review see 
Cichewicz, 2004). A growing body of literature attests to the interaction between 
opioids and cannabinoids with respect to reward processes. Self-administration 
studies have provided the most direct evidence for interaction in addiction, for 
example SR141716 reduced self-administration of heroin in rats and mice (Chaperon 
et al., 1998; Braida et al., 2001; Mas-Nieto et al., 2001; Navarro et al., 2001; De 
Vries et al., 2003) whilst the opioid antagonists naloxone and naltrexone reduced self- 
administration of A9-THC in squirrel monkeys (Tanda et al., 2000; Justinova et al., 
2003; 2004; for review see Tanda and Goldberg, 2003). Results from CB1 receptor 
knock-out mice suggest interactions between reward pathways do exist. Ledent et al. 
(1999) reported CB, receptor knock-out mice do not appear to self-administer 
morphine. However, contradictory results in different lines of CB, receptor knock-out 
mice suggest that different compensative adaptations to the lack of CB, receptors 
occurred in the different lines (for reviews see Viganö et al., 2005; Tanda and 
Goldberg, 2003). 
4.1.5 Opioids in myenteric plexus 
The first observation of a specific opioid effect in vitro was made in the guinea pig 
ileum by Trendelenburg (1917) who showed that morphine inhibited the peristaltic 
reflex. Both the preparatory phase, comprising a contraction of the longitudinal 
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muscle, and the emptying phase, comprising contractions of the circular muscle, were 
shown to be inhibited by opioids (Kosterlitz and Robinson, 1957). Inhibition was 
shown to be due to an action upon neurones, rather than directly on the muscle layers 
themselves as contractions evoked by acetylcholine acting at muscarinic receptors on 
the muscle was not affected by morphine (Kosterlitz and Robinson, 1958), whereas 
cholinergic contractions evoked indirectly by nicotine (Kosterlitz and Robinson, 1958; 
Gaddum and Picarelli, 1957; Schaumann, 1955), 5-HT (Kosterlitz and Robinson, 
1958; Gaddum and Picarelli, 1957), and neurotensin (Huidobro-Toro et al., 1984) 
were inhibited. 
Immunohistochemical studies have reported the presence of µ-, S- and K-receptors in 
enteric neurones of rat, guinea-pig and porcine gastrointestinal tract. In the rat, p- and 
K-receptors have been localised to myenteric and submucosal neurones, fibres 
distributed in the muscle layer, mucosa, blood vessels and lymphatic nodes, and to 
putative interstitial cells of Cajal (ICC) in the myenteric plexus and deep muscular 
plexus (Bagnol et al., 1997). In contrast, [t-receptor immunoreactivity in the guinea- 
pig distal ileum has been localised predominantly to myenteric neurones and dense 
neuropil in the muscle layer and deep muscular plexus (Sternini et al., 1995; 1996; Ho 
et al., 2003). 6-receptors have been located in both myenteric and submucosal 
plexuses where it is predominantly found in varicose fibres in the plexuses, muscle 
and mucosa (Sternini et al., 2004). K-receptor immunoreactivity appears to be 
confined to the myenteric plexus and to bundles of fibres in the muscle (Sternini et al., 
2004). In porcine ileum, 6-receptors have been localised to both submucosal and 
myenteric neurones and to fibres in the muscle and mucosa, whereas K-receptors are 
found only in the myenteric plexus (Poonyachoti et al., 2002). 
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Inhibition by opioids of electrically evoked contractions of myenteric plexus- 
longitudinal muscle segments was demonstrated to be due to depression of the release 
of acetylcholine from the myenteric plexus (Paton, 1957; Schaumann, 1957; Cox and 
Weinstock, 1966; Paton and Zar, 1968; Szerb, 1982; Vizi et al., 1984). Opioids have 
also been shown to decrease the release of acetylcholine evoked by agents that elicit 
action potentials in myenteric neurones, such as substance P (Vizi and Bartho, 1985, 
Yau et al., 1986), PGE1 (Jaques, 1969; Yagasaki et al., 1981), neurotensin (Yau et al., 
1983a), and caerulein (Yau et al., 1983b). The release of and contractions mediated 
by Substance P, which is released from myenteric neurones by high frequency 
electrical stimulus (Franco et al., 1979), has been shown to be depressed by opioids 
(Holzer, 1984; Gintzler and Scalisi, 1982; Bartho et al., 1982). 
In acutely isolated longitudinal-muscle myenteric-plexus preparations from the 
guinea-pig intestine, opioids have been shown to inhibit action-potential firing of 
myenteric neurones through the use of extracellular recording techniques (Ehrenpreis 
et al., 1976; North and Williams, 1977; Karras and North, 1981). The use of receptor 
selective agonists suggested that single neurones from guinea-pig ileum myenteric 
plexus coexpressed both µ- and 6-receptors and that activation of either receptor 
inhibited neuronal firing (Egan and North, 1981). Intracellular recording 
demonstrated, through the use of selective agonists, that µ-receptors were present on 
both S- and AH-type neurones and that morphine induced activation of a potassium 
channel mainly through an action on [i-receptors (Galligan and North, 1991; North 
and Tonini, 1977). Application of opioids by iontophoresis was shown to induce 
potassium channel activation when applied to the surface of the ganglion and not 
soma, suggesting opioid receptors are not expressed on the soma (North et al., 1979). 
Intriguingly, intracellular recordings from AH-neurones have suggested µ- and K- 
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opioid receptors play different roles in governing inhibition. p-receptors have been 
shown to prolong the calcium-dependent after-hyperpolarisation without altering peak 
amplitude, whilst, in contrast, K-receptor receptor activation reduces the duration of 
calcium spikes through inhibition of N-type neurones (Cherubini and North, 1985; 
Kojima et al., 1994). A reduced calcium entry would be expected to reduce activation 
of the calcium-dependent potassium channels which after-hyperpolarisation is 
dependent on. However, an inhibition of calcium entry would also be expected to 
reduce the calcium-dependent transmitter release, suggesting multiple mechanisms 
are involved in the inhibition of transmitter release by opioids. 
4.1.6 Opioids and cannabinoids in myenteric plexus 
Few studies have been performed examining the interaction between acute 
administration of cannabinoids and opioids in the ileum. Coutts and Pertwee (1997) 
reported, with a supermaximal dose of WIN 55,212-2 (1.2 µM), a 35.6% inhibition of 
maximal electrically evoked acetylcholine release. Additional application of 
normorphine (400 nM), which expresses greater affinity for [t-receptors than other 
opioid receptors, decreased release to 65.6% of maximal release (Coutts and Pertwee, 
1997). 
Withdrawal contraction, resulting from the antagonism of chronic opioid receptor 
stimulus, has been shown to be inhibited by cannabinoids. Hine et al. (1975) showed 
inhibition by A9-THC, but not cannabidiol, of the naloxone induced heightened gastric 
activity in morphine dependent rats. Frederickson et al. (1976) demonstrated 100 nM 
L9-THC induced a stereospecific, 100 fold inhibitory shift in naloxone induced 
withdrawal contracture in the MPLM preparation derived from guinea-pigs treated in 
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vivo 25 hours before with morphine. More recent work found 50 nM WIN 55,212-2 
completely blocked withdrawal contracture induced by 10 µM naloxone in guinea-pig 
MPLM exposed for 5 hours to 100 nM morphine (Basilico et al., 1999), suggesting 
the existence of some form of interaction. Cross-tolerance between morphine and 
WIN 55,212-2 was also reported. A5 hour incubation with either morphine or WIN 
55,212-2 reduced the inhibitory effects of the other drug (Basilico et al., 1999). 
4.1.7 The NG108-15 neuronal cell line 
The NG 108-15 neuronal cell line is a hybrid cell line derived from the fusion of 
mouse neuroblastoma N 18TG-2 and rat glioma C6BU-1 (Klee and Nirenberg, 1974). 
These cells display a wide range of membrane currents (for review see Hamprecht, 
1977) including TTX-sensitive sodium currents (Bodewei et al., 1985) and M-type 
potassium currents (Brown and Higashida, 1988). The low voltage activated T-type 
and Q-type calcium currents, and the high voltage activated (HVA) L-type current 
have been reported to be present in undifferentiated cells whilst the HVA N-type 
calcium current has been reported after differentiation (Lukyanetz, 1998). 
4.1.8 Opioids and cannabinoids in the NG108-15 neuronal cell line 
Expression of opioid receptors in this cell line was first observed by Klee and 
Nirenberg (1974) in binding assays, with sole expression of the 6-subtype established 
pharmacologically by Chang et al. (1978). Opioid inhibition of HVA calcium currents 
in NG 108-15 cells was first reported by Tsunoo et al. (1986) through the use of the 
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whole-cell patch clamp technique and shown to be G, /,, -protein mediated (McFadzean 
and Docherty, 1989). 
The presence of a cannabinoid receptor in NG 108-15 cells was demonstrated by A9- 
THC and da-l-nan inhibition of cAMP accumulation through a PTX sensitive 
mechanism (Devane et al., 1986, Law et al., 1982, Howlett et al., 1986). Using the 
whole-cell patch clamp technique, Mackie and Hille (1992) reported inhibition of N- 
type voltage-gated calcium channels by WIN 55,212-2 and CP 55,940. Inhibition was 
shown to be blocked by prior treatment with pertussis toxin, and no inhibition was 
observed with exposure to the inactive enantiomer WIN 55,212-3 (Mackie and Hille, 
1992; Caulfield and Brown, 1992). Sugiura et al. (1997) demonstrated an inhibition of 
the rise in intracellular calcium caused by voltage-activated calcium channel opening 
with the use of fura-2 imaging in differentiated NG108-15 cells through a SR141716 
sensitive mechanism. 
Interaction of cannabinoid and opioid agonists have been reported in both the NG 108- 
15 cell line and the parental N 18TG-2 cell line. Long-term exposure has been reported 
to induce desensitization of the ability of alternative agonists to inhibit cAMP 
production in N18TG-2 and NG 108-15 cells (Dill and Howlett, 1988; Law et al., 
1982, Di Toro et al., 1998), and reduce receptor binding and increase mRNA 
production in NG 108-15 cells (Di Toro et al., 1998). The modulation of opioid 
receptor properties, induced by long-term exposure to A9-THC were both SR 141716 
and PTX sensitive suggesting CB, receptor modulation. In N18TG-2 cells, Shapira et 
al. (1998,2000) demonstrated, through the use of [35S]GTPyS binding, that 
interaction between the opioid agonist etorphine and the cannabinoid agonist 
desacetyl-levonantradol (DALN) was solely additive, suggesting responses were 
evoked through independent mechanisms. Partial ablation of the G-protein reservoir 
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with a low concentration of PTX did not modify this additive interaction, indicating 
that opioid and cannabinoid receptors activated different pools of G-proteins in these 
cells, comprising of either different subtypes of G110-proteins or the same protein 
compartmentalized in separate segments within the cell (Shapira et al., 1998). In 
contrast, COS cells transfected with opioid and cannabinoid receptors showed 
inhibitory interaction with maximal inhibition of [35S]GTPyS binding by one receptor 
type blocking inhibition evoked by the other receptor type (Shapira et al., 2000). 
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4.2 Methods 
4.2.1 Guinea-pig ileum myenteric plexus-longitudinal muscle preparation 
(MPLM) 
Methods for preparation of the MPLM preparation are detailed in Section 2.3.1.1. 
Briefly, Heston-2 guinea-pigs (300-500 g) of either sex were killed by cervical 
dislocation and strips of myenteric plexus-longitudinal muscle derived from segments 
of small intestine were prepared using the method of Paton and Zar (1968). Tissues 
were immersed in Krebs solution, maintained at 37°C and supplied with 95% 02 and 
5% CO2. 
4.2.2 Disassociated myenteric neurone patch-clamp preparation 
Methods for disassociation of myenteric neurones are detailed in Section 2.3.2.1. 
Briefly, sections of myenteric plexus-longitudinal muscle were first digested in HBSS 
containing 0.01 ml/ml papain. This was followed by tituration whilst digesting in 1 
mg/ml collagenase Type 1 and 3.1 mg/ml dispase. Cells were incubated in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 5% FBS, 1 mM L-glutamine, 
8.3 mM glucose, 5 µM cytosine ß-D-arabinofuranoside hydrochloride, 50 µM (+)-5- 
fluorodeoxyuridine, 2.5 µM uridine, 150 units/ml penicillin and 150 µg/ml 
streptomycin, plated on to collage-coated glass slides and incubated at 37°C in an 
atmosphere of 95% CO2 and 5% 02. 
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4.2.3 NG108-15 patch-clamp preparation 
4.2.3.1 Cell culture 
The NG 108-15 cell line was a gift from Professor Graeme Henderson from the 
University of Bristol. Cell monolayers were cultured continuously in 25 cm3 vented 
tissue culture flasks at 37°C in growth media consisting of Dulbecco's Modified 
Eagle's Medium (DMEM), supplemented with 10% foetal calf serum, hypoxanthine 
(0.1 mM), aminopterin (0.4 µM), thymidine (160 pM), penicillin (50 pg/ml), 
streptomycin (50 µg/ml) and L-glutamine (2 mM) in 95% CO2 and 5% 02. Every 
three days, upon reaching confluency, cells were harvested by means of a plastic 
scraper and transferred to a 15 ml Falcon tube. Cells were pelleted by means of 
centrifugation and resuspended in 5 ml fresh growth media. A 1: 5 dilution was made 
by transferring 1 ml of this solution into a fresh 25 cm3 culture flask and adding 4 ml 
fresh growth media. Vials of cells (passage 20) in DMSO were kept frozen in liquid 
nitrogen until required. New batches of cells were grown when passage number 
reached over 30 as expression of calcium channels diminished. 
To induce differentiation for patch clamping, cells were plated onto glass cover slips 
in 9.6 cm3 6-well plates, resuspended in differentiation media, consisting of growth 
media with the addition of prostaglandin El (10 µM) and isobutyl-l-methylxanthine 
(50 µM), and incubated for three days at 37°C in 95% CO2/5% 02. All culture media 
and supplements were obtained form Gibco, UK with the exception of isobutyl- l- 
methylxanthine, which was obtained from SigmaAldrich, UK. 
158 
4.2.3.2 NG108-15 neurone patch-clamp preparation 
Techniques similar to those detailed in Section 2.4.3 were applied to obtain gigaseal 
and patch formation. 
4.2.3.3 Patch clamp techniques: current clamp 
To observe changes in membrane potential a fixed current, determined by the current 
required to maintain a holding potential of -70 mV, was passed into the cell to account 
for leakage via the patch. 
4.2.3.4 Patch clamp techniques: voltage clamp 
Voltage clamp and recording of calcium currents were performed using similar 
techniques detailed in section 3.4.1. In recording of G-protein activated inward 
rectifier potassium currents, changes in current characteristics were examined prior to 
and post ligand application in response to a 100 ms step in membrane potential to 
voltages ranging from -120 mV to -50 mV. After each step, membrane potential 
returned to holding potential and positive/negative (P/N) leak subtraction was 
performed. Voltages were increased cumulatively in 10 mV increments. Recording 
was performed in both extracellular solution and 50 mM potassium extracellular 
solution (detailed in section 4.3.5). 
159 
4.2.4 Analysis of data 
Electrical stimulus: Each value is expressed as the mean ± standard error of mean 
(S. E. M. ) of experiments on tissues obtained from at least three individual animals. 
The effects of cannabinoid receptor ligands are expressed as percentage inhibition of 
contraction. This was calculated by comparing the amplitude of the electrically 
evoked contraction immediately prior to adding any compound to the amplitude of the 
contraction at the maximal effect of the compound. 
GraphPAD Prism 4 statistical software (GraphPAD Software Inc, San Diego, CA., 
U. S. A. ) was used to fit the concentration-response results to a sigmoidal function and 
generate 95% confidence intervals using the equation: 
I= 
1max 
1+ 100091. - 
- 
logdruc): " Hill slope 
, 
Significant difference between mean values were calculated using Student's unpaired 
t-test, aP value of < 0.05 being taken as significant. Mean values of multiple data sets 
were compared using either one way or two way-ANOVA followed by either 
Dunnetts or Newman-Keuls multiple comparison post hoc tests. Comparison of fitted 
concentration-response curves was performed using the f-test. 
4.2.5 Drugs 
Morphine and carbachol were obtained from SigmaAldrich, UK. Other drugs used are 
detailed in previous chapters. 
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4.2.6 Solutions 
Krebs, extracellular and intracellular solutions have been detailed in section 2.4.4.50 
mM potassium extracellular solution comprised of (mM): NaCl 81, KC150, MgC12 
2.5, NaH2PO4 1.2, Hepes 10, glucose 11, sucrose 67, CaC12 1.2; pH 7.35. 
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4.3 Results 
4.3.1 Effects of morphine on electrically evoked contractions of the myenteric 
plexus-longitudinal muscle preparation 
Supermaximal electrical stimulus of the MPLM preparation at a frequency of 0.1 Hz 
evoked a contraction of 0.44 ± 0.03 g (n = 53). The opioid receptor agonist morphine 
inhibited electrically evoked contractions in a concentration-dependent manner (EC50 
= 17 nM, 95% confidence limits of 16 and 18 nM, n=9, figure 4.1). 1 µM morphine 
evoked maximal inhibition, reducing contraction by 40.0 ± 5.8% (n = 9) of untreated 
contraction. Inhibition developed rapidly and remained for the duration of the 
experiment. Inhibition was reversed by washing with Krebs. 
4.3.2 Interaction of cannabinoids with morphine inhibition of electrically 
evoked contractions in the myenteric plexus-longitudinal muscle preparation 
To investigate the possibility of interaction between opioid and cannabinoid inhibitory 
mechanisms, concentration-response curves for morphine inhibition of electrically- 
evoked contraction of the guinea-pig MPLM, in the presence of varying levels of CP 
55,940, were examined. 
CP 55,940 (0.1 nM) administered alone did not reduce the size of electrically evoked 
contraction (n = 3, figure 4.2). In the presence of 0.1 nM CP 55,940, the morphine 
concentration-response curve did not differ from that evoked in the absence of CP 
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Figure 4.1 (a) Mean concentration-response curves for the inhibition by morphine of 
contraction of the MPLM preparation evoked electrical stimulus ("). Data is 
expressed as a percentage of contraction evoked in the absence of morphine. 
Preparations were exposed for five minutes to ascending concentrations of morphine. 
Each symbol represents the mean amplitude of peak contraction expressed as a 
percentage of the amplitude of peak contraction derived prior to application of 
morphine. Each symbol comprises of at least nine different MPLM preparations. 
Vertical lines indicate S. E. M. (b) Sample trace demonstrating inhibition of electrically 
evoked contraction by morphine (100 nM) in the MPLM preparation. 
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Figure 4.2 Mean concentration-response curves for the inhibition by morphine of 
contraction of the MPLM preparation evoked electrical stimulus (") in the presence 
of 0.1 nM (0), 1 nM (V) and 10 nM (A) CP 55,940. Data is expressed as a 
percentage of contraction evoked in the absence of morphine and CP 55,940. 
Preparations were exposed to CP 55,940 for 20 minutes prior to ascending 
concentrations of morphine for five minutes. Each symbol represents the mean 
amplitude of peak contraction expressed as a percentage of the amplitude of peak 
contraction derived prior to application of morphine. Each symbol comprises of at 
least three different MPLM preparations. Vertical lines indicate S. E. M. 
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55,940 (EC50 = 7.3 nM, 95% confidence limits of 1.1 to 48.9 nM compared with 17 
nM, 95% confidence limits of 16 to 18 nM). 1 µM morphine, in the presence of 0.1 
nM CP 55,940, reduced the size of electrically evoked contraction by 36.5 ± 12.0% (n 
= 3) of untreated contraction amplitude. Inhibition evoked by 1µM morphine in the 
presence of 0.1 nM CP 55,940 did not significantly differ from that evoked in the 
absence of CP 55,940. CP 55,940 (1 nM) administered alone reduced the size of 
electrically evoked contraction by 12.0 + 2.9% (n = 7). In the presence of 1 nM CP 
55,940, the morphine concentration-response curve remained parallel with that 
evoked in the absence of CP 55,940 (EC50 = 6.4 nM, 95% confidence limits of 5.8 to 
7.1 nM, p>0.05, f-test, n=7, figure 4.2). 1 µM morphine, in the presence of 1 nM 
CP 55,940, reduced the size of electrically evoked contraction by 53.9 ± 8.4% (n = 7) 
of untreated contraction amplitude. Inhibition evoked by 1 µM morphine in the 
presence of 1 nM CP 55,940 did not significantly differ from that evoked in the 
absence of CP 55,940. 
CP 55,940 (10 nM) alone reduced the size of electrically evoked contraction by 26.8 ± 
5.6% (n = 11). The morphine concentration-response curve remained parallel with 
that evoked in the absence of CP 55,940 (EC50 = 10.5 nM, 95% confidence limits of 
9.3 to 11.9 nM, p>0.05, f-test, n=8, figure 4.2). 1 µM morphine, in the presence of 
10 nM CP 55,940, reduced the size of electrically evoked contraction by 62.7 ± 3.4% 
(n = 11) of untreated contraction amplitude. Inhibition evoked by 1 µM morphine in 
the presence of 10 nM CP 55,940 significantly differed from that evoked in the 
absence of CP 55,940 (p < 0.01, figure 4.2). Analysis of morphine inhibition, through 
the expression of inhibition evoked by morphine in the presence of 10 nM CP 55,940 
as a percentage of that evoked by 10 nM CP 55,940 alone, demonstrated no difference 
\VVhen compared to the control (figure 4.3). 
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Figure 4.3 Mean concentration-response curves for the inhibition by morphine of 
contraction of the MPLM preparation evoked electrical stimulus (") in the presence 
of 0.1 nM (0), 1 nM (0), 10 nM (A) and 100 nM (Q) CP 55,940. Data is expressed 
as a percentage of contraction evoked in the presence of CP 55,940. Preparations were 
exposed to CP 55,940 for 20 minutes prior to ascending concentrations of morphine 
for five minutes. Each symbol represents the mean amplitude of peak contraction 
expressed as a percentage of the amplitude of peak contraction derived prior to 
application of morphine. Each symbol comprises of at least three different MPLM 
preparations. Vertical lines indicate S. E. M. 
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Figure 4.4 Mean concentration-response curves for the inhibition by morphine of 
contraction of the MPLM preparation evoked electrical stimulus (") in the presence 
of 10 nM (A) and 100 nM (11) CP 55,940. Data is expressed as a percentage of 
contraction evoked in the absence of morphine and CP 55,940. Preparations were 
exposed to CP 55,940 for 20 minutes prior to ascending concentrations of morphine 
for five minutes. Each symbol represents the mean amplitude of peak contraction 
expressed as a percentage of the amplitude of peak contraction derived prior to 
application of morphine. Each symbol comprises of at least eight different MPLM 
preparations. Vertical lines indicate S. E. M. * indicates a significant difference of p< 
0.05 and ** indicates a significant difference of p<0.01 for inhibition of electrically- 
evoked contraction by morphine in the presence of 100 nM CP 55,940 compared with 
that observed in the presence of 10 nM CP 55,940. 
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100 nM CP 55,940 pre-treatment alone reduced the size of electrically evoked 
contraction by 40.8 ± 7.5% (n = 9, figure 4.4). In the presence of 100 nM CP 55,940, 
the morphine concentration-response curve EC50 remained significantly similar to that 
generated in the absence of CP 55,940 (EC50 = 9.8 nM, 95% confidence limits of 3.0 
to 30 nM, n=8, figure 4.4). 1 µM morphine, in the presence of 100 nM CP 55,940, 
reduced the size of electrically evoked contraction by 46.8 + 6.8% (n = 9), not 
significantly different from that evoked by CP 55,940 in the absence of morphine. 
However inhibition was significantly less than that evoked by 1 µM morphine in the 
presence of 10 nM CP 55,940 (p < 0.05, figure 4.4). Compensation for inhibition 
evoked by CP 55,940 (100 nM) demonstrated significant reduction in morphine 
evoked inhibition when compared to the control (p < 0.001, figure 4.3). 
To examine the role of the CB, receptor in modulating contraction, inhibition by 
morphine in the presence of the CB1 receptor specific antagonist SR141716 was 
explored. SR141716 (100 nM) induced an increase in the size of electrically evoked 
contractions of the guinea-pig ileum MPLM by 80.3 ± 26.6% (n = 7, figure 4.5). The 
concentration-response curve EC50 for morphine in the presence of SR141716 
remained statistically indistinguishable from that of morphine alone (EC50 = 10.5 nM, 
95% confidence limits of 9.9 to 11.3 nM, n= 7). 1 µM morphine, in the presence of 
100 nM SR141716, reduced the size of electrically evoked contraction to 49.0 ± 6.6% 
(n = 7) of the untreated electrically evoked contraction, which did not significantly 
differ from that induced by 1 µM morphine alone (figure 4.5a). Compensation for 
increased size of contraction evoked by SR141716 demonstrated significant increase 
in morphine evoked inhibition when compared to the control (p < 0.01, figure 4.5b). 
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Figure 4.5 Mean concentration-response curves for the inhibition by morphine of 
contraction of the MPLM preparation evoked electrical stimulus (") in the presence 
of 100 nM (X) SR 141716 and 10 nM (0) CP 55,940. (a) Data is expressed as a 
percentage of contraction evoked in the absence of and (b) in the presence of 
SR 141716. Preparations were exposed to SR 141716 for 20 minutes prior to ascending 
concentrations of morphine for five minutes. Each symbol represents the mean 
amplitude of peak contraction expressed as a percentage of the amplitude of peak 
contraction derived prior to application of morphine. Each symbol comprises of at 
least seven different MPLM preparations. Vertical lines indicate S. E. M. 
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4.3.3 Interaction of morphine with WIN 55,212-2 inhibition of electrically 
evoked contractions of the myenteric plexus-longitudinal muscle preparation 
To investigate whether the observed interaction of CP 55,940 with morphine was a 
CB1 or CB2 receptor mediated event, or a cannabinoid receptor independent event, the 
interaction between an alternative CB1 and CB2 receptor agonist, WIN 55,212-2 was 
examined. 
WIN 55,212-2 inhibited electrically evoked contractions in a concentration-dependent 
manner (EC50 = 206 nM, 95% confidence limits of 121 and 353 nM, n=3, figure 4.6). 
10 µM WIN 55,212-2 evoked maximal inhibition, reducing contraction by 73.7 + 
4.3% (n = 3) of untreated contraction. Inhibition developed rapidly and remained for 
the duration of the experiment. Inhibition was not reversed by washing with Krebs. 
Morphine (10 nM) alone reduced the size of electrically evoked contraction by 7.9 + 
3.3% (n = 7). The WIN 55,212-2 concentration-response curve obtained in the 
presence of 10 nM morphine remained similar to that evoked in the absence of 
morphine (EC50 = 269 nM, 95% confidence limits of 84 to 857 nM, figure 4.6). 1 µM 
WIN 55,212-2, in the presence of 10 nM morphine, reduced the size of electrically 
evoked contraction by 71.4 ± 11.9% (n = 2) of untreated contraction amplitude. 
Inhibition evoked by 1 µM WIN 55,212-2 in the presence of 10 nM morphine did not 
significantly differ from that evoked in the absence of morphine. 
Morphine (100 nM) alone reduced the size of electrically evoked contraction by 30.3 
± 5.8% (n = 8). The WIN 55,212-2 concentration-response curve significantly 
differed from that evoked in the absence of morphine, with WIN 55,212-2 inducing 
less inhibition of contraction (EC50 = 8.2 nM, 95% confidence limits of 0.013 to 5235 
nM, p<0.00 1,2-way ANOVA, figure 4.6). 1 pM WIN 55,212-2, in the presence of 
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Figure 4.6 Mean concentration-response curves for the inhibition by WIN 55,212-2 
of contraction of the MPLM preparation evoked electrical stimulus ( ) in the 
presence of 10 nM (0), 100 nM (0) and 1 µM (A) morphine. Data is expressed as a 
percentage of contraction evoked in the absence of morphine. Preparations were 
exposed to morphine for five minutes prior to ascending concentrations of WIN 
55,212-2 for 20 minutes. Each symbol represents the mean amplitude of peak 
contraction expressed as a percentage of the amplitude of peak contraction derived 
prior to application of morphine. Each symbol comprises of at least two different 
MPLM preparations. Vertical lines indicate S. E. M. 
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100 nM morphine, reduced the size of electrically evoked contraction by 65.8 + 5.5% 
(n = 6) of untreated contraction amplitude. Inhibition evoked by 1 pM WIN 55.212-2 
in the presence of 100 nM morphine did not significantly differ from that evoked in 
the absence of morphine. 
Morphine (1 µM) alone reduced the size of electrically evoked contraction by 42.4 ± 
1.5% (n = 13). The WIN 55,212-2 concentration-response curve significantly differed 
from that evoked in the absence of morphine, with WIN 55,212-2 inducing less 
inhibition of contraction (EC50 = 35.7 nM, p<0.00 1, figure 4.6). 1 µM WIN 55,212-2, 
in the presence of 1 µM morphine, reduced the size of electrically evoked contraction 
by 58.8 + 12.8% (n = 2) of untreated contraction amplitude. Inhibition evoked by 1 µM 
WIN 55,212-2 in the presence of 1 µM morphine did not significantly differ from that 
evoked in the absence of morphine. 
4.3.4 Interaction of cannabinoids with morphine withdrawal evoked 
contractions of the whole ileum 
Both opioids and cannabinoids have been demonstrated to produce contraction upon 
abrupt withdrawal, after prolonged exposure, in whole ileum, and so a possible 
interaction in the production of this contraction was explored. 
Opioid withdrawal, induced by the opioid receptor antagonist naloxone (10 µM) after 
three hour incubation with morphine (1 µM), evoked a rapid contraction of whole 
ileum of 1.77 1 0.43 g (n = 10, figure 4.7). Contraction was rapidly followed by 
relaxation to basal levels of contraction. Re-application of naloxone after washing did 
not induce a contraction. Tissue incubated in a similar manner contracted by 3.56 + 
0.37 g (n = 12) upon exposure to Carbachol (1 µM). 
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Figure 4.7 Effect of CP 55,940 on contractions of the whole ileum induced by abrupt 
withdrawal from 3 hr exposure to 1 pM morphine by the application of 10 µM 
naloxone. Each column represents the mean amplitude of peak contraction evoked by 
application of naloxone (10 pM) after exposure to CP 55,940 for 20 minutes. CCh 
represents control exposure to 1 pM carbachol. Nalox represents control exposure to 
naloxone in the absence of CP 55,940. Each comprises of at least 3 different MPLM 
preparations. Vertical lines indicate S. E. M. 
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CP 55,940, when applied 20 minutes prior to naloxone at doses ranging from 0.1 nM 
to 100 nM, did not induce significant changes in contraction (at least three different 
MPLM preparations were used for each concentration, p>0.05, ANOVA, figure 4.7) 
4.3.5 Effects of opioids on membrane hyperpolarisation in cultured myenteric 
neurones 
Stable whole-cell patch recordings were made from a total of 30 cultured myenteric 
neurones. To observe activation of potassium channels, and therefore membrane 
hyperpolarisation with exposure to opioids, myenteric neurones were held under 
current clamp, membrane potential was maintained at approximately -80 mV. 
Exposure to morphine (10 pM, n= 10, figure 4.8a) did not induce membrane 
hyperpolarisation. Increasing extracellular potassium concentration to 50 mM did not 
change lack of hyperpolarisation evoked by morphine (10 µM, n= 5). Action 
potentials were evoked by current steps to depolarise the membrane (n = 3, figure 
4.8b). Only single action potentials were evoked with each current step, probably as a 
result of after-hyperpolarisation observed after action potentials in myenteric 
AH-neurones. 
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Figure 4.8 Sample traces derived from myenteric neurones held under current clamp. 
(a) Trace depicts changes in membrane potential evoked by morphine (10 µM) in a 
single cell in which an initial membrane potential of approximately -80 mV was 
achieved through application of a sustained current. (b) Superimposed traces depict 
action potentials evoked by 100 ms current steps, each producing a rise in membrane 
potential of approximately 20 mV. 
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4.3.6 Effects of opioids on G-protein coupled inwardly rectifying potassium 
current in cultured myenteric neurones 
The G-protein coupled inwardly rectifying potassium current (GIRK) has been shown 
to be potentiated by both opioids (Galligan and North, 1991) and cannabinoids 
(Mackie et al., 1995). 
To observe potentiation of GIRKs with exposure to opioids, myenteric neurones were 
held under voltage clamp and membrane potential was stepped for 100 ms periods to 
potentials ranging from -120 to -20 mV (figure 4.9a). Voltage-gated sodium channel 
activation was observed at membrane potentials ranging from -40 to -20 mV. 
Potentiation of GIRKs would be expected to increase inward current at hyperpolarised 
potentials. However, five minutes exposure to morphine (10 µM, n= 8) did not 
induce a statistically significant deviation from control current levels (figure 4.9b). 
4.3.7 Effects of opioids on calcium current in cultured myenteric neurones 
Inhibition of voltage-gated calcium currents (Ica) by opioids have been demonstrated 
in many studies (Williams et al., 2001). To isolate lca in cultured myenteric neurones, 
sodium and potassium currents were inhibited through the application of TTX in 
176 
a 
b 
Membrane potential (mV) 
0" 
-5 
U- 
ý 
-10" 
-15 
-20- 
Figure 4.9 (a) Superimposed traces derived from cultured myenteric neurones held 
under voltage clamp. Traces depicts changes in current flow across the membrane 
evoked by 100 ms, 10 mV steps in membrane potential ranging from -120 to -20 mV. 
(b) Mean current-voltage relationship of 8 neurones prior to (") and post five minutes 
exposure to morphine (10 µM, 0). 
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Figure 4.10 Effect of morphine (10 µM) and DADLE (100 nM) on 'Ca in cultured 
myenteric neurones under voltage clamp. Each point represents the mean amplitude of 
peak current evoked by a 100 ms step in membrane potential from a holding current 
of -70 mV to 0 mV as a proportion of current evoked prior to application of opioids 
(n = 4). Vertical lines indicate S. E. M. 
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extracellular solutions, to block sodium currents, and TEA and Cs2+ in intracellular 
solutions, to block potassium currents. Application of both morphine (10 µM) and the 
6-receptor specific agonist, DADLE, (100 nM, n=4, figure 4.10) did not significantly 
inhibit the current. 
4.3.8 Effects of opioids on calcium current in the NG108-15 cell line 
The NG108-15 cell line is a well established model for investigating the modulation 
of Ica by opioids and cannabinoids and makes an ideal model for investigating any 
interaction between the two families (Tsunoo et al. 1986, Mackie and Hille, 1992). 
Stable whole-cell patch recordings were made from a total of 32 NG 108-15 neurones. 
To isolate ICa in NG 108-15 neurones, sodium and potassium currents were inhibited 
through the application of TTX in extracellular solutions, to block sodium currents, 
and TEA and Cs 2+ in intracellular solutions, to block potassium currents (figure 4.11). 
An inward Ca 2+ current of 316 ± 32 pA (6.6 ± 1.0 pA. pF-I) was elicited in 17 
neurones by a 100 ms depolarising pulse to 0 mV from a holding potential of -70 mV. 
The current consisted of a sharp transient increase followed by a slowly decreasing 
component (figure 4.11 c). Inward current initiated upon a depolarising pulse to -40 
mV and achieved a peak inward current at 0 mV (figure 4.12a and b). 
Treatment with the b-opioid receptor selective agonist DADLE depressed the 
amplitude of the Ca2+ current elicited by a depolarising pulse to 0 mV, with maximal 
inhibition occurring at 0 mV, at the peak of the I-V relationship (n = 6, figure 4.12b 
and d). Inhibition occurred over a concentration range of 10 pM to 100 nM (figure 
4.12c). Regression to a sigmoidal dose-response curve ascertained an ICSo for 
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Figure 4.11 Sample traces derived from a single NG 108-15 neurone held under 
voltage clamp. Traces depicts changes in current flow across the membrane evoked 
by 100 ms, 5 mV steps in membrane potential ranging from -80 to 90 mV. (a) Depicts 
current prior to blockade whilst (b) depicts current post IK blockade and (c) depicts Ica 
upon blockade of INa. (d) Demonstrates inhibition of ICa upon application of CP 
55,940 (10 µM). (e) NG108-15 under 500x magnification. 
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Figure 4.12 Modulation of calcium currents in NG108-15 neurones on exposure to 
DADLE. (a) Superimposed I-V curves of peak Ica, expressed as a proportion of 
inward current evoked by a 100 ms voltage step to 0 mV in the absence of (") and 
presence of DADLE (100 nM, 0). Each point represents the mean ± S. E. M. of at 
least five neurones. (b) magnification of figure 4.12a, amplifying inhibition evoked by 
DADLE. (c) DADLE inhibited peak Ca 2+ current elicited by a0 mV depolarising 
pulse. Points show the mean current, expressed as a proportion of inward current 
evoked by a 100 ms voltage step to 0 mV in the absence of DADLE, evoked in the 
presence of DADLE at concentrations ranging from 10 pM to 100 nM. Bars show 
S. E. M. Non-linear regression to a sigmoidal concentration-response curve presented 
an ICso and maximal blockade for DADLE of 67.3 pM and 40.4% respectively. (d) 
Sample trace derived from a single NG 108-15 neurone held under voltage clamp. 
Trace depicts changes in current flow across the membrane evoked by a 100 ms 
voltage step to 0 mV on application of 0.1,1 and 10 nM DADLE. 
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DADLE of 67.3 pM (95% confidence limits of 23.4 to 193 pM) and a maximum 
reduction of current of 40.4 ± 0.03%. 
4.3.9 Effects of cannabinoids on calcium current in the NG108-15 cell line 
WIN 55,212-2 depressed the amplitude of the Ca 2+ current elicited by a depolarising 
pulse to 0 mV (n = 5). Inhibition occurred over a concentration range of 1 nM to 10 
µM (figure 4.13a). Regression to a sigmoidal dose-response curve ascertained an IC50 
for WIN 55,212-2 of 58.3 nM (95% confidence limits of 35.6 to 93.4 pM) and a 
maximum reduction of current of 51.7 ± 0.04%. Maximal inhibition occurred at 0 mV, 
at the peak of the I-V relationship (n = 6, figure 4.13b). 
4.3.10 Interaction between cannabinoids and opioids on calcium current in the 
NG108-15 cell line 
DADLE (100 nM) which, when applied alone, induced maximal inhibition, reducing 
inward current, evoked by a voltage step to 0 mV, by 32.2 + 2.4% (n = 3). WIN 
55,212-2 (10 µM) applied alone also induced maximal inhibition, reducing current by 
26.6 ± 3.0% (n = 3). With prior exposure to WIN 55,212-2 (10 µM), addition of 
DADLE (100 nM) induced a further inhibition of inward current of 10.3 ± 1.0% 
(figure 4.14, n= 3). Inhibition was significantly smaller than that evoked by DADLE 
(100 nM) in the absence of WIN 55,212-2 (p < 0.01). 
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Figure 4.13 Modulation of calcium currents in NG 108-15 neurones on exposure to 
WIN 55,212-2. (a) WIN 55,212-2 inhibited peak Ca 2+ current elicited by a0 mV 
depolarising pulse. Points show the mean peak current, expressed as a proportion of 
inward current evoked by a 100 ms voltage step to 0 mV in the absence of WIN 
55,212-2, evoked in the presence of WIN 55,212-2 at concentrations ranging from 1 
nM to 10 µM. Bars show S. E. M. Non-linear regression to a sigmoidal concentration- 
response curve presented an IC50 and maximal blockade for WIN 55,212-2 of 58.3 
nM and 51.7% respectively. (b) Superimposed I-V curves of peak ICa, expressed as a 
proportion of inward current evoked by a 100 ms voltage step to 0 mV in the absence 
of (") and presence of WIN 55,212-2 (1 µM, 0). Each point represents the mean ± 
S. E. M. of at least six neurones. 
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Figure 4.14 WIN 55,212-2 reduces DADLE inhibition of Ca 2+ currents in NG108-15 
neurones. WIN 55,212-2 (10 µM) significantly reduced inhibition evoked by DADLE 
(100 nM) of peak Ca 2+ current elicited by a0 mV depolarising pulse (**, p<0.01, t- 
test). Columns show the mean current, expressed as a proportion of inward current 
evoked by a 100 ms voltage step to 0 mV in the absence of WIN 55,212-2 and 
DADLE and consists of at least three neurones. Bars show S. E. M. 
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4.4 Discussion 
It is now generally well accepted now that both cannabinoid and opioid receptors act 
through G; /. -protein mediated pathways to modulate cellular activity (Pertwee, 1997; 
Williams et al., 2001). As a result, some degree of interaction may be hypothesised to 
exist within the myenteric plexus given the major role both receptors families play in 
governing motility. 
Data presented in this chapter and in chapter 2 clearly demonstrate both CP 55,940 
and morphine inhibit electrically evoked contraction of the guinea-pig MPLM 
preparation in a concentration-dependent manner, with CP 55,940 showing SR141716 
sensitivity similar to that observed by Paton (1957) and Pertwee et al. (1996). 
This study showed with morphine producing identical concentration-response curves, 
that inhibition produced by CP 55,940 at concentrations of 10 nM and below is 
evoked independently to that produced by morphine. While exposure to 100 nM CP 
55,940 prevented all morphine-evoked inhibition. The presence of this blockade of 
morphine evoked inhibition by 100 nM CP 55,940, and its absence at lower 
concentrations, suggests either the exhaustion of a shared intracellular messenger or 
the activation by 100 nM CP 55,940 of an additional receptor or cannabinoid receptor 
mediated intracellular mechanism to interact with the opioid signalling mechanisms 
(figure 4.15). However, the possibility of the exhaustion of a shared intracellular 
messenger is ruled out by the observation that inhibition evoked by 1 µM morphine 
and 100 nM CP 55,940 was smaller than that evoked by 1 µM morphine and 10 nM 
CP 55,940. Should inhibition be dependent upon a shared intracellular messenger, 
inhibition produced by morphine in the presence of CP 55,940 would be expected to 
be limited, but not reduced in the presence of high CP 55,940 concentrations. This 
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interaction between cannabinoids and opioids is supported by the reduced potency 
displayed by WIN 55,212-2 in inhibiting contraction in the presence of 100 nM and 1 
µM morphine. 
If it is assumed that inhibition of endogenous tonically active cannabinoids are 
responsible for the increased amplitude of contractions evoked by SR 141716, and 
these endogenous cannabinoids possess similar pharmacological properties to CP 
55,940, then morphine would be expected to display the same additive interaction in 
the presence of SR141716 as displayed with low levels of CP 55,940. The observation 
of increased inhibition by morphine in the presence of SR141716 suggests the 
increase in the amplitude of contractions evoked by SR 141716 is not due to inhibition 
of tonically active endogenous cannabinoids. 
The lack of any significant modulation of opioid withdrawal evoked contractions by 
CP 55,940 is intriguing as Basilico et al. (1999) demonstrated cross-inhibition in the 
guinea-pig MPLM preparation. One possible explanation for the lack of inhibition 
observed may lie in the high variability of the data. Some reduction of the mean 
contraction size is apparent, but with the large variability this is not significant. 
The lack of opioid inhibition of both potassium and calcium currents in myenteric 
neurones was anticipated in retrospect. Intracellular recording by North et al. (1979) 
observed potassium channel activation when opioids were applied by iontophoresis to 
the surface of the ganglion and not soma, inferring that opioid receptors are not 
expressed on the soma. In generating primary cultures of myenteric neurones 
mechanical force is applied through tituration of enzymatically digested tissue. It is 
probable that this mechanical force would split the soma and ganglia and so prevent 
patch clamping, which is performed upon the soma, from detecting opioid activity. 
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Figure 4.15: Hypothesised intracellular interaction between cannabinoids and opioids. 
(a) A shared intracellular messenger may be responsible for conveying signalling 
within a cell. Depletion of this shared messenger through activation of one receptor 
pathway will prevent stimulation of the other pathway from acting. (b) Both CB, and 
opioid receptors may possess independent mechanisms by which each evoke 
inhibition. The interaction observed may not be the result of greater CB, receptor 
stimulus and an increased role of already active intracellular mechanisms, but may be 
due to activation of an alternate mechanism (CBx) to interact with the opioid receptor 
or associated mechanisms. 
188 
The observation that DADLE, at a concentration which produces maximal inhibition 
of Ca 2+ currents, producing a reduced inhibition in the presence of WIN 55,212-2, 
also at a concentration which produces maximal inhibition, is interesting as Shapira et 
al. (1998) demonstrated no interaction between opioid and cannabinoid receptors with 
[35S]GTPyS binding in N18TG-2 cells. The maintained lack of interaction in the 
presence of partial G-protein activity led Shapira et al. (1998) to conclude that 
receptors acted on different pools of G-proteins within the cell. Suppression of 
calcium currents in NG 108-15 cells has been shown to be mediated by Go-proteins, a 
member of the collection of G-proteins, which are deemed G110-proteins and are 
inhibited by PTX (Hescheler et al., 1987). It is possible that Go-proteins are shared 
between opioid and cannabinoid receptors in the inhibition of calcium currents, but 
they make up a small proportion of the G; io-proteins that bind to these receptors. As a 
result, measurement of [35S]GTPyS binding would fail to pick up the interaction 
observed. Unfortunately, difficulties in culturing neurones led to the cessation of work 
in this area as further examination of this interaction would prove interesting. 
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Chapter 5- Modulation of the rat mesolimbic dopaminergic reward pathway by 
cannabinoids 
5. Chapter 5- Modulation of the rat mesolimbic dopaminergic reward 
pathway by cannabinoids 
5.1. Introduction 
Dopamine was recognised as a neurotransmitter in the late 1950s through the 
demonstration of its non-uniform distribution in the brain, which suggested a specific 
functional role for dopamine. Realisation of its role in certain brain diseases, for 
example Parkinson's disease and schizophrenia, led to a large increase in research. 
5.1.1. Dopaminergic receptors and ligands 
The dopamine receptor family consists of at least five different receptors, grouped 
into subfamilies termed D1-like (D1 and D5) and D2-like (D2, D3 and D4). Both D1-like 
and D2-like receptors are G-protein coupled receptors consisting of a single amino 
acid chain comprising of seven transmembrane domains interspaced by intracellular 
and extracellular loops. D1-like receptors are GS-protein coupled while D2-like 
receptors are G110-protein coupled (Vallone et al., 2000). 
D1-like receptors have been shown to increase intracellular cAMP levels, resulting in 
the activation of protein kinase A, and increasing and inhibiting differing calcium and 
potassium currents. D1-like receptors also inhibit arachidonic acid synthesis (Vallone 
et al., 2000). D2-like receptors induce a wide variety of responses including inhibition 
of adenylate cyclase, modulation of outward potassium current, and direct G-protein 
inhibition of voltage operated calcium channels (Vallone et al., 2000). 
191 
Within the rat brain the D, receptor is mainly expressed in the caudate-putamen, 
nucleus accumbens (NAcc), olfactory tubercle, cerebral cortex and amygdala. In 
addition, Di receptors have been detected at lower levels in the island of Calleja, in 
the subthalamic nucleus and in the substantia nigra pars reticulate (Jackson and 
Westlind-Danielsson, 1994). D5 receptor expression is more restricted, having only 
been detected in the hippocampus, lateral mammillary nucleus, and in the 
parafascicular nucleus of the thalamus. The D2 receptor is predominantly expressed in 
the caudate-putamen, NAcc and olfactory tubercle. This receptor is also expressed in 
the substantia nigra pars compacta and in the ventral tegmental area (VTA). D3 
receptor mRNA is restricted to a few regions including the islands of Calleja, septal 
nuclei, hypothalamus, and distinct regions of the thalamus and cerebellum. The D4 
receptor is highly expressed in the frontal cortex, amygdala, the olfactory bulb, 
hippocampus, hypothalamus and mesenchephalon (Jackson and Westlind-Danielsson, 
1994). D1-like receptors are thought to be exclusively postsynaptic while D2-like 
receptors may have presynaptic locations (Civelli et al., 1991). 
5.1.2. Dopaminergic signalling physiology and psychostimulants 
Dopamine, a catecholamine comprising of a catechol group and a ethylamine side 
chain, is produced from tyrosine by tyrosine hydroxylase and aromatic 1-amino acid 
decarboxylase and stored in secretory vesicles, from which dopamine is directly 
released into the synapse. After signalling, dopamine is taken up from the synapse by 
the dopamine transporter into the presynaptic terminal and transported into vesicles 
by the vesicular monoamine transporter 2 (Gainetdinov et al., 2002). Cocaine blocks 
the dopamine transporter causing an accumulation of dopamine within the synapse. 
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Amphetamine enters the presynaptic terminal and vesicle, via the dopamine 
transporter and the vesicular monoamine transporter 2, causing a disruption in 
vescular pH gradient and redistribution of dopamine into the cytoplasm. 
Amphetamine induces a reversal of the dopamine transporter causing a massive 
outflow of dopamine into the synapse. In addition, amphetamine blocks monoamine 
oxidase thereby decreasing intracellular metabolism of dopamine (Gainetdinov et al., 
2002). 
5.1.3. The rat mesocorticolimbic reward pathway 
The mesocorticolimbic pathway is considered to play an important role in mediating 
reward within the brain and is therefore an interesting location to examine the 
interaction between cannabinoids and other drugs of abuse. The role of 
psychostimulants is well characterised in the reward pathway, producing an ideal 
location for investigating interactions with cannabinoids. 
5.1.3.1. Neuroanatomy and physiology 
The mesocorticolimbic pathway originates as a diffuse collection of soma, located 
within the anterior ventral limbic forebrain bundle, converging through myelinated 
moderately fast-conducting pathways to synapse on dopaminergic neurones in the 
VTA (figure 5.1). Primary excitatory and inhibitory input occurs via glutamatergic 
(from prefrontal cortex, the pedunculopontine nucleus and the bed nucleus of the stria 
terminalis) and GABAergic (mainly from the NAcc but also from the ventral 
pallidum) neurones. Additional modulation has been observed through the actions of 
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catecholamines, amino acids, neuropeptides and endocannabinoids (Mathon et al., 
2003). Within the VTA the principle neurones have been shown to be dopaminergic 
neurones (Johnson and North, 1992), while secondary neurones are considered to be 
GABAergic interneurones and projection neurones (Steffensen et al., 1998; Can and 
Sesack, 2000). In the brain, dopaminergic neurones are divided into cell groups, 
ranging from A8 to A17, on the basis of locations originating from and projecting to. 
The A8-A10 cell groups innervate the substantia nigra, the adjacent retrorubral field 
and the VTA, with A8 projecting from the retrorubral field to the locus ceruleus and 
leteral parabrachial nucleus, A9 projecting from the substantia nigra pars compacta to 
the prefrontal cortex, and A10 projecting from the VTA to the NAcc. 
The NAcc forms part of the striatum (Bolam et al., 2000), and comprises mainly 
(about 90-95% of the neuronal population) of medium-sized spiny neurones (MSNs), 
a class of GABAergic cells. In the NAcc, MSNs receive extensive glutamatergic input 
from different limbic areas such as prefrontal cortex, thalamus, hippocampus, and 
basolateral amygdala, as well as dopaminergic input. Dopaminergic input is mediated 
by both DI-like and D2-like receptors within the NAcc (Spanagel and Weiss, 1999). 
MSNs project their output to downstream areas of the mesocorticolimbic system like 
the ventral pallidum, the lateral hypothalamus, and mesencephalic dopaminergic areas 
(Chang and Kitai, 1985; Groenewegen and Russchen, 1984; Nauta et al., 1978), as 
well as branching within the NAcc (Pennartz et al., 1991) and projecting to the VTA 
to provide feedback tonic inhibition (Gardner and Vorel, 1998). 
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5.1.3.2. Addiction 
Within the mesolimbic system addiction is considered to occur through the increased 
release of dopamine in the NAcc. Cocaine and amphetamine have been shown to act 
in the NAcc by inhibiting presynaptic dopamine transporters and inducing the release 
of vesicular monoamines from vesicles to the cytoplasm (Gainetdinov et al., 2002), 
while opioids are considered to act through the inhibition of GABAergic inhibitory 
neurones innervating the VTA (Spanagel and Weiss, 1999). 
5.1.3.3. Role of cannabinoids within the mesocorticolimbic pathway 
Extracellular recordings of spontaneous firings within the VTA in anaesthetised rats 
were shown to increase in the presence of systemically administered A9-THC and 
WIN 55,212-2, but not in the presence of the inactive enantiomer WIN 55,212-3 
(French et al., 1997a). Further experiments carried out by French (1997b), using 
single-cell recording techniques, showed systemic exposure to SR141716 not only 
blocked cannabinoid induced increases in firing rate, but produced a decrease, 
suggesting tonic activation by endocannabinoids. However, this decrease was not 
replicated by other in vivo studies (Cheer et al., 2003; Gessa et al., 1998). The opioid 
receptor antagonist naloxone did not affect the cannabinoid response, suggesting that 
cannabinoids were not acting through GABAergic neurones (French, 1997). 
Microinjection of A9-THC into the VTA did not increase dopamine release in the 
NAcc, but increased levels in the VTA. Infusion of the cannabinoid directly into the 
NAcc increased levels in this dopaminergic terminal area (Chen et al., 1993), 
suggesting cannabinoid modulation of dopamine release and not firing. Szabo et al. 
(2002) demonstrated, using rat coronal midbrain slices, a SRI 417 16- sensitive, WIN 
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55,212-2-dependent inhibition of GABA release in the VTA, measured via GABAA 
receptor mediated inhibitory postsynaptic currents within dopaminergic neurones. 
This suggests the presence of CB, receptors on GABAergic neurones in the VTA. 
A sizeable body of evidence exists demonstrating a cannabinoid dependent increase in 
dopamine release in the NAcc. In vivo studies showed systemic A9-THC increased 
extracellular concentrations of dopamine in the NAcc in Lewis rats (Chen et al., 1990, 
1991). Sprague Dawley rats displayed a reduced increase while no increase was found 
in Fisher and Long Evans rats (Castaneda et al., 1991). Rodriguez de Fonseca et al. 
(1992) and Navarro et al. (1993) showed conflicting levels of dopamine in the NAcc 
results when examining response to systemic application of cannabinoids ex vivo. The 
differing release of dopamine in response to cannabinoids within the NAcc may be 
due to increased release being only apparent in sections of the NAcc. Microdialysis 
experiments showed a SR141716-sensitive cannabinoid dependent increase in 
extracellular dopamine in the shell, but not the core, of the NAcc, in a manner similar 
to that induced by heroin (Tanda et al., 1997). µ receptor antagonists inhibited both 
A9-THC and heroin, which led the authors to suggest a common opioid receptor 
mediated mechanism governing release, conflicting with the opioid independence 
observed by French in the VTA. Szabo et al. (1999) showed, through the use of fast 
cyclic voltammetry recordings, cannabinoids did not increase electrically evoked 
dopamine release in brain slices. This ruled out a presynaptic modulation of dopamine 
release. Cannabinoids have been shown to act presynaptically to inhibit glutamatergic 
transmission in the NAcc and so affecting firing of MSNs (Pistis et al., 2002; Robbe 
et al., 2001,2002), which feedback to the VTA and so may modulate dopaminergic 
firing. 
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Herkenham et al. (1991) showed through in vitro autoradiography studies a lack of 
CB, receptors in the VTA and intermediate levels in the NAcc. This was substantiated 
by studies demonstrating the lack of expression of CB, receptor mRNA within the 
VTA (Matsuda et al., 1993) and the presence of CB1 receptor immunoreactive fibres 
in the NAcc, but not in the VTA (Tsou et al., 1998; Patel and Hillard, 2003). 
In summary, cannabinoids have been shown to reduce GABA release and increased 
spontaneous firing in dopaminergic neurones within the VTA through 
electrophysiological studies, but the CB, receptor has been shown not to be present in 
the VTA. Cannabinoids have been shown to inhibit dopamine release in particular 
segments of the NAcc that are innervated by the mesocorticolimbic pathway and 
inhibit glutamatergic input into the NAcc. 
Evidence for an influence of cannabinoids on spontaneous action potential activity in 
neurones in the VTA was sought in rat midbrain slices using the blind whole-cell 
patch-clamp technique. 
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5.2. Methods 
5.2.1. Preparation of rat brain slice 
Eighteen to twenty four-day-old Wistar female rats were sacrificed by cervical 
dislocation and decapitated. The brains were rapidly removed and placed in ice-cold 
artificial cerebrospinal fluid (ACSF; see section 5.4.3 for composition) gassed with 
95% 02 and 5% CO2.300-400 µm thick coronal midbrain slices containing the 
ventral tegmental area were cut (at 0°C) using a vibratome (l 000plus; Vibratome, 
USA). Slices were stored in a Gibbs chamber (see figure 5.1) containing ACSF. In 
order to support the recovery of neurones, slices were kept at 35°C for one hour and 
subsequently stored at room temperature. 
5.2.2. Blind whole-cell patch-clamp recordings 
Brain slice extracellular recording allows the measurement of small field potentials, 
which arise from the flow of ionic current through extracellular fluid triggered by 
neural firing. These are measured by the insertion of a pipette filled with a conducting 
media (usually 3M KCl) into the brain or brain slices. To achieve this, the brain slice 
must be kept in a bath mimicking, as closely as possible, the environment the tissue is 
exposed to in vivo whilst the recording pipette is coarsely positioned. Blind patch- 
clamp recording in brain slices is a combination of extracellular and whole-cell patch 
clamping techniques, but instead of the high-magnification visual guidance that is 
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required for approaching the cell in single-cell patch clamping, proximity to a cell is 
determined solely through a change in resistance at the pipette tip. 
Slices were attached to the glass bottom of a 150 pI superfusion chamber (RC-26; 
Warner Instruments Inc., USA) with a nylon grid on a stainless steel frame and 
superfused with ACSF at a flow rate of 1.2 mu min. The superfusion chamber was 
maintained at 35°C using a TC324B single channel automatic heater controller 
(Warner Instruments Inc., USA). Brain segments were observed using a Meiji EMT- 
2PB stereo microscope (Meiji Techno Co., Japan). The pipette was visually 
positioned over the VTA and gently lowered into the slice. Contact with surrounding 
support cells caused a slight increase in resistance. Upon contact with a neurone there 
would be a further and larger increase in resistance. Techniques for gigaseal and patch 
formation are detailed in section 2.4.2. 
5.2.2.1. Patch clamp techniques: current clamp 
To observe spontaneous action potentials, membrane potential was allowed to 
fluctuate at will although a fixed current, determined by the current required to 
maintain a holding potential of -70 mV, was passed into the cell to account for 
leakage via the patch. 
5.2.3. Analysis of data 
Significant difference between mean values were calculated using the Friedman test, a 
non-parametric repeat measures test, followed by a Dunn multiple comparison post 
hoc test, with aP value of < 0.05 being taken as significant. 
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5.2.4. Solutions 
Brain slices were maintained in artificial cerebral-spinal fluid (ACSF), which 
contained (mM): NaCl 126, KC1 2.5, MgCl2 1.2, NaH2PO4 1.2, NaHCO3 21.4, 
glucose 11.1, CaC12 2.4, ascorbic acid 0.1. All drugs were administered in ACSF, 
superfused at a rate of 1.2 ml/min. 
5.2.5. Drugs 
Dopamine (SigmaAldrich, UK) was dissolved in 0.1 M citric acid and kept on ice. 
Fresh solution were prepared daily. Other drugs used are detailed in previous 
chapters. 
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5.3. Results 
Electrical recordings were obtained from 15 slices obtained from 12 animals. On 
patching a spontaneous action potential was observed displaying a transient 
depolarisation, followed by a hyperpolarisation (figure 5.2). Action potentials fired at 
a mean rate of 4.4 ± 0.8 Hz (n = 10). 
5.3.1. Effects of dopamine on spontaneous firing frequency 
Application of 1 µM dopamine significantly decreased mean firing rate to 3.2 ± 1.0 
Hz and 3.2 + 1.0 Hz after 1.5 and 2.5 minutes respectively (n = 6, P<0.01, 
Friedman's test, figure 5.3a and b). Post hoc comparison with control reported aP 
value of < 0.05 for both 1.5 and 2.5 minutes (Dunn's test). 10 µM dopamine 
significantly decreased mean firing rate to 2.5 ± 1.2 Hz and 2.3 ± 1.2 Hz after 1.5 and 
2.5 minutes respectively (n = 6, P<0.05, Friedman's test). Post hoc comparison with 
control showed significance at 2.5 minutes (P < 0.05, Dunn's test) 
5.3.2. Effects of CP 55,940 on spontaneous firing frequency 
Application of 10 µM CP 55,940 induced no change in firing rate, producing a mean 
firing rate after 1.5 and 2.5 minutes of 4.3 ± 1.4 Hz and 4.5 ± 1.3 Hz respectively (n = 
5, figure 5.3). 
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Figure 5.2 (a) Sample spontaneous action potential recorded from a neurone within 
the VTA of a rat brain slice through the use of blind patch clamping. (b) Sample 
recording from a neurone within the VTA demonstrating the reduction in firing 
frequency induced by application of dopamine. 
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Figure 5.3 Modulation of spontaneous firing frequency in neurones within the VTA 
by dopamine and CP 55,940. (a) Each line represents the firing frequency of a single 
cell over a period of time prior to and post application of dopamine (1 and 10 PM) 
and CP 55,940 (10 µM). (b) Each column represents the mean firing frequency, 
expressed as a percentage of untreated firing frequency at differing time points prior 
to and post application of dopamine (1 µM, n=6 and 10 µM, n= 6) and CP 55,940 
(10 µM, n= 5). Vertical lines indicate S. E. M. The significance of the difference 
between columns was calculated using Friedman's test followed by Dunn's test with 
indicating a significant difference ofp < 0.05 versus control. 
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5.4. Discussion and conclusion 
With the addictive properties of cannabinoids there is evidently a possible role for 
cannabinoids in modulating the activity of the ventral tegmental area. The present 
data, however showed no direct modulation of spontaneous action potential firing 
within neurones upon exposure to CP 55,940. In contrast, dopamine reduced the 
frequency of firing probably through a mechanism similar to that reported by Lacey et 
al. (1987), who observed a D2-like receptor mediated hyperpolarisation through 
increasing potassium conductance in A9 dopaminergic neurones in the substantia 
nigra zona compacta. 
The lack of inhibition of action potential firing displayed by CP 55,940 is not 
unexpected as midbrain dopaminergic neurones have been shown not to express CB I 
cannabinoid receptors (Mailleux and Vanderhaeghen, 1992; Matsuda et al., 1993). 
Proof that the neurones recorded from were dopaminergic was demonstrated by 
Johnson and North (1992) who observed the presence of two types of neurone in the 
VTA, a dopaminergic neurone which displayed spontaneous action potential firing 
and made up 77% of neurones present, and a neurone which responded to opioid 
agonists and did not show spontaneous firing. 
Within the VTA in rat brain slices, Szabo and colleagues reported WIN 55,212-2 to 
elicit inhibition of electrically induced GABA release from adjoining neurones onto 
dopaminergic neurones. Direct action at GABAA receptors on dopaminergic neurones 
was excluded through the observation that WIN 55,212-2 did not alter miniature 
IPSP, a measure of spontaneous opening of GABAA channels (Szabo et al., 2002). In 
support of this study, extracellular recordings of VTA neural firing in rat brain slices 
was shown to be increased by the synthetic cannabinoid agonist HU210 (Cheer et al., 
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2000). Bicuculline also increased the firing rate of VTA neurones and occluded the 
effect of the synthetic cannabinoid HU210 (Cheer et al., 2000). 
In conclusion, data derived in this and other studies suggest cannabinoids do not 
directly modulate the firing of VTA dopaminergic neurones, but may act to suppress 
inhibitory regulation of these neurones by GABAergic neurones within the VTA. 
The aim of this chapter was to investigate the interaction between cannabinoids and 
psychostimulants in the VTA. Unfortunately, difficulties in preparing viable slices led 
to the prevention of further work in this area. A brief sabbatical to the laboratory of 
Prof. Henderson in Bristol confirmed the quality of techniques and equipment 
employed in the preparation of slices, but unfortunately did not improve the quality of 
slices derived. One possible cause for this difficulty may have been the distance 
between rooms in which sacrifice occurred and recording performed. Shaking during 
transport may have caused physical damage to tissue, while lack of oxygenation may 
have resulted in oxygen starvation. 
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General Conclusion 
6. General Conclusion 
With the recent discovery of cannabinoid receptors and endogenous ligands for these 
receptors and the rising illegitimate use of cannabis the necessity for further research 
into the role cannabinoids play in the body has become apparent. This has been 
further emphasised by the growing use of cannabinoid ligands in the treatment of 
pathological conditions, examples of which include the use of Sativex for the 
treatment of neuropathic pain in multiple sclerosis sufferers and Marinol for the 
treatment of anorexia associated with weight loss in AIDS patients. 
Although cannabinoid inhibition, through a SR 141716 sensitive pathway, of 
gastrointestinal motility and electrically evoked contraction of the MPLM was first 
observed over ten years ago (Pertwee et al., 1996; Izzo et al., 1999), few studies have 
been performed to try to establish the mechanisms by which inhibition occurs. The 
presence of the CB1 receptor was confirmed with binding and immunohistochemical 
studies (Lynn & Herkenham, 1994; Coutts et al., 2002), and by the detection of CB, 
receptor mRNA within the MPLM (Griffin et al., 1997). Debate as to whether the 
CB, receptor was the only mechanism through which cannabinoid ligands act in the 
intestinal tract was sparked by the observation by Mang et al. (2001) of a mechanism 
through which cannabinoid agonists act that requires higher SR141716 concentrations 
than expected for action at the CB, receptor. Intracellular recording of action 
potentials in myenteric S-type neurones in vitro by Lopez-Redondo et al. (1997) 
suggested CB1 receptor independent cannabinoid activity through SR141716 alone 
producing inhibition, while DeMuth et al. (2004) observed a SR141716-independent 
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cannabinoid inhibition of nicotinic currents through a G; /,, -protein independent 
mechanism. 
6.1. The interaction between cannabinoids and the nACh receptor in the 
guinea-pig ileum myenteric plexus 
Within the enteric nervous system, the nicotinic acetylcholine receptor predominantly 
mediates interneuronal excitatory transmission (Galligan & North, 2004). Oz and 
colleagues reported cannabinoid inhibition of nicotinic 0 homomeric receptors, 
expressed in Xenopus oocytes, through a CB, and CB2 receptor independent 
mechanism, suggesting cannabinoids may act through this mechanism to inhibit 
intestinal motility (Oz et al., 2003; 2004). Through the use of nicotine evoked 
contraction of the MPLM preparation, this study observed cannabinoid inhibition 
occurring through both a CB, receptor dependent and an independent mechanism. 
These mechanisms demonstrated some degree of selectivity dependent upon the level 
of stimulus evoked by nicotine, with contraction evoked by 100 µM nicotine 
demonstrating CB, receptor independence whilst contraction evoked by 10 µM 
nicotine showed SR141716 sensitivity. This decrease in sensitivity to cannabinoids 
may resemble the decreased sensitivity to morphine observed with higher frequency 
electrically induced acetylcholine release in the MPLM (Cowie et al., 1968). Higher 
concentrations of nicotine may result in a large depolarisation of the soma and so 
initiate the firing of multiple action potentials, in a manner similar to that evoked by 
high frequency electrical stimulation, while lower concentrations of nicotine may 
result in a single firing of or provoke a low frequency firing of action potential similar 
to that evoked by low frequency electrical stimulation and so possess more 
210 
susceptibility to a G-protein mediated inhibition. This would suggest that the CB, 
receptor acts to inhibit an action potential, but in doing so induces some form of 
desensitisation allowing high frequency trains of action potentials to overcome 
inhibition. This work also suggests, with the suppression of the CB, receptor, a CB1 
receptor independent mechanism also exists through which cannabinoids, at higher 
concentrations, act to inhibit nicotine evoked contraction. 
Cannabinoid inhibition of nicotinic receptors in cultured myenteric neurones was 
confirmed using the whole cell patch clamp technique. Similar levels of inhibition of 
nicotine evoked current by both active and inactive WIN 55,212 stereoisomers 
suggested activity through a CB, and CB2 receptor independent mechanism. Previous 
work observed inhibition by PEA, an endogenous cannabinoid shown to be inactive at 
CB, and CB2 receptors, and showed not only a lack of blockade by SR141716, but an 
inhibition by this CB 1 receptor selective antagonist (DeMuth et al., 2004). 
Furthermore, previous data showed inhibition was not sensitive to either pertussis 
toxin treatment, while current work observed no modulation of inhibition by the 
membrane-permeable cAMP analogue 8-Br-cAMP, suggesting inhibition involved a 
mechanism independent of the G170-protein and the adenylate cyclase/cAMP 
intracellular signalling mechanisms. Although it is possible that inhibition may be 
occurring through an unknown receptor and second messenger mediated pathway, the 
lack of effect of PTX and 8-Br-cAMP, coupled with the work of Oz and colleagues 
(Oz, 2006), suggests that a direct cannabinoid action on the nicotinic receptor may be 
occurring. 
Arachadonic acid, a metabolite of anandamide, has been reported to inhibit Torpedo 
and chick a7 nicotinic receptors, expressed in oocytes, through a blockade of the 
Ca, }-modulatory sites (Nishizaki et al., 1998). Further work examining whether the 
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cannabinoid inhibition observed occurred through this mechanism would be 
intriguing. 
6.2. Cannabinoid modulation of calcium channel activity in guinea-pig 
myenteric AH neurones 
CB, receptor inhibition of N-type voltage-gated calcium channels was first observed 
in 1992 (Mackie & Hille, 1992; Caulfield & Brown, 1992). In the enteric nervous 
system the N-type voltage-gated calcium channel has been shown to play a major role 
in governing the action potential in AH-neurones (Hirst et al., 1974; Rugiero et al., 
2002). Using the whole cell patch clamp technique, the cannabinoid CB 1 and CB2 
receptor agonists CP 55,940 and WIN 55,212-2 were shown to inhibit voltage-gated 
calcium currents in cultured myenteric neurones. However, the CB, receptor specific 
antagonists SR141716 and AM251, and the CB2 receptor specific antagonist 
SR144528 did not prevent CP 55,940 inhibition, but when both CB, and CB2 receptor 
antagonists were applied, blockade of CP 55,940 action was observed. Inhibition was 
both pertussis toxin sensitive and showed some stereospecificity suggesting action 
through a G110-protein coupled receptor. Intriguingly, at 10 µM SR141716 and the 
"silent" CB, receptor antagonist 02050 induced inhibition of voltage-gated calcium 
currents. These findings led us to hypothesise that either cultured myenteric neurones 
express both CB, and CB2 receptors and SR141716, at 10 µM acts non-specifically to 
produce inhibition, or that a novel non-CB 1, CB2 G! o-protein coupled receptor may 
exist possessing multiple binding sites for cannabinoids presenting sensitivity to either 
CB1 or CBS receptor antagonists. The likelihood of the CBS receptor being present is 
strengthened by the work of Mathison et al. (2004) and Duncan et al. (2005; 2006) 
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who reported the presence of the CB2 receptor in rat ileum after LPS treatment. This 
opens up the possibility that the act of culturing myenteric neurones may be evoking 
expression of the CB2 receptor. Alternatively, the presence of a novel cannabinoid 
receptor is supported by the reported blockade by SR141716 of cannabinoid 
inhibition at higher concentrations than expected for action at the CB, receptor (Mang 
et al., 2001). In this study, the high concentration of cannabinoid agonists may have 
masked the reduced inhibition produced by SR141716, resulting in the lack of 
inhibition observed. Further investigation into the presence of the CB2 receptor, 
through the use of CB2 receptor selective agonists and using immunohistochemical or 
binding studies, would prove interesting, distinguishing which proposed mechanism 
governed observed effects. 
6.3. Cannabinoid modulation of opioid activity in guinea-pig myenteric 
neurones and NG108-15 neurones 
A growing body of literature suggests an interaction between cannabinoids and 
opioids may exist in the CNS, while within the gut, studies have shown the existence 
of some interaction in governing agonist withdrawal (Basilico et al., 1999). In this 
study, examination of cannabinoids and opioids in the inhibition of electrically 
evoked contraction of the MPLM preparation suggests an interaction occurs between 
cannabinoid and opioid signalling pathways at high concentrations of agonist in 
which an inhibition of response is observed. The observation that maximal opioid 
inhibition of electrically evoked contraction in the presence of 100 nM CP 55,940 was 
smaller than that produced in the presence of 10 nM CP 55,940 suggests depletion of 
a shared pool of intracellular messenger is not responsible for this blockade, as a 
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similar level of inhibition would be expected with 10 and 100 nM CP 55,940 should a 
shared second messenger be depleted. As a result this suggests that CP 55,940 acts 
upon the ileum through multiple pathways, one independent of, and another 
interacting with opioid pathways. 
The increased morphine inhibition in the presence of SR 141716 poses an interesting 
story. Should the increase in size of contraction observed with exposure to SR 141716 
be due to the blockade of endogenous cannabinoid inhibition, and should these 
endogenous cannabinoids act in a similar manner to low concentrations of CP 55,940, 
then morphine would be expected to produce an inhibition similar to that produced in 
the absence of cannabinoids. However, the observed increased opioid inhibition 
disputes this hypothesis suggesting the effects produced by SR141716 may be due to 
inverse agonism or action at an alternate site. 
Unfortunately, a lack of opioid activity in cultured myenteric neurones led to the 
examination of interaction in NG 108-15 neurones. However, difficulties in 
maintenance of cultures resulted in the cessation of this avenue of research, but 
preliminary data did suggest that some degree of reduction in morphine inhibition of 
calcium currents by WIN 55,212-2 was present, supporting the premise of 
cannabinoid and opioid interaction. Further work into the intracellular mechanisms 
through which this interaction occurs would provide interesting support to the 
findings and may provide help in the treatment of opioid withdrawal and open up 
greater opportunities for the medicinal use of opioids. 
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6.4. Modulation of the rat mesolimbic dopaminergic reward pathway by 
cannabinoids 
With the growing use of cannabis as a drug of abuse, further work into elucidating the 
mechanism by which addiction occurs is necessary. The mesolimbic pathway plays a 
major role in governing reward, with addiction occurring as a result of increased 
release of dopamine in the NAcc. Using the blind whole cell patch clamp technique, 
CP 55,940 was shown not to modulate spontaneous action potential firing in 
dopaminergic neurones within the rat ventral tegmental area. This was expected as 
midbrain dopaminergic neurones have been shown not to express CB, cannabinoid 
receptors (Mailleux & Vanderhaeghen, 1992; Matsuda et al., 1993). However, work 
by Szabo et al. (2002) reported cannabinoid inhibition of GABAergic neurones within 
the VTA, suggesting cannabinoids may act in a manner similar to opioids. 
Unfortunately, difficulties in deriving and maintaining viable slices made work in this 
area unfeasible, even though a possible interaction between cannabinoids and opioids 
on GABAergic neurones within the VTA would prove very interesting. 
In summary, a growing wealth of evidence is developing suggesting the presence of 
more sites of action for cannabinoids than the accepted CB, and CB2 receptors. This 
is certainly true within the intestinal tract where data suggests multiple sites of action 
for cannabinoids exist. 
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